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Chapter 1 
Signals controlling the expression of the human c-siî/PDGF В gene 
Introduction 
Platelet-derived growth factor (PDGF) is an important polypeptide growth factor to 
which a variety of physiological and pathological roles have been attributed. Expression of 
PDGF is regulated in a cell type- and developmental-stage-specific manner and is subject 
to modulation by diverse extracellular stimuli. In a given cell type, regulation of PDGF 
expression may occur at the transcriptional, posttranscriptional, translational and/or 
posttranslational level. This introduction intends to give an overview of the cell types that 
express PDGF, the factors that affect PDGF expression and the mechanisms that are 
involved in regulation of PDGF expression. 
Platelet-derived growth factor 
PDGF is first of all known for its activity as a serum mitogen for cultured smooth 
muscle cells (SMCs) (Ross et al., 1974), fibroblasts (Kohler and Lipton, 1974) and glial 
cells (Westermark and Wasteson, 1975) and, secondly, as a chemoattractant for SMCs 
(Grotendorst et al., 1981) and fibroblasts (Seppä et al., 1982). In addition, it acts as a 
potent vasoconstrictor on rat aortic strips (Berk et al., 1986) and as a survival factor for 
cultured oligodendrocytes and their precursors (Barres et al., 1992). Whereas these 
activities seem to primarily serve normal physiological processes, such as early 
development and wound healing, aberrant expression of PDGF may also play a role in the 
etiology of atherosclerosis (reviewed in Baumgartner and Hosang, 1988), fibrosis, 
neoplasia (reviewed in Westermark and Heldin, 1991) and desmoplasia (reviewed in Ross 
et al., 1986). 
PDGF is a collective term for the three dimeric disulfide bond-linked proteins that 
can be constituted out of type A and/or type В polypeptide chains (reviewed in Heldin, 
1992). The responsiveness of cells to PDGF is mediated by two specific receptors: the a 
receptor binds PDGF AA, AB and BB with high affinity, whereas the β receptor binds BB 
with high affinity and AB with low affinity and has negligible affinity for AA homodimers 
(Heldin et al., 1988; Hart et al., 1988). The receptor specificity of the PDGF A and В 
chains is determined by very subtle structural differences. The change of only a few 
amino acids is sufficient to confer PDGF /3 receptor binding specificity to the PDGF A 
chain (LaRochelle et al., 1992; Jaumann et al., 1992). Binding of PDGF to its receptor 
induces dimerization and tyrosine-specific phosphorylation of the receptor (Ek et al., 
1982; Nishimura et al., 1982; Ek and Heldin, 1982; Heldin et al., 1989; Seifert et al., 
1989; Li and Schlessinger, 1991), which initiates a signal transduction cascade and 
ultimately confers specific phenotypical changes to the responsive cell (reviewed in Ross 
et al., 1986; Williams, 1989). PDGF a and /3 receptor cDNA clones have been isolated 
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(Yarden et al., 1986; Claesson-Welsh et al., 1988; Escobedo et al., 1988; Gronwald et 
al., 1988) and are currently being used to unravel the mechanistic pathways that are 
triggered by PDGF (reviewed in Williams, 1989; Heldin and Westermark, 1990; Pazin 
and Williams, 1992). Whereas all three dimeric forms of PDGF are mitogenic and 
chemotactic (Sturani et al., 1989; Hosang et al., 1989), only В chain homodimers 
transform NIH 3T3 fibroblasts with high efficiency (Clarke et al., 1984; Josephs et al., 
1984b; Gazit et al., 1984; Beckmann et al., 1988). This seems to be caused by differences 
in the signal transduction cascade that is initiated by a and β receptors, as activation of 
the catalytic domain of the β receptor in NIH 3T3 cells leads to 17-fold higher 
transforming activity than is achieved by activation of the corresponding α receptor 
domain (Heidaran et al., 1993). 
PDGF genes and proteins 
PDGF was originally purified from human platelets and characterized as a cationic 
30-kDa protein, consisting of 14-kDa and 17-kDa disulfide-linked polypeptide chains 
(Heldin et al., 1979; Antoniades et al., 1979). Elucidation of their amino acid sequence 
revealed that it consists of two homologous polypeptide chains, the A and В chains 
(Antoniades and Hunkapiller, 1983). The discovery that the PDGF В chain is the human 
homologue of the transforming protein р28 ш of simian sarcoma virus (SSV) (Robbins et 
al., 1983; Waterfield et al., 1983; Doolittle et al., 1983) enabled the rapid isolation of the 
human c-sis/PDGF В gene, a single copy gene located on chromosome 22 (Dalla Favera 
et al., 1982; Swan et al., 1982; Johnsson et al., 1984; Chiù et al., 1984; Josephs et al., 
1984a). The complete structure of the human PDGF В gene transcription unit was 
determined by cDNA cloning, nuclease SI mapping and primer extension. Seven exons 
spanning approximately 22 kb give rise to a 3.5-kb mRNA, a large part of which consists 
of nontranslated sequences. A 1022-bases long leader and a 1625-bases long trailer flank a 
723-bases long open reading frame. The location of the transcriptional promoter was 
confirmed by the presence of a consensus TATA box sequence at 30 bp upstream of the 
transcription start site (Rao et al., 1986; van den Ouweland et al., 1987) and by 
demonstrating its activity in a transient reporter gene assay (Van den Ouweland et al., 
1986; Ratner et al., 1987). The first human PDGF A cDNA clone was isolated much later 
than its В chain counterpart (Betsholtz et al., 1986) and shortly thereafter the PDGF A 
chain gene was isolated and characterized. It is a single copy gene located on chromosome 
7 (Betsholtz et al., 1986) and, similar to the В chain gene, contains seven exons spanning 
approximately 22 kb (Rorsman et al., 1988; Bonthron et al., 1988). The transcription start 
site was localized at approximately 36 bp downstream of a TATA box by nuclease SI and 
13 
primer extension mapping (Bonthron et al., 1988; Takimoto et al., 1991). The promoter 
was shown to be active in an in vitro transcription assay and a transient reporter gene 
assay (Takimoto et al., 1991). 
The availability of PDGF A and В cDNA clones enabled a detailed analysis of the 
structure/function relationship and of the processing of the corresponding polypeptides 
(reviewed in Hannink and Donoghue, 1989; Heldin, 1992). Whereas the В chain has 
higher transforming activity, the A chain is much more efficiently secreted (Beckmann et 
al., 1988). PDGF А/В chimeras were used to map a membrane retention signal to amino 
acids 212-226 of the В chain. An analogous region is present in the A chain, but normally 
subject to proteolytic cleavage (LaRochelle et al., 1990,1991). PDGF В residues 105-144 
are responsible for β receptor interaction (LaRochelle et al., 1990). Newly synthesized 
PDGF A and В chain precursors dimerize and undergo N-glycosylation and proteolytic 
processing in the endoplasmic reticulum (ER) and Golgi system. 30-kDa PDGF AA, AB 
and BB dimers arc secreted via exocytosis, but the major part of PDGF BB is generated 
by additional proteolysis in the Golgi system and is expressed as a 24-kDa BB homodimer 
that remains membrane associated or is degraded in lysosomes (Graves et al., 1986; 
Igarashi et al., 1987; Ostman et al., 1988, 1992; Bywater et al., 1988). As PDGF was 
also detected in the cell nucleus, it may act via hitherto unknown mechanisms (Rakowicz-
Szulczynska et al., 1986; Van den Eijnden-Van Raaij et al., 1988). 
Sites of expression of PDGF 
PDGF is expressed in a broad but specific subset of cell types and in a 
developmental stage-specific manner. The current idea is that its major function is in 
wound healing (reviewed in Pierce et al., 1991, and Deuel et al., 1991) and early 
development. Upon deregulation it may play a role in the etiology of certain cancers and 
of atherosclerosis. Several normal cell types express PDGF in culture and/or in situ (most 
of them are listed in Table 1). In nearly every cell type the expression of PDGF can be 
modulated by extracellular stimuli, which allows the cell to adapt the production of PDGF 
to changes in its environment. 
Endothelial cells 
Cultured vascular endothelial cells were among the first normal cells found to 
secrete PDGF (Dicorleto and Bowen-Pope, 1983) and express PDGF A and В mRNA 
(Barrett et al., 1984; Sitaras et al., 1987; Collins et al., 1987b). As they lack PDGF 
receptors, expression of PDGF has been thought to act in a paracrine way on connective 
tissue cells during development, maintenance and repair of the vasculature. The discovery 
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Table 1. Normal human cell types that are capable of PDGF expression. 
cell type 
vascular endothelial cells 
vascular smooth muscle cells 
megakaryocytes/platelets 
monocytes, macrophages 
placental cytotrophoblasts 
oocyte, blastocyst 
kidney mesangial cells 
fibroblasts 
neurons 
astrocytes 
skeletal myoblasts 
uterus endometrium/myometrium 
mammary epithelial cells 
retinal pigment epithelial cells 
PDGF 
A, 
A, 
A, 
A, 
A, 
A 
A, 
A, 
A, 
A 
A 
A, 
A, 
A, 
В 
В 
В 
В 
В 
В 
В 
В 
В 
В 
В 
reference 
DiCorleto and Bowen Pope, 1983 
Seifert et al , 1984 
Kaplan et al , 1979, Vinci et al , 1984 
Shimokado et al , 1985, Martinet et al , 1986 
Goustin et al , 1985 
Rappolee et al , 1988a, Mercóla et al , 1988 
Abboud et al , 1987 
Paulsson et al , 1987 
Yeh et al , 1991 
Raff et al , 1988, Noble et al , 1988, 
Richardson et al , 1988 
Sejersen et al , 1986 
Boehm et al , 1990, Mendoza et al , 1990 
Bronzert et al , 1990 
Campochiaro et al , 1989 
that endothelial cells from microvessels but not large blood vessels express PDGF 
receptors in culture and in situ led to the hypothesis that PDGF may also have an 
angiogenic function (Smits et al , 1989, Bar et al , 1989, Beitz et al , 1991) Coexpression 
of PDGF В and PDGF /3 receptor was also observed in proliferating vascular endothelial 
cells of hyperplastic capillaries within gliomas in situ, which suggests an autocrine role in 
vascularization of tumors (Hermansson et al , 1988, 1992, Maxwell et al , 1990b) 
Several factors have been shown to affect expression of PDGF in endothelial cells 
Both cultured and freshly isolated human umbilical vein endothelial cells (HUVECs) and 
bovine aortic endothelial cells (BAECs) express PDGF В mRNA, but the expression level 
increases strongly upon proliferation in vitro (Barrett et al , 1984) Vice versa, withdrawal 
of endothelial cell growth factor (ECGF) from the culture medium of HUVECs inhibits 
their proliferation and triggers their organization into tubular structures, which is 
accompanied by a strong decrease in PDGF В mRNA content (Jaye et al , 1985) PDGF 
A and В mRNA levels are differentially affected by ECGF (Tong et al , 1987) Thrombin 
and transforming growth factor-0 (TGF-0) stimulate expression of PDGF by vascular 
endothelial cells, but apparently through different mechanisms Thrombin may stimulate 
PDGF secretion at the posttranslational level (Harlan et al , 1986) In addition, both 
factors increase the transcription rate of the PDGF В gene, but do not affect the PDGF В 
mRNA half-life (70-90 min in human kidney microvascular endothelial cells (HKMECs)) 
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(Starksen et al., 1987; Daniel et al., 1987; Daniel and Fen, 1988; Kavanaugh et al., 
1988). TGF-/3 also stimulates transcription of the PDGF A gene (Starksen et al., 1987; 
Daniel et al., 1987; Kavanaugh et al., 1988). The effect of thrombin is mimicked by 
phorbol ester suggesting that it acts through protein kinase С (PKC) (Daniel et al., 1986), 
whereas TGF-/3 acts independently of PKC (Daniel and Fen, 1988). Elevated cAMP levels 
(induced by forskolin) block the expression of PDGF A and В mRNA and inhibit the 
effect of thrombin and TGF-0 on PDGF В mRNA expression, but not of TGF-0 on PDGF 
A mRNA induction (Starksen et al., 1987; Daniel et al., 1987; Kavanaugh et al., 1988). 
The thrombin mediated increase in PDGF production by human aortic endothelial cells 
was shown to be dependent on Na+-H+-exchange and on G proteins, whereas the 
thrombin mediated increase in PDGF A and В mRNA levels appeared to be independent 
of Na+-H+-exchange (Shankar et al., 1992a). The thrombin stimulated production of 
PDGF is inhibited at the transcriptional level by 3-deazaadenosine, which possibly acts via 
inhibition of S-adenosylhomocysteine hydrolase. This could result in accumulation of S-
adenosyl homocysteine, a potent inhibitor of certain transmethylation reactions (Shankar et 
al., 1992b). Oxidized low density lipoprotein (LDL) and fish oil suppress the production 
of PDGF-like proteins by vascular endothelial cells, probably at the posttranscriptional 
level (Fox and DiCorleto, 1986, 1988; Fox et al., 1987). 
Several other factors were reported to stimulate PDGF mRNA and/or protein 
expression, such as tumor necrosis factor (TNF) (Hajjar et al., 1987; Calderón et al., 
1992), bacterial endotoxin (Albelda et al., 1989), lipopolysaccharides (LPS) (Suzuki et al., 
1989), interleukin-1 (IL-1) (Suzuki et al., 1989; Calderón et al., 1992) and IL-6 (Gay and 
Winkles, 1990; Calderón et al., 1992). Basic fibroblast growth factor (bFGF) reversably 
downregulates expression of PDGF В mRNA and secretion of PDGF by HUVECs 
(Kourembanas and Faller, 1989). Acidic fibroblast growth factor (aFGF) transiently 
stimulates PDGF A gene transcription and PDGF secretion, but does not affect the В gene 
(Gay and Winkles, 1990). The half-life of PDGF A and В mRNA in quiescent HUVECs 
(2.4 and 1.8 h, respectively) is not affected by aFGF (Gay and Winkles, 1991). 
Interferon-gamma (IFN-γ) suppresses PDGF A and В mRNA levels and release of PDGF-
like proteins in vascular endothelial cells (Suzuki et al., 1989; Calderón et al., 1992). 
Hypoxie conditions (0-3% oxygen environment) reversibly stimulate PDGF В gene 
transcription in cultured HUVECs (Kourembanas et al., 1990). H 20 2 induces fourfold 
increased PDGF В mRNA levels in cultured bovine pulmonary artery endothelial cells 
(Montisano et al., 1992). Finally, physiological shear stress was reported to stimulate 
PDGF A and В mRNA levels in cultured endothelial cells; possibly through protein kinase 
С (Hsieh et al., 1991, 1992). In contrast, Mitsumata et al. (1993) found that the PDGF В 
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mRNA level was induced by shear stress via a protein kinase С independent mechanism, 
wherease the PDGF A mRNA level was not affected. Stimulation of PDGF В by shear 
stress is at the transcriptional level and a shear-stress-responsive element was mapped in 
the PDGF В gene promoter by reporter gene analysis and gel shift assays (Resnick et al., 
1993). Conflicting data were published by other investigators, which showed that in 
bovine aortic endothelial cells shear stress reduced PDGF В mRNA levels by 4-fold 
(Maleketal., 1993). 
Smooth muscle cells 
Expression of PDGF by vascular smooth muscle cells (SMCs) is developmentally 
regulated. Cultured aortic SMCs from rat pups secrete at least 60-fold more PDGF than 
SMCs from adult rats (Seifert et al., 1984; Majesky et al., 1988). Prolonged culture 
triggers the adult rat cells to change from a contractile to a synthetic phenotype, which is 
accompanied by the expression of PDGF (Nilsson et al., 1985). Comparably, SMCs 
derived from injured rat arteries show a synthetic phenotype (Walker et al., 1986). PDGF 
A and В mRNA are expressed at similar low levels in intact aortas from newborn and 
adult rats. Upon culturing PDGF В mRNA accumulates in passaged newborn but not adult 
rat SMCs, whereas PDGF A mRNA is found in comparable amounts in cells from both 
groups. PDGF В mRNA in newborn rat cells is shortlived, whereas PDGF A mRNA is 
more stable (Sejersen et al., 1986; Majesky et al., 1988; Sjolund et al., 1988). Cultured 
adult rat SMCs also express PDGF receptors and secrete PDGF upon exposure to PDGF 
itself (Sjolund et al., 1988). Although normal blood vessel walls have a low cell turnover, 
PDGF A and В mRNA expression was detected in situ in the tunica media and the tunica 
adventitia, respectively. A nonmitogenic maintenance function of PDGF in the normal 
vessel wall was suggested (Barrett and Benditt, 1988). PDGF and PDGF receptor are 
expressed at specific times and places in injured carotid artery, which suggests a role in 
regulating arterial wound repair (Majesky et al., 1990b). PDGF expression levels were 
found to be elevated in atheroma and atherosclerotic plaques compared with normal 
arteries, which suggested that PDGF may play a paracrine or autocrine role in the etiology 
of atherosclerosis and/or other pathological conditions (Barrett and Benditt, 1987; Wilcox 
et al., 1988; Libby et al., 1988). Within the plaques, PDGF A mRNA expression 
correlates with SMCs, whereas PDGF В mRNA and protein are predominantly expressed 
in macrophages (Barrett and Benditt, 1988; Ross et al., 1990). A direct causal role of 
PDGF in atherosclerosis has never been proven. 
Analogous to vascular endothelial cells, PDGF expression in SMCs is also affected 
by diverse factors. Angiotensin II induces PDGF A mRNA and PDGF protein expression 
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in cultured quiescent rat aortic SMCs (Naftilan et al., 1989). Angiotensin II was 
demonstrated to specifically induce expression of an alternatively spliced PDGF A mRNA 
species in cultured rabbit aortic SMCs (Nakahara et al., 1992). TGF-/3, uric acid and 
thrombin-α promote the proliferation of vascular SMCs via induction of PDGF A mRNA 
and protein expression, thus creating an autocrine loop (Majack et al., 1990; Rao et al., 
1991; Kanthou et al., 1992; Okazaki et al., 1992). Dexamethasone inhibits the thrombin 
induced induction of PDGF A secretion and the constitutive expression of PDGF A at the 
transcriptional level in SMCs (Nakano et al., 1993). PDGF A mRNA levels in cultured 
human vascular SMCs are also stimulated by serum, phorbol ester, aFGF, TNFa 
(Winkles and Gay, 1991), oxidized LDL (Zwijsen et al., 1992) and the α-adrenergic 
agonist phenylephrine (PE) (Majesky et al., 1990a). PE also induces a transient 10-fold 
increase in PDGF В mRNA content in rat thoracic aorta (Majesky et al., 1990a). Similar 
to vascular endothelial cells, vascular smooth muscle cells respond to mechanical strain by 
production of growth factors among which PDGF AA and BB. In addition the strain 
induces increased proliferation of the smooth muscle cells, which can be partly neutralized 
by anti-PDGF antibodies. Thus strain-induced proliferation may act via an autocrine 
PDGF loop (Wilson et al., 1993). 
Megakaryocytes/platelets 
PDGF is stored within α-granules of platelets, from which it is released during the 
clotting process (Kaplan et al., 1979) suggesting a role in wound healing. PDGF from 
human platelets consists of AA, AB and BB dimers (Hammacher et al., 1988a; Hart et 
al., 1990; Soma et al., 1992), whereas PDGF from porcine platelets consists solely of BB 
homodimers (Stroobant and Waterfield, 1984). Blood platelets are particles derived from 
bone marrow megakaryocytes and lack a transcriptional machinery. As expected, PDGF 
was detected by immunofluorescence in cultured human megakaryocyte colonies (Vinci et 
al., 1984) and PDGF В mRNA in isolated human bone marrow megakaryocytes (Gladwin 
et al., 1990). Megakaryocytes form only a minor population of the bone marrow cells and 
therefore have been difficult to study. Phorbol ester treatment of the human hematopoietic 
stem cell line K562 was found to induce megakaryoblastic differentiation, which is 
accompanied by PDGF A and В mRNA expression and secretion of PDGF. The induction 
of PDGF В gene expression by phorbol ester is regulated at the transcriptional level 
(Colamonici et al., 1986). At present, phorbol ester treated K562 cells are generally 
accepted as a model for bone marrow megakaryocytes (reviewed in Alitalo, 1990). PDGF 
В but not A mRNA expression is also induced by sodium butyrate mediated erythroid 
differentiation of K562 cells (Alitalo et al., 1987) and by phorbol ester mediated 
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megakaryocyte differentiation of human erythroleukemia cell line HEL (Weich et al., 
1987). 
Monocytes/macrophages 
In accordance with its putative role in wound healing, expression of PDGF A and В 
mRNA and PDGF protein was found in cultured human alveolar and peritoneal 
macrophages and in in vitro maturated or activated human monocytes (Shimokado et al., 
1985; Martinet et al., 1986; Rappolee et al., 1988b; Allam et al., 1992). Human blood 
monocytes were found to secrete a PDGF-like mitogen resembling a monomer (Pencev 
and Grotendorst, 1988). Concomitantly, human wound fluid contains PDGF-like peptides 
of 16-17 kDa and 34-36 kDa (Matsuoka and Grotendorst, 1989), which may correspond 
with monomeric and dimeric forms of PDGF. Oxidized LDL inhibits constitutive 
expression of PDGF В mRNA and protein by adherent cultures of human blood 
monocyte-derived macrophages. Oxidized LDL also attenuates LPS-induced PDGF В 
mRNA expression (Maiden et al., 1991). Enhanced expression of PDGF by macrophages 
was also found in association with pathological conditions. E.g., alveolar macrophages 
from patients with idiopathic pulmonary fibrosis (IPF) release four times more PDGF 
(Martinet et al., 1987) and express threefold higher PDGF A and В mRNA levels than 
alveolar macrophages derived from healthy persons (Nagaoka et al., 1990). Expression of 
PDGF В mRNA and of PDGF was also detected in situ in epithelial cells and 
macrophages of lungs from patients with IPF, where it could play a role in the abnormal 
fibroblast proliferation and collagen production (Antoniades et al., 1990). Transcription of 
the PDGF В gene in bronchoalveolar mononuclear cells from patients with pulmonary 
sarcoidosis (Deguchi and Kishimoto, 1990) or with autoimmune diseases with lung 
involvement is enhanced compared with cells derived from healthy persons (Deguchi and 
Kishimoto, 1989). In vitro maturation of monocytes to macrophages is accompanied by 
increased transcription rates of the PDGF A and В genes. This results in increased PDGF 
В mRNA and protein but does not affect PDGF A mRNA levels, suggesting that PDGF A 
expression is regulated at the posttranscriptional level. Similarly, alveolar macrophages 
transcribe the PDGF A and В genes at similar rates, whereas the steady state PDGF В 
mRNA and protein levels are 5-fold higher than those of the PDGF A chain. Whereas 
resting monocytes express only the short PDGF A mRNA that lacks the exon 6-derived 
sequences, in vitro maturated monocytes and alveolar macrophages express both the short 
and the long PDGF A mRNA species (Nagaoka et al., 1992). 
Analogous to the megakaryocyte differentiation of K562 cells, some leukemia cell 
lines can be induced to differentiate along the monocyte/macrophage pathway. In addition, 
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various factors have been shown to affect PDGF mRNA and protein expression in these 
cell lines. Phorbol ester induces monocytic differentiation of human myeloid leukemia cell 
lines HL-60 and U-937, which is accompanied by expression of PDGF A and В mRNA 
and synthesis and secretion of PDGF-like proteins. In contrast, PDGF A and В mRNA are 
not expressed in untreated HL-60 cells or in HL-60 cells induced to differentiate along the 
granulocyte pathway (Pantazis et al., 1986; Alitalo et al., 1987; Sariban and Kufe, 1988). 
Phorbol ester treatment of THP-1 monocytic leukemia cells induces only PDGF A mRNA 
expression. Cycloheximide induces PDGF В mRNA expression in monocytes, but whether 
the PDGF В gene is transcriptionally active in resting monocytes was not examined 
(Sariban and Kufe, 1988). IFN-γ mediated monocytic differentiation of HL-60 cells is not 
accompanied by PDGF В mRNA expression (Sariban et al., 1987). IFN-γ suppresses 
PDGF mRNA and protein production by phorbol ester activated THP-1 cells, but does not 
affect PDGF mRNA stability. IFN-γ also inhibits PDGF mRNA expression in monocyte-
derived macrophages cultured in the presence of GM-CSF (Kosaka et al., 1992). TNF-α 
and dexamethasone induce expression of, respectively, PDGF A and В mRNA in HL-60 
cells (Alitalo et al., 1987; Haynes and Shaw, 1992). TGF-ß stimulates PDGF A mRNA 
expression in U-937 and T-cell leukemia MOLT-4 cells and also induces PDGF A mRNA 
expression in HL-60 and Jurkat T-cell leukemia cells. TGF-0 mediated induction is stable 
in U-937 and transient in HL-60 cells and is accompanied by secretion of PDGF-like 
protein (Makela et al., 1987). 
Although PDGF is not expressed in normal lymphocytes, HTLV-infected 
lymphocytes were shown to express PDGF A and В mRNA (Pantazis et al., 1987; 
Goustin et al., 1990). 
Early development 
PDGF A mRNA and protein are expressed in mouse blastocysts and the mRNA is 
expressed as a maternal transcript in unfertilized ovulated oocytes (Rappolee et al., 1988a) 
and in Xenopus eggs (Mercóla et al., 1988). PDGF A mRNA is also detectable in bovine 
preimplantation embryos (Watson et al., 1992), where PDGF stimulates development of 
bovine embryos during the fourth cell cycle (Larson et al., 1992). Early studies already 
demonstrated expression of PDGF В mRNA during embryonic and fetal development of 
the mouse (Slamon and Cline, 1984). PDGF and its receptor can be detected in central 
and peripheral nervous system, gastrointestinal and gastrourinary system, respiratory tract, 
muscle and cartilage of day 16 embryonic rats. In day 18 embryonic rats the expression 
peaks and is detectable in almost all organs, whereas after day 18 expression is especially 
seen in stomach, kidney, liver, pancreas and sex cords (Burton et al., 1993). Recently 
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expression of the PDGF β receptor was examined in situ during organogenesis in the 
mouse embryo. The PDGF β receptor was first detected in the periaortic mesenchyme and 
later particularly in derivatives of the primitive gut. Expression was exceptionally high in 
mesenchyme directly supporting epithelia of many organs, such as trachea and intestine. 
High expression levels were also detected in endothelium of small blood vessels and in 
vascular structures, such as hyaloid plexus and choroid plexus. In large blood vessels the 
receptor was expressed in mesenchyme surrounding the epithelium (Shinbrot et al., 1994). 
The importance of PDGF В and the PDGF β receptor in mouse embryonic development 
has recently been demonstrated by the analysis of null-mutant mice (Leveen et al., 1994; 
Soriano, 1994). PDGF В null mutants die perinatally from fatal bleedings and suffer from 
erythoblastosis, macrocytic anemia and thrombocytopenia. The bleedings may result from 
deficiencies in blood clotting, reduced platelet function or lack of function and integrity of 
the vascular wall. The mutant mice lack kidney mesangial cells and glomerular tufts. The 
heart and some large arteries are dilated, possibly due to the lack of vasoconstrictive 
activity of PDGF (Leveen et al., 1994). The PDGF β receptor null mutant mice exhibit 
the same blood and kidney deficiencies as were found in the PDGF В null mutants and 
also die perinatally from fatal bleedings. Their major blood vessels and heart appear 
normal, possibly because the role of the PDGF β receptor can be partially compensated by 
the α receptor. Since the clotting capacity of the blood was not affected, the fatal bleeding 
may result from defects in the microvasculature (Soriano, 1994). Normal human fetal 
kidney cells secrete PDGF and express PDGF A mRNA (Fraizer et al., 1987). PDGF В 
and β receptor are detectable immunocytochemically during the development of glomeruli 
in human kidneys of 54 to 105 days gestational age. During early glomerulogenesis, 
PDGF В expressed in the epithelium may act in a paracrine way, whereas later PDGF В 
and the β receptor are coexpressed in mesangial cells and, thus, may play an autocrine 
role (Alpers et al., 1992). PDGF A but not В mRNA is expressed in 6.5-8.5 day mouse 
embryonic and postembryonic tissues and both α and β receptor mRNA are expressed in 
early embryos (Mercóla et al., 1990). PDGF A and a receptors are coexpressed in 
preimplantation mouse embryos and, thus, may play an autocrine role (Palmieri et al., 
1992). Following implantation, PDGF A is mainly expressed in the epithelium, whereas 
the receptor is expressed in the mesenchyme, which suggests a paracrine activity across 
cell layers (Palmieri et al., 1992; Orr-Urtreger and Lonai, 1992). 
A role for PDGF in embryonic development has also been studied in tumor cell 
models. Murine and human embryonal carcinoma cell lines were found to express PDGF 
A mRNA and secrete PDGF (Rizzino and Bowen-Pope, 1985; Tiesman et al., 1988; Van 
Zoelen et al., 1989; Mercola et al., 1990). TGF-/3 induces PDGF В mRNA and PDGF 
21 
secretion in mouse embryo-derived AKR-2B cells, which may play a role in an autocrine 
loop (Leof et al., 1986). Human teratocarcinoma stem cell line Tera-2 expresses high 
levels of PDGF A but not В mRNA and the PDGF A mRNA level is markedly reduced 
upon retinole acid mediated endodermal or neuroectodermal differentiation (Weima et al., 
1988). Undifferentiated murine teratocarcinoma cell line F9 also expresses PDGF A 
mRNA and protein and much lower levels of PDGF В mRNA. Exposure of F9 cells to 
retinole acid induces differentiation to endoderm-Iike cells, which is accompanied by 
cessation of PDGF A production, but not of PDGF A mRNA expression. Whereas in 
undifferentiated F9 cells the PDGF A mRNA is present in polyribosomes, in differentiated 
cells the mRNA colocalizes with the free ribosome fraction, which indicates that the 
PDGF A mRNA is not translated in differentiated cells (Wang and Stiles, 1993). 
A role for PDGF in placental development was proposed upon the discovery that 
PDGF В mRNA is expressed in human placental cytotrophoblasts in situ. As 
cytotrophoblasts also express PDGF receptors, an autocrine mechanism in placental 
development was suggested (Goustin et al., 1985; Holmgren et al., 1992). Expression of 
PDGF by the placenta is under apparent developmental control, with a peak during the 
second trimester (Goustin et al., 1985; Taylor and Williams, 1988). Coexpression of 
PDGF В and β type receptor was also observed in microcapillary endothelial cells of first 
trimester human placentae, suggesting that an autocrine loop may play a role in placental 
angiogenesis as well (Holmgren et al., 1991). 
Kidney mesangial cells 
Cultured human glomerular mesangial cells release PDGF and express PDGF A and 
В mRNA. They respond mitogenically to PDGF suggesting an autocrine role in mesangial 
cell proliferation (Mene et al., 1987; Abboud et al., 1987; Shultz et al., 1988). Moreover, 
PDGF AB and BB induce synthesis of PDGF A and В mRNA in mesangial cells (Abboud 
et al., 1994). A normal monkey kidney cell line secretes PDGF and expresses PDGF В 
mRNA, which is stimulated by TGF-/J and ADP (Kartha et al., 1988). PDGF В mRNA is 
also expressed in baby hamster kidney (BHK) cells upon transfection with foreign DNA 
(Sakariassen et al., 1989). Thrombin (Shultz et al., 1989), phosphatidic acid (Knauss et 
al., 1990) and endothelin (Jaffer et al., 1990) stimulate expression of PDGF mRNA and 
phorbol ester stimulates PDGF A gene transcription in human mesangial cells (Bhandari 
and Abboud, 1993). Several factors that are mitogenic for mesangial cells, such as serum, 
PDGF, EGF, TGF-a, bFGF and TNF-a stimulate PDGF mRNA expression. TGF-0 also 
induces PDGF mRNA expression, but inhibits proliferation of mesangial cells (Jaffer et 
al., 1989; Silver et al., 1989). In a rat model of mesangial proliferative glomerulonephritis 
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PDGF В mRNA and protein are expressed in situ and PDGF A and В mRNA levels are 
increased in glomerular RNA, corresponding to mesangial cell proliferation. In addition, 
PDGF β receptor mRNA and protein are increased in glomerular nephritis (Iida et al., 
1991; Yoshimura et al., 1991). Recently, rat visceral glomerular epithelial cells were also 
shown to express PDGF В mRNA and protein in culture and in situ, but PDGF β receptor 
mRNA or protein could not be detected (Floege et al., 1993). 
Fibroblasts 
PDGF mRNA and protein are not constitutively expressed in cultured human dermal 
fibroblasts (Barrett et al., 1984; Collins et al., 1987b). However, transient expression of 
PDGF A mRNA and protein occurs when cultured dermal fibroblasts are exposed to 
PDGF, EGF (Paulsson et al., 1987), TGF-/3 (Soma and Grotendorst, 1989; Battegay et 
al., 1990), TNF (Paulsson et al., 1989) or IL-1 (Raines et al., 1989), suggesting that these 
factors stimulate mitogenesis through autocrine production of PDGF A. Recently it was 
shown that the PDGF В induced PDGF A production is reduced in fibroblasts from old 
donors compared with fibroblasts derived from embryonic and neonatal donors, suggesting 
developmental stage-specific regulation of PDGF or PDGF receptor expression (Karlsson 
and Paulsson, 1994). Following cutaneous injury in pigs, PDGF В and PDGF β receptor 
mRNA and protein are reversibly coexpressed in situ in skin epithelial cells and in 
fibroblasts, whereas PDGF is not detectably expressed in unwounded skin in situ 
(Antoniades et al., 1991). PDGF A mRNA and/or protein expression in fibroblasts was 
also observed under certain pathological conditions, e.g. in a strain of Hutchinson-Gilford 
(progeria) syndrome fibroblasts (Winkles et al., 1990) and in primary cultures of breast 
fibroblasts derived from benign and malignant lesions of breast tumors (Cullen et al., 
1991). PDGF A is also expressed in cultured rat lung fibroblasts (Fabisiak et al., 1992), 
and recently expression of PDGF A and В and of the PDGF β receptor was detected in 
fetal rat lung fibroblasts. The expression of PDGF A was constantly low during late 
gestation and did not significantly change subsequently, whereas the expression of the 
PDGF В chain was maximal at embryonic day 19 and decreased sharply thereafter (Buch 
et al., 1994). 
Neural tissues 
Human brain tissue expresses PDGF A and PDGF β receptor mRNA but not PDGF 
В mRNA (Maxwell et al., 1990b). Rat brain expresses PDGF mRNA throughout 
gliogenesis (Richardson et al., 1988) and rat brain neurons express PDGF β receptors in 
vitro and in vivo. Moreover, primary rat brain cells can be mitogenically stimulated by 
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PDGF (Smits et al., 1991). Whereas the transcription rates of the A and В chain genes in 
the rat central nervous system are similar, the mRNA level of the В chain is 10-fold lower 
than that of the A chain, suggesting differences in mRNA half-life (Reddy and Pleasure, 
1992). PDGF A mRNA and protein are also expressed at high levels in situ in neurons of 
embryonic and adult mice, where they may regulate proliferation and differentiation of 
glial cells (Yeh et al., 1991; Hutchins and Jefferson, 1992). Specific imrnunostaining for 
PDGF В chains was found in primate neurons, principal dendrites, some axons, and 
terminals throughout the brain; in the dorsal horn of the spinal chord and the posterior 
pituitary. PDGF A and В and receptor mRNA are expressed throughout the brain and 
posterior pituitary; a transgenic model in which the chloramphenicol acetyltransferase 
(CAT) reporter gene was driven by the PDGF В promoter revealed preferential expression 
within neuronal cell bodies in the cortex, hypocampus and cerebellum. Thus, PDGF may 
act as a neuronal regulatory agent (Sasahara et al., 1991). PDGF is expressed in neonatal 
rat peripheral nervous system (PNS), Schwann cells and less in neurons. In adult rat, 
myelinated nerve fibers express low PDGF levels, whereas unmyelinated nerve fibers 
express high levels. PDGF a and β receptors are expressed in neonatal PNS. In adult rat, 
both receptors are expressed in unmyelinated nerves (Eccleston et al., 1993). In cultures 
of rat neurons and astroglial cells PDGF and its receptors are coexpressed suggesting an 
autocrine role in neuronal differentiation (Hutchins and Ard, 1993). 
PDGF A is secreted by type-1 astrocytes present in the developing rat optic nerve 
and stimulates in vitro proliferation of 0-2A progenitor cells, which express 
predominantly PDGF a receptors (Raff et al., 1988; Noble et al., 1988; Richardson et al., 
1988; Pringle et al., 1989; reviewed in Anderson, 1989). Axonal electrical activity may 
control production and/or release of PDGF (Barres and Raff, 1993). After rat embryonic 
day 16, PDGF a receptor mRNA is expressed in a subset of glial cells, predominantly 
cells of the 0-2A lineage, but not by neurons (Pringle et al., 1992). 
Other cell types 
PDGF A mRNA and/or protein expression was detected in myoblast cell lines, 
primary rat skeletal myoblasts and developing rat crude muscle tissue (Sejersen et al., 
1986; Jin et al., 1990). PDGF В (two mRNA species) is expressed in human uterus 
endometrium and myometrium samples (Boehm et al., 1990). PDGF A mRNA is also 
expressed in the uterus and the expression level increases in myometrial SMC in situ 
during pregnancy and diminishes again during the Puerperium. This implicates a role for 
PDGF in uterine expansion during pregnancy (Mendoza et al., 1990). 
Cultured normal human mammary epithelial cells (HMECs) express PDGF A 
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mRNA and protein but little or no PDGF В mRNA. TGF-/3, which inhibits growth of 
HMECs, induces a 20-40-fold increase of PDGF В mRNA, a 2-fold increase of PDGF A 
mRNA and a 2-3-fold increase of PDGF secretion. Sodium butyrate and phorbol ester, 
which also inhibit growth of HMECs, do not affect PDGF expression (Bronzert et al., 
1990). 
PDGF A and В mRNA are expressed in rat lung and upon exposure to hyperoxia 
(87% oxygen) the PDGF A mRNA level increases and transcription of the PDGF В gene 
increases by up to 10-fold. Elevated PDGF expression preceeds a proliferative response of 
microvascular adventitial fibroblasts, precursor SMCs and epithelial cells (Powell et al., 
1992; Han et al., 1992). 
Cultured human retinal pigment epithelial (RPE) cells secrete PDGF (Campochiaro 
et al., 1989) and express PDGF A and В and PDGF a and β receptor mRNA. Phorbol 
ester and thrombin induce a 16-20-fold increase of the PDGF В mRNA level in RPE cells 
(Yoshida et al., 1992). PDGF A mRNA was also detected in situ in rat RPE cells as well 
as in retinal neurons and ganglion cells. PDGF A protein was detectable in ganglion 
neurons of the mouse retina and PDGF a receptor mRNA in retinal astrocytes. Therefore, 
a short range paracrine role for PDGF A in the retina was suggested (Mudhar et al., 
1993). Recent studies indicated that the PDGF receptors on RPE cells cultured in serum-
free medium are autophosphorylated and that suramin blocks the autophosphorylation. 
Moreover, anti-PDGF antibodies inhibit the growth of RPE cells in serum-free medium. 
Together, these studies strongly suggest that RPE cells use an autocrine PDGF loop for 
serum-independent growth (Campochiaro et al., 1994). PDGF В and β receptor mRNA 
were detected in the vascular systems of the eye, probably in the capillary endothelial cells 
(Mudhar et al., 1993). As PDGF BB also induces proliferation of rabbit retina capillary 
endothelial cells, an autocrine PDGF pathway may play a significant role in angiogenesis 
(Koyama et al., 1994). PDGF В and the PDGF β receptor are coexpressed in many cells 
of proliferative human retinal membranes, where they could contribute to pathogenesis of 
different proliferative retinopathies by paracrine or autocrine stimulation of cell migration 
and growth (Robbins et al., 1994). Recently, PDGF a receptors were identified in the 
peripheral epithelium of the chicken lens, where PDGF may control lens growth (Potts et 
al., 1994). 
Human primary osteoblastic bone cells and cultured fetal osteoblast cells express 
PDGF A (Zhang et al., 1991; Rydziel et al., 1992) and the human cells also express 
PDGF a and β receptors, raising the possibility of autocrine growth stimulation (Zhang et 
al., 1991). TGF-/81 increases PDGF A mRNA and protein expression by 3-6-fold in the 
fetal osteoblast cells (Rydziel et al., 1992). IL-1/3 stimulates proliferation of rabbit 
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articular chondrocytes and induces synthesis and release of PDGF. The IL-10 effect is 
specific for PDGF AA and acts at the transcriptional level. TGF-/Î inhibits IL-1/î 
induction of PDGF A (Peracchia et al., 1991). 
Cultured human keratinocytes express PDGF A and trace amounts of PDGF В 
mRNA and secrete PDGF AA protein. II-la induces PDGF В expression, whereas TGF-/3 
induces both PDGF A and В mRNA expression. PDGF AA and BB protein are also 
present in normal human epidermis in situ. PDGF receptor is not detectable in cultured 
keratinocytes or epidermis, which suggests that PDGF is not part of an autocrine loop in 
these cells (Ansel et al., 1993). 
Expression in transformed cells 
Shortly after the identification of PDGF it was discovered that certain human 
osteosarcoma and glioma cell lines secrete PDGF-like proteins, which led to the 
hypothesis that expression of PDGF may be associated with the etiology of these cancers 
(Heldin et al., 1980; Nister et al., 1982). The current idea is that PDGF may play an 
autocrine and/or paracrine role in tumorigenesis dependent on whether a tumor cell 
coexpresses PDGF and its receptor or whether it stimulates adjacent receptor expressing 
cells; through paracrine stimulation of connective tissue and blood vessels, PDGF secreted 
by tumor cells may induce desmoplasia and angiogenesis. Indeed, stable transfection and 
expression of PDGF В in an originally PDGF В negative melanoma cell line induces the 
development of a vascular connective tissue stroma in subsequent xenografts {Forsberg et 
al., 1993). 
The list of tumor species that express PDGF is still increasing (see e.g. Table 2) and 
in some cases the expression level was shown to be affected by extracellular factors. The 
expression level of PDGF may be an important parameter for its putative role in 
tumorigenesis: e.g., the level of PDGF В mRNA expression in 3T3 cells determines the 
acquisition of features of transformation in a dose-dependent manner (MacArthur et al., 
1992). Glucocorticoids suppress the expression of PDGF A mRNA and protein by a rat 
hepatoma cell line (Haraguchi et al., 1991), whereas expression of PDGF by MCF-7 cells 
is induced by 17/3-estradiol (Bronzert et al., 1987). PDGF A and В mRNA levels in 
cultured human pancreatic adenocarcinoma cells are stimulated by TNF-a and TNF-/3. 
Inhibition of PKC by staurosporin and stimulation of PKC by phorbol ester increases 
PDGF В mRNA levels (Kalthoff et al., 1991). Phorbol ester, TGF-0 and diacylglycerol 
(DAG) induce a transient increase of the transcription rate of the PDGF В gene in A172 
cells, but phorbol ester and TGF-0 use different signal transduction pathways (Press et al., 
1989). An increase of the cellular с AMP level blocks PDGF В mRNA expression in some 
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Table 2. Expression of PDGF mRNA and protein and of PDGF receptor in transformed cells in 
culture (С), in situ (S) or in tumor biopsies (Bi). "-", not determined 
Tumor species 
sarcoma (C) 
osteosarcoma (C) 
mesenchymal (C) 
glioma (C,S) 
mouse neuroblastoma (C) 
prostate carcinoma (C,S) 
glioblastoma (C,Bi,S) 
fibrosarcoma (C,S) 
melanoma (C) 
giant cell of bone (Bi) 
mesothelioma (C) 
nephroblastoma (C) 
breast carcinoma (C,S) 
lung carcinoma (C,S) 
gastric carcinoma (C.Bi.S) 
ovarian carcinoma (C) 
hepatoma (C) 
medulloblastoma (C) 
colon adenocarcinoma (C) 
astrocytoma (Bi,S) 
meningioma (S.Bi) 
Kaposi sarcoma (S) 
midgut carcinoid (S) 
endocrine pancreatic (C,S) 
neurinoma (Bi) 
choriocarcinoma (C,S) 
SV40 transformed BHK (C) 
HSV-transformed 3T3 (C) 
MoSV transformed NRK (C) 
PDGF 
mRNA 
A,B 
A,B 
-
A,B 
В 
Α,Β 
В 
В 
Α,Β 
В 
Α,Β 
А 
Α,Β 
Α,Β 
Α,Β 
Α,Β 
yes 
-
Α,Β 
Β 
Α,Β 
yes 
Α,Β 
Β 
Β 
Β 
Α 
Α 
PDGF 
protein 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
-
yes 
yes 
yes 
yes 
yes 
yes 
-
yes 
yes 
-
yes 
-
yes 
yes 
-
-
-
-
PDGF 
receptor 
yes 
yes 
yes 
yes 
-
yes 
-
-
yes 
-
-
yes 
no 
yes 
yes 
no 
yes 
-
-
yes 
yes 
yes 
yes 
yes 
-
yes 
-
-
-
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human glioma and osteosarcoma cell lines without affecting stability of PDGF В mRNA 
(Harsh et al., 1989). PDGF stimulates PDGF A mRNA expression in cultured Kaposi's 
sarcoma derived cells (Werner et al., 1990). Sodium butyrate inhibits growth and induces 
differentiation of F-98 rat glioma cells. The differentiation is accompanied by a significant 
and irreversible increase of the PDGF В mRNA level, which is at least partly caused by 
an increase of the mRNA half-life from 40 to 100 minutes (Tang et al., 1990). 
Regulation of PDGF expression 
From the above overview one could get the impression that PDGF can be expressed 
in any cell type. However, the fact that aberrant expression of PDGF В in e.g. fibroblasts 
may lead to oncogenic transformation already implicates that the expression must be 
tightly regulated. Thusfar, the majority of research on regulation of expression of PDGF 
has been descriptive. The molecular mechanisms that are involved in regulation of 
expression of the PDGF genes are only beginning to be understood. Since there are almost 
innumerable manners in which the expression of the PDGF genes can be modulated, it is 
not surprising that these mechanisms have evolved into a highly complicated network. 
Regulation of transcription rate 
Transcription of the PDGF genes can be modulated by very diverse extracellular 
stimuli, such as mitogens, cytokines, tumor promoters, shear stress, uric acid and oxygen 
concentration (reviewed in Kaetzel et al., 1993). The response of the PDGF genes to these 
stimuli and the cell type- and developmental-stage-dependent transcription of the genes are 
mediated by the interaction between specific DNA elements in the PDGF genes and 
regulatory transcription factors, which trigger the transcriptional machinery. These 
regulatory DNA elements have been mapped in only a few cell types, whereas the 
transcription factors that interact with the elements and their link to second messenger 
pathways are largely unknown. 
Given the fact that the PDGF A and В genes are often independently expressed, it is 
not surprising that their promoter sequences are not homologous. Actually, one of the few 
similarities is the presence of a TATA box at approximately 30 bp upstream of either 
gene. Fig. 1 gives an overview of regulatory DNA elements that have thus far been 
identified in the promoters of the PDGF A and В chain genes. Immediately upon the 
cloning of PDGF В exon 1, it was shown that the first 386 bp upstream of the 
transcription start site are sufficient for promoter activity in HeLa cells (Van den 
Ouweland et al., 1986). The first cell type in which the PDGF В promoter was analysed 
in detail was the megakaryocyte cell line K562. Upon treatment with phorbol ester these 
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cells differentiate towards megakaryocytes This is accompanied by a more than 200-fold 
increase in PDGF В mRNA level, which is dependent on protein synthesis By reporter 
gene analysis it was shown that the first 72 bp upstream of the transcription start site are 
essential for minimal promoter activity in umnduced K562 cells A region between -101 
bp and -58 bp appeared to be essential for TPA inducibihty Deletion of the region 
between -105 bp and -85 bp led to a three-fold decrease of TPA inducibihty, and deletion 
of the region between -105 bp and -41 bp reduced promoter activity to background levels 
By means of gel retardation experiments nuclear factors from K562 cells were shown to 
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Fig. 1. Regulatory DNA elements ¡η the promoters of the PDGF A and В chain genes. Black bars 
indicate the positions of the regulatory elements 
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bind specifically to the region between -103 bp and -60 bp and the binding activity 
increased upon TPA treatment (Pech et al., 1989b). In a recent linker scanning analysis, 
the region between -64 bp and -39 bp appeared to be essential for TPA inducibility of the 
PDGF В promoter (Jin et al., 1993). This is supported by in vivo footprint analysis of 
phorbol ester-treated megakaryocyte K562 cells, which showed that the region between 
-61 bp and -54 bp is bound by a potent transcriptional activator. In a similar way it was 
shown that the region between -64 bp and -60 bp is bound by a weak transcriptional 
activator required for basal promoter activity in uninduced K562 cells and in HeLa, PC3 
and JEG-3 cells (Dirks et al., 1995a). In the nucleus, sites of DNA-protein interactions 
are usually located in nucleosome-free regions, which can be identified by their 
hypersensitivity to DNase I. The DNase-I-hypersensitive (DH) site at the PDGF В 
promoter in TPA-treated K562 cells extends from -90 bp to +60 bp indicating that only 
one nucleosome is displaced. The first 112 bp upstream of the PDGF В transcription start 
site are sufficient for a 15-30-fold increase in PDGF В promoter activity during phorbol 
ester mediated megakaryocyte differentiation of K562 cells (Dirks et al., 1993a), whereas 
DH sites far upstream of the gene coincide with transcriptional enhancers that together 
with the promoter could result in a 100-1000-fold increase in promoter activity (Dirks et 
al., 1993b). By reporter gene analysis of deletion mutants a region located between -292 
bp and -278 bp was shown to contain a positive transcription regulatory element that is 
required for full promoter activity in HOS osteosarcoma cells and A172 glioblastoma 
cells. Further deletion up to -99 bp reduced promoter activity to background levels in 
these cells. By cotransfection experiments it was demonstrated that the first 1.4 kb 
upstream of PDGF В gene harbours a binding site for the HTLV-I and II derived 
transcription activating tat proteins, but the exact location of this binding site has thusfar 
not been described (Ratner, 1989). Nucleosome-free regions were also mapped in PDGF 
В intron 1. In cultured primary placental cytotrophoblasts, DH sites were localized at 1.6 
kb, 3.8 kb, and 4.3 kb downstream of the transcription start site, whereas these sites were 
not found in placental fibroblasts. In JEG-3 choriocarcinoma cells DH sites were found at 
1.6 kb and 3.8 kb downstream of the start site, and in U2-OS osteosarcoma cells a single 
site at +6.3 kb was found. Fragments that contained either the hypersensitive site at +1.6 
kb or at +3.8 kb enhanced promoter activity respectively by 4-fold and 8-fold in JEG-3 
cells, whereas the entire PDGF В intron 1 was found to enhance activity of the PDGF В 
promoter by 26-fold in JEG-3 cells (Franklin et al., 1991). This is in contrast with the 
observation that the DH sites at +1.6 kb and +3.8 kb act as potent silencers of the PDGF 
В promoter in JEG-3 cells and also in K562 cells (Dirks et al., 1993a). These conflicting 
results may be partly explained by the recent discovery that the DH site at +3.8 kb 
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coincides with an alternative transcription initiation site (Dirks et al., 1995b). Thus, in the 
reporter gene constructs described by Franklin et al. (1991) and Dirks et al. (1993a) two 
promoters were present in one single plasmid, which may have affected the activity of 
either promoter. A fragment that contained the DH sites at +6.3 kb silenced the PDGF В 
promoter activity by 2-3-fold in U2-OS cells (Franklin et al., 1991). The relative activity 
of the PDGF В promoter in HeLa cells and PC3 prostate carcinoma cells is not 
significantly different, although the PC3 cells express a much higher level of PDGF В 
mRNA than the HeLa cells. DH sites at -9.9 kb and +25 kb contain enhancers that may 
explain the increased activity of the PDGF В promoter in PC3 cells compared with HeLa 
cells (Dirks et al., 1993a,b). By reporter gene analysis of deletion mutants and site 
directed mutants it was shown that an ETS-like sequence between -80 bp and -70 bp and 
an AP-1-like sequence between -92 bp and -85 bp relative to the transcription start site are 
important for activity of the PDGF В promoter in vascular endothelial cells. Synthetic 
oligonucleotides containing either the ETS-like element or the AP-1-like element interact 
with proteins present in endothelial cell nuclear extracts, but recombinant AP-1 and ETS-
like protein GABPa do not interact with the PDGF В promoter in vitro. Mutagenesis of 
the Spl-like CCACCC sequence between -61 bp and -56 bp reduced activity of the PDGF 
В promoter in endothelial cells by twofold. The -61/-56 sequence interacts with a nuclear 
protein from endothelial cell and with purified Spi, suggesting that an Spl-like protein is 
involved in regulation of transcription of the PDGF В gene in vascular endothelial cells 
(Khachigian et al., 1994). By linker scanning analysis of the PDGF В promoter in U2-OS 
osteosarcoma cells, regions at -63/-44 bp, -102/-95 bp and -244/-203 bp were identified as 
important positive regulatory elements. The -63/-44 element increased activity of a 
heterologous TATA box by 5-fold. By site directed mutagenesis the CCACCC sequence at 
-61/-56 bp was shown to be essential for the activity of the element and found to interact 
with an Spl-like factor present in U2-OS nuclear extracts (Jin et al., 1994). 
The PDGF В gene is also subject to negative transcription regulation, as e.g. dermal 
fibroblasts contain a transcriptional activator directed toward the PDGF В promoter but do 
not express PDGF В mRNA. The PDGF В promoter is unmethylated and not located 
within a DH site in fibroblasts (Dirks et al., 1993a, 1995a). No DNA-protein interactions 
could be detected by in vivo footprint analysis of the PDGF В promoter in fibroblasts 
(Dirks et al., 1995a). In addition, a silencer could not be found within a region that 
extends from -12 kb to +25 kb relative to the transcription start site in fibroblasts (Dirks 
et al., 1993a,b). We must therefore conclude that the inhibition of transcription of the 
PDGF В gene in fibroblasts is mediated by a mechanism that has not yet been unraveled. 
One of the few possibilities that remain is that the accessibility of the PDGF В promoter 
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for the transcriptional activator is blocked by histones, as a result of specific nucleosome 
phasing. A DH site that is located immediately downstream of the PDGF В promoter in 
fibroblasts might play a direct role in the phasing of nucleosomes (Dirks et al., 1993a). 
By analysis of somatic cell hybrids between PDGF В expressing melanoma cells and 
hamster fibroblasts it was shown that the negative regulation of the PDGF В chain is 
probably mediated by a frani-acting factor (Leveen et al., 1993). It would be interesting 
to test whether this factor acts by introducing changes in the chromatin structure at the 
PDGF В gene promoter. 
In contrast to the PDGF В promoter, the PDGF A promoter is exceptionally G/C-
rich (Rorsman et al., 1988; Bonthron et al., 1988). Eight consensus binding sites for 
transcription factor Spi are located within the first kb upstream of the transcription start 
site. The region between -447 bp and +387 bp has promoter activity in an in vitro 
transcription assay using HeLa nuclear extract and in a reporter gene assay using RD 
rhabdomyosarcoma cells (Takimoto et al., 1991). A region between -69 bp and -60 bp, 
immediately downstream of a 13-bp oligo(dG) stretch exhibits supercoiling dependent 
nuclease-Sl-hypersensitivity in vitro. It contains three Spi consensus binding sites and is 
required for full activity of the PDGF A promoter in HeLa cells. A synthetic 
oligonucleotide complementary to the nuclease SI hypersensitive site (SHS) of the PDGF 
A promoter protects this site against nuclease SI and reduces promoter activity in a 
transient reporter gene assay (Wang et al., 1992a,b). Another supercoiling dependent SHS 
is located immediately upstream of the 13-bp oligo(dG) stretch between -96 bp and -90 
bp. By gel shift analysis the -96/-90 and -69/-60 regions were shown to interact 
specifically with proteins present in nuclear extracts from RD cells. Reporter gene analysis 
of deletion mutants demonstrated that the first 72 bp upstream of the transcription start 
site are already sufficient for promoter activity in RD cells and that the -69/-60 region is 
important for activity (Wang et al., 1992b). Spl-like elements between -82 bp and -40 bp 
are also required for full activity of the PDGF A promoter in African green monkey 
(BSC-1) cells (Kaetzel et al., 1994). The first 600 bp of the PDGF A promoter contain at 
least six consensus binding sites for transcription factors EGR-1 and the Wilms' tumor 
associated WT1. Coexpression of EGR-1 and a PDGF A promoter/reporter gene construct 
indicated that EGR-1 can either activate or repress activity of the PDGF A promoter 
dependent on the cell type examined. WT1 was shown to interact in vitro with the PDGF 
A promoter and abolishes its activity in a reporter gene assay. As PDGF A is 
overexpressed in certain Wilms' tumors, this raises the possibility that deregulation of 
WT1 or PDGF A may contribute to the etiology of this tumor (Wang et al., 1992c; 
Gashler et al., 1992). The repression of PDGF A promoter activity by WT1 requires the 
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presence of WTl-binding sites both upstream and downstream of the transcription start 
site. The presence of either an upstream or a downstream binding site results in WT1 
mediated transcriptional activation. Different domains of WT1 are involved in 
transcriptional repression and activation (Wang et al., 1993b). Deletion mutant analysis in 
HeLa cells demonstrated that a negative transcription regulatory element is located 
upstream of -618 bp, probably between -1.9 kb and -0.9 kb (Lin et al., 1992). A similar 
reporter gene analysis in African green monkey (BSC-1) cells identified two negative 
elements between -1029 bp and -880 bp and between -1800 bp and -1029 bp (Kaetzel et 
al., 1994). Positive elements were mapped in HeLa cells between -558 bp and -447 bp 
and downstream of -150 bp. By DNase I footprint analysis the region between -89 bp and 
-33 bp was found to interact in vitro with purified Spi. A serum response element (SRE) 
located between -477 bp and -468 bp appeared to be required for growth factor mediated 
induction of PDGF A promoter activity in human foreskin fibroblasts. The SRE interacts 
in vitro with a serum response factor- (SRF-) like protein present in HeLa nuclear ectract 
(Lin et al., 1992). The SRE also coincides with a supercoiling dependent SHS. The 
noncoding strand of the SRE was found to interact specifically with a single-stranded 
DNA-binding protein present in a HeLa cell nuclear extract (Wang et al., 1993a). Another 
supercoiling dependent SHS is located between -495 bp and -484 bp immediately upstream 
of the SRE. It interacts specifically with proteins present in nuclear extracts from HeLa 
and A172 cells and slightly increases activity of a heterologous promoter (Wang et al., 
1994b). A supercoiling dependent SHS located between +50 bp and +67 bp relative to 
the transcription start site interacts in vitro with purified transcription factors Spi and 
EGR-1 (Wang and Deuel, 1992). Finally, a supercoiling dependent SHS was detected in a 
147-nucleotides long region in the first intron of the PDGF A gene. By reporter gene 
analysis the intron element was shown to silence the PDGF A promoter and a 
heterologous promoter in HeLa cells. The element specifically interacts with a protein 
present in nuclear extracts from HeLa cells (Wang et al., 1994a). In vitro methylation of 
the PDGF A gene promoter resulted in strongly reduced activity in a transient reporter 
gene assay in HeLa cells. DNA methylation might cause the low PDGF A mRNA level in 
these cells. However the methylation state of the endogenous PDGF A promoter in HeLa 
cells was not examined. Purified Spi, which is thought to play a role in regulation of 
transcription of the PDGF A gene, binds to the PDGF A promoter irrespective of its 
methylation state (Lin et al., 1993). 
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Alternative transcription initiation sites 
Small PDGF В mRNA species are induced by treatment of vascular endothelial cells 
with cycloheximide and TGF-/31. A 2.8-kb transcript initiates 15 nucleotides upstream of 
the translation start site, whereas a 3.0-kb transcript initiates 200 nucleotides further 
upstream. The expression of truncated PDGF В mRNA species may provide a way to 
escape from the potent translation inhibitory activity of the exon 1-derived 5' untranslated 
sequence (Fen and Daniel, 1991). The expression level of a 2.5-kb PDGF В mRNA 
expressed in melanoma cell line WM115 also highly increases by treatment with 
cycloheximide (Leveen et al., 1993), whereas the expression level of a 2.7-kb PDGF В 
mRNA in rat lung increases upon exposure to hypoxic conditions (Katayose et al., 1993). 
The 2.8-kb and 3.0-kb PDGF В mRNA species seem to have an intact PDGF В open 
reading frame. In contrast, JEG-3 choriocarcinoma cells express a 2.6-kb PDGF В mRNA 
species that initiates at an alternative promoter located within intron 1 and lacks the code 
for the signal peptide of the PDGF В chain precursor. The resulting protein product may 
be targeted to the nucleus due to the presence of a nuclear localization signal encoded by 
PDGF В exon 6 (Dirks et al., 1995b). 
Nuclease SI and reporter gene analysis demonstrated that the PDGF A gene uses 
two promoters. The regular transcription start site is located approximately 35 bp 
downstream of the TATA box, whereas the alternative initiation site is located 470 bp 
downstream of the first site, but still 380 bp upstream of the translation start site 
(Rorsman et al., 1992). A novel PDGF A cDNA clone isolated from a rat macrophage 
cDNA library lacks exon 6- derived sequences and has a 588-nucleotides coding region 
that is 91% identical with the human PDGF A code. The 79 nucleotides immediately 
upstream of the PDGF A open reading frame are 92% identical in the human and the rat 
mRNA, whereas the similarity in the remaining part of the 5' untranslated sequence is less 
than 30%. It was hypothesized that the rat PDGF A mRNA could be initiated at an 
alternative promoter. The 5' untranslated sequence of the rat cDNA clone contains an 
ATG codon that is in frame with the PDGF A open reading frame. Translation initiation 
from this upstream ATG would add 118 amino acids to the N-terminus of the PDGF A 
chain. Except in macrophages, the alternative PDGF A transcript is also expressed in 
fetal, newborn and adult brain and kidney (Feng et al., 1993). 
Regulation of mRNA stability 
In general, the widely varying PDGF В mRNA levels result from differences in 
transcription rate of the gene, rather than from differences in mRNA stability (Colamonici 
et al., 1986; Kavanaugh et al., 1988). The PDGF В mRNA half-life varies roughly from 
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1-3.5 h in rat smooth muscle cells (Majesky et al., 1988), vascular endothelial cells 
(Daniel and Fen, 1988; Gay and Winkles, 1991), bladder carcinoma cell line T24 (Press 
et al., 1988), glioblastoma cells (Press et al., 1988,1989; Harsh et al., 1989), РСЗ 
prostate carcinoma cells and phorbol ester treated K562 cells (Dirks et al., 1993a). 
Regulation of translation 
The 3.5-kb PDGF В transcript contains a 1-kb long GC-rich leader that inhibits 
translation in vitro up to 40-fold. A highly GC-rich 140-bases long sequence located 
immediately upstream of the PDGF В open reading frame is nearly as effective an 
inhibitor as the entire leader. The inhibitory activity is relieved by deletion of nucleotides 
154-378 or 398-475. The PDGF В leader also significantly reduces the transforming 
efficiency of the PDGF В gene in NIH 3T3 cells (Ratner et al., 1987; Rao et al., 1988; 
Ratner, 1989). Cultured primate aortic SMCs express PDGF A and В mRNA but do not 
express or secrete PDGF-like protein, suggesting negative regulation at the translational 
level (Valente et al., 1988). 
The PDGF A 5' untranslated sequence contains three ATG codons (Bonthron et al., 
1988), the function of which is unknown. In a recent study the region between +99 bp 
and +184 bp relative to the PDGF A transcription start site, which lacks an ATG codon, 
was shown to inhibit translation in RD rhabdomyosarcoma cells, but the inhibitory effect 
could be overcome by sequences located between +184 bp and +338 bp (Takimoto and 
Kuramoto, 1994). 
Alternative polyadenylation sites 
The PDGF A gene uses three alternative polyadenylation sites. In combination with 
the regular transcription start site these yield mRNA species of 2.3 kb, 2.8 kb and 3.6 kb. 
When combined with the alternative transcription start site, transcripts of 1.8 kb, 2.4 kb 
and 3.2 kb are generated. Since these PDGF A mRNA species can also be subjected to 
alternative splicing of exon-6, the theoretical number of different PDGF A mRNA species 
increases to twelve (Rorsman et al., 1992). Human papillary carcinoma cell line NPA 
expresses a monomeric PDGF-like protein and a 1.4-kb PDGF В mRNA that hybridizes 
with 5' cDNA probes but not with 3' probes, which could result from alternative 
polyadenylation (Matsuo et al., 1993). 
Alternative splicing 
Alternative splicing of PDGF mRNA (reviewed in Khachigian and Chesterman, 
1992a) was first discovered when PDGF A cDNA clones were isolated from a human 
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glioma cell line that represent two alternatively spliced transcript species differing by exon 
6-encoded 69 bases at the 3' part of the open reading frame; normal HUVECs express a 
short PDGF A chain precursor that lacks the 15 C-terminal highly basic amino acids 
encoded by the larger exon 6-containing glioma cDNA (Collins et al., 1987a; Tong et al., 
1987; Bonthron et al., 1988). Both the short and the long PDGF A mRNA species are 
expressed in a variety of normal tissues and transformed cells and in diverse mammalian 
species (Matoskova et al., 1989; Young et al., 1990; Langerak et al., 1992). In constrast 
with the short PDGF A chain, which is efficiently secreted, the long version of the A 
chain remains predominantly cell associated. Several lines of evidence suggest that the 
exon 6-encoded basic C-terminus associates with heparan-sulphate proteoglycans within 
the cell membrane and the cellular matrix. The PDGF В chain contains a homologous 
region in its C-terminus that determines its association with the cell membrane and cellular 
matrix. Alternative splicing of exon 6 may thus be a mechanism to regulate the formation 
of secreted or cell-associated forms of PDGF A (Ostman et al., 1991; Raines and Ross, 
1992; Khachigian et al., 1992; Kelly et al., 1993). A synthetic peptide that corresponds 
with the 18-amino-acids-long hydrophilic C-terminus inhibits the specific binding of 
growth factors to cells bearing their respective receptors and inhibits serum induced 
mitosis in cultured fibroblasts (Khachigian and Chesterman, 1992b, 1994). The 
alternatively spliced exon 6 of PDGF A also contains a nuclear targeting signal that is 
capable of targeting a non-secreted form of the PDGF A chain to the nucleus (Mäher et 
al., 1989). By PCR analysis two transformed human cell lines were shown to express 
PDGF A transcripts lacking exon 2-derived sequences, which generates truncated and non-
functional polypeptides (Sanchez et al., 1991). Aberrant splicing was found to occur 
between a cryptic splice donor site in the short PDGF A chain cDNA and a viral splice 
acceptor site present in a eukaryotic expression vector, which resulted in the synthesis of a 
non-secreted PDGF A chain (Wise et al., 1989). A novel PDGF A chain cDNA clone 
(A3), which was generated by alternative splicing of a 110 bp segment, was isolated from 
a rabbit embryonic aorta cDNA library (Nakahara et al., 1992). 
Alternative splicing of PDGF В mRNA was observed in a recombinant retrovirus 
that expresses the wildtype PDGF В chain and induces fibrosarcomas in mice. Proviruses 
derived from the tumors had lost a 149-bases sequence derived from exon 7, due to 
alternative splicing. Interestingly, an identical splice event is visible in the SSV genome, 
which suggests that these 149 bases are detrimental for retroviral expression or replication 
(Pech et al., 1989a). The mouse PDGF В gene has the same exon-intron structure as the 
human gene. Their coding regions are 89% identical and the first 120 nucleotides of the 
untranslated exon 7 are even 94% identical, but are followed by a highly divergent 
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sequence. It was hypothesized that this sequence could be involved in alternative splicing 
of exon 6, as is also observed for the PDGF A gene. An alternative PDGF В transcript 
that lacks exon 6 derived sequences has not yet been described (Bonthron et al., 1991). 
Posttranslational regulation 
It has become clear that a given cell type can qualitatively or quantitatively affect the 
expression of the PDGF chains at the transcriptional, posttranscriptional and translational 
level. However, even after efficient transcription of a PDGF gene and translation of its 
mRNA, the decision on whether or not to express the PDGF protein can still be made at 
the posttranslational level. PDGF purified from platelets consists as two polypeptides, 
PDGF-I and PDGF-II (Antoniades, 1981), which differ in carbohydrate composition 
(Deuel et al., 1981). The role of glycosylation in PDGF activity, processing and transport 
is not clear, and glycosylation is probably not essential for one of these processes. 
Activity of PDGF released in vivo may be regulated by association with a2-
macroglobulin, to which a large part of PDGF binds reversibly (Raines et al., 1984; 
Huang et al., 1984; Bonner et al., 1992). 
Another protein that may regulate activity of PDGF is the extracellular glycoprotein 
SPARC (secreted protein, acidic and rich in cysteine). It binds specifically to PDGF AB 
and BB, but not to AA, and inhibits binding of PDGF AB and BB to the PDGF receptor. 
Therefore, it may regulate activity of specific dimeric forms of PDGF (Raines et al., 
1992). Recent studies on vascular endothelial cells that had been stably transfected with a 
PDGF В expression vector provided evidence for yet another level of regulation. A major 
part of the PDGF В expressed by the transfectants remained associated with the 
extracellular matrix. Thrombin induced a rapid release of PDGF В by selective proteolytic 
cleavage of the membrane associated PDGF precursor protein. In this way a cell can 
quickly respond to a sudden need for growth factor, even in the absence of mRNA and 
protein synthesis (Soyombo and DiCorleto, 1994). 
Conclusions and future aspects 
Since its purification, some fifteen years ago, it has become clear that PDGF is a 
highly important polypeptide growth factor that plays an essential role during early 
mammalian development and is associated with wound healing in the adult. PDGF acts via 
the binding to and the activation of specific high affinity cell surface receptors. Both the 
PDGF A and В chain genes and the PDGF a and /3 receptor genes have been isolated and 
characterized, which has enabled the detailed structural and functional analysis of their 
protein products. A broad range of cell types has been described that are capable of 
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expressing either or both of the two PDGF genes, sometimes in a developmental stage-
specific manner. Moreover, many factors have been identified that can modulate the 
expression (level) of PDGF in a given cell type. Finally, several pathological phenomena 
have been found associated with increased expression levels of PDGF. 
Now that the place and time of expression of PDGF have largely been settled, 
research has focused more on the mechanistic aspects of PDGF expression. The signal 
transduction cascade that is initiated by activation of the PDGF receptors is rapidly being 
elucidated. Knowledge of the molecular mechanisms that are involved in regulation of 
expression of the PDGF genes is still limited, but rapidly accumulating. In principle, the 
expression of PDGF genes can be modulated by regulating the initiation, the initiation rate 
or the initiation site of transcription, by alternative splicing, by alternative 
polyadenylation, by varying the mRNA stability, by regulation of translation efficiency 
and by regulation at the posttranslational level. In general, regulation at the transcription 
level has been found to play a decisive role in regulation of expression of PDGF per se. 
In a number of cell types the DNA elements that mediate transcription of PDGF genes 
have now been characterized, which will soon be followed by the isolation and 
characterization of the transcription factors that bind to them. Identification of these 
transcription factors will enable one to elucidate the mechanisms that link the changes in 
the cells' environment or developmental stage with the changes in the transcription rate of 
the PDGF genes. This is not only important for extending the fundamental insight in 
regulation of the PDGF genes in normal cells, but will also lead to a better understanding 
of the changes in PDGF expression under pathological conditions. Ultimately, this may 
lead to the development of novel strategies in the ongoing fight against disease. 
OUTLINE OF THIS THESIS 
The aim of the study described in this thesis was to unravel the mechanisms 
involved in regulation of the expression level of C-JIJ/PDGF В mRNA. Therefore we used 
a panel of human cell lines that express widely varying PDGF В mRNA levels. Initially, 
it was determined whether the PDGF В mRNA level is regulated at the transcriptional or 
at the post-transcriptional level. Since the first appeared to be the case, the attention was 
next focused on the localization and characterization of transcription regulatory elements 
in the promoter. Soon it became clear that the different PDGF В mRNA levels did not 
always fit with differences in the activity of the promoter alone. Therefore, the research 
was extended towards the identification of transcription regulatory elements located 
outside of the promoter. In vivo, the binding of transcription factors to regulatory elements 
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generally occurs in nucleosome-free regions, which have increased susceptibility to 
DNases, such as DNase I. To reduce the chance of mapping irrelevant regulatory 
elements, these DNase-I-hypersensitive regions were localized and subsequently tested for 
the presence of transcription regulatory elements. The results of this approach are 
presented in chapters 2 and 3. The promoter region itself was studied in more detail by in 
vivo binding studies, methylation analysis and reporter gene assays, the results of which 
are presented in chapter 4. Finally, the characterization of an aberrant C-JW/PDGF В 
mRNA species, which is expressed in certain choriocarcinoma cell lines, is presented in 
chapter 5. 
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Chapter 2 
Localization and functional analysis of DNase-I-hypersensitive sites in the human c-
ÌIÌ/PDGF В gene transcription unit and its flanking regions 
Ron P.H. Dirks, Hans J. Jansen, Jort Gerritsma, Carla Onnekink and 
Henri P.J. Bloemers 
Eur. J. Biochem. 211, 509-519 (1993) 
SUMMARY 
We studied the regulation of the expression of the human C-J/'J/PDGF В gene in the 
following panel of cell lines: K562 cells, in which expression is inducible by phorbol 
esters; cytotrophoblast-derived cell lines JEG-3 and JAR; carcinoma-derived cell lines 
PC3, T24 and HeLa, which show extensive differences in c-sis mRNA content; dermal 
fibroblasts, which do not express the gene. We demonstrate that the wide variety of levels 
of c-sis mRNA in these cells is mainly determined at the transcription level. Extensive 
gene rearrangements or amplifications, or significant differences in the stability of the c-
sis transcript could not be found. In fibroblasts and placenta cell lines, inaccessibility of 
the c-sis promoter, rather than the absence of transcription factors that activate it, inhibits 
expression of the endogenous gene. Examination of the chromatin structure of the 
transcription unit and immediate flanking regions revealed several cell-type-specific 
DNase-I-hypersensitivity (DH) sites. Functional analysis of genomic fragments harbouring 
one or more DH sites showed the presence of negative regulatory elements within intron 
1, and of an activating element downstream of the gene. A DH site, located immediately 
downstream of the promoter in dermal fibroblasts, may regulate accessibility of the 
promoter by means of specific nucleosome phasing. 
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INTRODUCTION 
The human c-sis proto-oncogene encodes the В chain of platelet-derived growth 
factor (PDGF; Waterfield et al., 1983; Doolittle et al., 1983; Chiù et al., 1984), a major 
mitogen for cultured cells of mesenchymal origin. Functional PDGF is a dimer of 
cysteine-linked A and/or В chains and exerts its function through binding to specific 
plasma-membrane receptors. A wide variety of phenotypic effects have been ascribed to 
binding of PDGF to responsive cells (reviewed in Ross et al., 1986; Hannink and 
Donoghue, 1989). PDGF is thought to play a role in wound healing and early vertebrate 
development. This is reflected by the cell types that contain or produce PDGF-like 
proteins, namely platelets (Heldin et al., 1979; Antoniades et al., 1979), vascular 
endothelial cells (DiCorleto and Bowen-Pope, 1983), smooth muscle cells (Seifert et al., 
1983), placental cytotrophoblasts (Goustin et al., 1985), macrophages (Shimokado et al., 
1985) and monocytes (Martinet et al., 1986). While PDGF is not expressed in cultured 
primary fibroblasts (Eva et al., 1982; Graves et al., 1984) and glial cells (Lens et al., 
1986; Press et al., 1988), these cells express receptors for PDGF and respond 
mitogenically to it (Heldin et al., 1981). Overexpression of normal PDGF В chains 
induces cellular transformation of NIH 3T3 cells (Clarke et al., 1984; Gazit et al., 1984), 
and, as part of an autocrine loop, could play a role in the development and/or maintenance 
of certain mesenchymal tumors, such as gliomas and fibrosarcomas (Eva et al., 1982), 
and epithelial tumors, such as lung carcinomas (Antoniades et al., 1992). The 
transforming potential of the PDGF A chain has been shown to be 10-100-fold lower than 
that of the В chain (Beekman et al., 1988). 
The mature A and В chains are identical in 60% of their amino acid sequences 
(Betsholtz et al., 1986). Their genes are located on human chromosomes 7 (Betsholtz et 
al., 1986) and 22 (Dalla Favera et al., 1982; Swan et al., 1982), respectively, and are 
expressed independently (Betsholtz et al., 1986). Overexpression of В chains could result 
from increased translation of с-ш mRNA or from increased с-ш mRNA levels. The c-sis 
leader is known to inhibit translation in vitro (Ratner et al., 1987) and in reporter-gene 
studies (Rao et al., 1988). However, it does not prevent the development of tumors in 
mice, since a recombinant retrovirus that expresses high levels of the intact c-sis mRNA is 
still tumorigenic in mice (Pech et al., 1989a). This suggests that inhibition of translation 
of c-sis mRNA is of less importance for tumor prevention than regulation of c-sis mRNA 
levels. 
The half-life of c-sis mRNA has been shown to vary between 40-50 min in rat 
smooth muscle cells (Majesky et al., 1988) and approximately 3 h in certain human 
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glioma cell lines (Press et al., 1988). While the transcription initiation site of the human 
c-sis gene has been determined in several different cell types (Rao et al., 1986; Van den 
Ouweland et al., 1987), little is known at the molecular level about the regulation of 
transcription of the gene, c-sis mRNA levels can be transiently modulated in certain tumor 
cells and endothelial cells by transforming growth factor /3, thrombin, phorbol esters and 
cAMP (Daniel et al., 1986; Daniel and Fen, 1988; Press et al., 1989), but the DNA 
elements and transcription factors responsible for these effects have not been described. 
Phorbol ester induces megakaryocyte differentiation of the leukemia cell line K562, which 
is accompanied by stable activation of transcription of the c-sis gene (Colamonici et al., 
1986). Reporter-gene studies showed that DNA elements within the first 100 bp upstream 
of the transcription start site are important for phorbol-ester-mediated inducibility in vitro 
(Pech et al., 1989b). Recently, DNase-I-hypersensitivity (DH) sites located in c-sis intron 
1 of placental cytotrophoblasts were shown to enhance activity of the c-sis promoter in 
placental cells (Franklin et al., 1991). 
In order to extend this knowledge on the regulation of transcription of the human c-
sis gene, we studied a diverse panel of human cell lines of different tissue origin and with 
widely varying c-sis mRNA levels. Examination of the chromatin structure of the c-sis 
gene transcription unit and its flanking regions in these cells revealed the presence of 
several DH sites, many of which were cell-type specific. We systematically tested whether 
genomic fragments that contained one or more of these DH sites could influence activity 
of the c-sis promoter. The putative functions of the DH sites with respect to cell-type-
specific regulation of transcription of the human c-sis gene are discussed. 
MATERIALS AND METHODS 
Cell culture 
Cell lines K562, JEG-3, JAR, HeLa, T24 and PC3 were all from the American 
Type Culture Collection (Rockville, USA). Primary human dermal fibroblasts (Hufi) were 
derived from fresh foreskin biopsies, which were a kind gift of the Dept. of Surgery 
(Radboud University Hospital, Nijmegen). Cells were grown in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal calf serum and 125 IU/ml streptomycin and 
125 IU/ml penicillin. Megakaryocyte differentiation of K562 cells was induced by 
addition of 12-O-tetradecanoylphorbol 13-acetate (TPA; Sigma, St Louis, USA) to the 
culture medium (final concentration 2 ng/ml). 
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Isolation and analysis of RNA 
Total cellular RNA was isolated according to the LiCl/urea method (Auffray and 
Rougeon, 1980). RNA was glyoxylated, electrophoresed in 1% agarose gels containing 10 
mM Na2HP04, pH 7.0, and transferred to Hybond-N filters (Amersham, UK) as described 
(Sambrook et al., 1989). RNA was hybridized overnight in 0.5 M Na2HP04, pH 7.2, 1% 
bovine serum albumin, 7% SDS, 1 mM EDTA at 65°C with 32P-labeled DNA probes. 
Filters were washed at 65°C in 0.1 M Na2HP04, 0.5% SDS, 1 mM EDTA and exposed 
to Kodak XAR5 X-Ray film with two Cronex intensifying screens (Du Pont). 
Nuclear run-on assay 
Plasmid DNA (5 μg/slot) was denatured by alkali treatment and spotted onto 
nitrocellulose with a Schleicher and Schuell slot-blot apparatus. Nuclei were isolated 
according to Zenke et al. (1988). In each run-on experiment 2 χ IO7 nuclei were incubated 
in 300 μ\ run-on buffer (5 mM Tris/HCl, pH 8.0, 2.5 mM MgCl2, 150 mM KCl, 0.25 
mM each of ATP, GTP and CTP, 160 дСі [a-32P]UTP (3000 Ci/mmol and 50 U RNasin) 
at 37 °C for 20 min. Isolation of nuclear RNA and hybridization with plasmid DNA were 
performed according to Linial et al. (1985). Filters were washed in 40 mM sodium 
phosphate, pH 7.2, and exposed to Kodak XAR5 X-Ray films. 
Mapping of DH sites 
Cells (3 χ 108) were grown on 600-cm2 tissue culture dishes (Nunc, Denmark) to 
subconfluency, washed three times with buffer A (140 mM NaCl, 2.5 mM KCl, 8.1 mM 
Na2HP04, 1.5 mM KH2P04, pH 7.5) and scraped off the dishes with a cell lifter (Costar, 
Cambridge, USA). Pelleted cells (5 min, 600 χ g) were resuspended and lysed in lysis 
buffer (0.15 mM spermine, 0.5 mM spermidine, 15 mM Tris/HCl, pH 7.4, 60 mM KCl, 
15 mM NaCl, 2 mM EDTA, 0.5 mM EGTA, 500 mM sucrose, 1 mM 
phenylmethylsulfonyl fluoride, 0.5% Triton X-100) by ten strokes in a pestle-B Dounce 
homogenizer (Kontes). Nuclei were washed three times in wash buffer (lysis buffer 
without Triton X-100 and with 350 mM sucrose) and resuspended in DNase-I digestion 
buffer (0.15 mM spermine, 0.5 mM spermidine, 15 mM Tris/HCl, pH 7.4, 60 mM KCl, 
15 mM NaCl, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride) at a 
concentration of 2 χ 10e nuclei/ml. Digestions were performed at 0°C in 500-μ1 volumes 
containing 5 χ 107 nuclei and various concentrations of DNase I (bovine pancreatic DNase 
I type II, Boehringer Mannheim, FRG). Reactions were started by the addition of MgCl2 
to a final concentration of 5 mM and stopped after 15 min by the addition of EDTA to 
give a final concentration of 10 mM. Pelleted nuclei (5 min, 600 χ g) were resuspended in 
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proteinase К buffer (50 raM Tris/HCl, pH 8.0, 2 mM EDTA, 0.1% SDS) and treated 
overnight with proteinase К (400 ^g/ml final concentration) at 37 °C. Proteinase К activity 
and SDS were removed by three ethanol precipitations. RNA was digested with DNase-
free RNase A (50 fig/ad in 10 mM Tris/HCl, pH 8.0, 1 mM EDTA; buffer В ) for 30 
min at 37 "C and the DNA was precipitated again with ethanol and dissolved in buffer B. 
Purified DNA (50 ¿ig samples) was digested to completion with EcóBl or Hindlll (both 
obtained from GIBCO Laboratories, Grand Island, USA), extracted once with phenol and 
chloroform, precipitated with ethanol and dissolved in 40 μΐ H 20. The //indili fragments 
of phage λ (400 ng/lane) and the Haelll fragments of phage ΦΧ174 (200 ng/lane) were 
added to each sample as internal molecular size markers. DNA samples were 
electrophoresed in vertical 1% agarose gels (6 mm thick) and transferred to Hybond-N 
filters according to the Amersham protocol. DNA was hybridized overnight in 0.75 M 
NaCI, 75 mM sodium citrate, 0.1% SDS, 0.1% Ficoll, 0.1% bovine serum albumin, 
0.1% polyvinylpyrrolidone, 100 ¿¿g/ml herring sperm DNA at 68°C with 32P-labeled DNA 
probes. Filters were washed at 68°C in 15 mM NaCI, 1.5 mM sodium citrate and 0.1% 
SDS, then exposed to X-ray film with two intensifying screens. 
DNA probes 
Genomic c-sis probes (depicted in Fig. 2) were prepared as follows. PR5 is the 
0.25-kb HindUl-Sphl fragment of pA0152; PR7 is the 0.35-kb Pstl-Hindlll fragment of 
pA0121; PR8 is the 0.6-kb ВатШ-ЕсоШ fragment of pA0125; PR9 is the 0.3-kb EcóRl-
Pstl fragment of pA068; PR16 is the 0.38-kb Pstl-Pvull fragment of pA0121. pA068, 
pA0121, pA0125, and pA0152 are subclones of genomic c-sis clone ALLW-1283-C1 21 
(Van den Ouweland et al., 1985). pA068 and pA0121 have been described earlier (Van 
den Ouweland et al., 1985, 1986). pA0125 consists of a 14-kb Hindttl-EcoKl fragment 
cloned in pAT153; pA0152 consists of a 1.9-kb Hindlll-BamUl fragment cloned in 
pAT153. The c-sis cDNA clone pSM-1 was a kind gift of Dr S.T. Josephs. pUCsis 
consists of the 2-kb Xhol fragment of pSM-1 cloned in pUC18. pUCactin consists of the 
1.25-kb Pstl fragment of 0-actin cDNA clone pAct (Dodemont et al., 1982) cloned in 
pUC18. 
Reporter gene constructs 
All recombinant DNA constructs were made according to standard protocols 
(Sambrook et al., 1989). psis-112/+43CAT and psis-1758/+43CAT were made by 
cloning, respectively, the 155-bp BstVl-Fspl fragment of pA0121 and the 1801-bp 
ВатШ-Fspl fragment of genomic c-sis clone ALLW-1283-C1 21 (Van den Ouweland et 
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al., 1985) into the unique Hindlll site of pSuperCAT. pSuperCAT is a promoterless 
clüoramphenicol acetyltransferase (CAT) gene vector, a kind gift of Dr В. Dekker. All 
other sis-CAT fusion constructs were made by cloning the following genomic fragments 
into the unique Smal site located immediately upstream of the c-sis promoter in 
psis-112/+43CAT (Fig. 5): 2(s/a) contains the 170-bp Hinñ-Xhol fragment (positions 
+302 to +472) of pA0121; 3(s/a) contains the 297-bp Xhól-ВатШ fragment (positions 
+472 to +761) of pA0121; 4(s/a) contains the 449-bp BamHl-BstEll fragment (positions 
+761 to +1210) of pA0121; 5(s/a) contains the 0.7-kb Pstl fragment of pA078; 6(s/a) 
contains the 3.4-kb Kpnl fragment of pA078; 7(s/a) contains the 2-kb Hindlll fragment of 
pA078; 8(s) contains the 3.2-kb EcoRl-Xbal fragment of pA068; 9(s/a) contains the 0.6-
kb Xbal-ЕсоШ fragment of pA068; psisDH+0.2CAT contains the 429-bp Fspl-Xhol 
fragment (positions +43 to +472) of pA0121. pA078 consists of an 8-kb ВатШ 
fragment of clone ALLW-1283-C1 21 cloned in pBR322. pADACAT, which is a kind gift 
of Dr. T.M. Berkvens, consists of the human adenosine deaminase gene promoter cloned 
in pSuperCAT (Valerio et al., 1985). pCHllO, which contains the /3-galactosidase gene 
driven by the Simian virus 40 (SV40) promoter enhancer, was purchased from Pharmacia 
LKB Biotechnology (Sweden). 
Electropermeation and CAT assays 
Supercoiled plasmid DNA was purified by CsCl gradient centrifugation (Sambrook 
et al., 1989) and quantitated by means of both EtBr staining and spectrophotometric 
measurement. Cells were washed twice with buffer A. 3-5 χ IO7 cells were mixed with 10 
/ig pCHllO and 10 pmol CAT construct in 500 μ\ buffer A. After a 10-min incubation on 
ice, cells were electropermeated in a 1 ml electropermeation cuvette (Eurogentec, 
Belgium) by a 2 kV pulse from an ISCO type-494 power supply and immediately replated 
on 10-cm dishes. All cells except K562 were harvested 24-48 h after electropermeation. 
Immediately after electropermeation K562 cells were divided equally over two dishes. 
TPA was added to one dish and 24 h later both undifferentiated and TPA treated cells 
were harvested. Cell lysates were prepared according to Sambrook et al. (1989). The 
protein content of each lysate was determined in a protein assay (Bio-Rad, Richmond, 
USA) and fixed amounts of protein were tested for /3-galactosidase activity according to 
Edlund et al. (1985). Amounts of protein corresponding to equal /3-galactosidase activity 
were compared for CAT activity according to the method of Gorman et al. (1982). First, 
pilot assays were carried out to determine what time and amount of protein derived from 
reference sample psis-112/+43CAT would yield approximately 10% conversion of 
[14C]chloramphenicol after subtraction of the background CAT activity of pSuperCAT. 
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These parameters were then used to determine the relative CAT activities of all other 
constructs. Radioactive spots were quantitated by measuring in a liquid scintillation 
counter, from which the percentage acetylated chloramphenicol could be determined. CAT 
values were corrected for background activity by subtracting the mean values of 
pSuperCAT. 
RESULTS 
Differential expression of c-sis mRNA in a panel of diverse cell lines is regulated at the 
transcriptional level 
In order to gain insight into the mechanism of regulation of c-sis mRNA expression 
we examined a panel of cell lines with different tissue origin and with large differences in 
C-sis mRNA content (Fig. 1A). Cell lines HeLa, T24 and PC3, which were originally 
derived from cervix, bladder and prostate carcinomas, respectively, constitutively express 
28S -
В 
Hufl PC3 
pUC -
pUCactin -
pUCsis -
W 
-
— 
— 
w 
— 
Fig. 1. Analysis of c-sis 
expression. (A) Northern-blot 
analysis of C-ÍÍÍ mRNA in a 
diverse panel of human cell 
lines. Total RNA (30 μ% per 
lane) was hybridized with the 
2-kb SamHI fragment of C-ÍÍÍ 
cDNA clone pSM-1 and with 
a 28S rRNA probe. (B) Run-
on analysis of C-ÍÍÍ gene 
expression in nuclei from 
dermal fibroblasts (Hufi) and 
PC3 cells. 32P-labeled nuclear 
RNA was hybridized with the 
indicated plasmid DNA (5 
/ig/lane). 
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3 5-kb c-sis mRNA The steady-state expression levels of the 3 5-kb c-sis transcript show 
considerable variation in these cells, the level being highest m PC3 cells and very low in 
HeLa cells Chonocarcinoma-derived cell lines JEG-3 and JAR were chosen as a model 
for placental cytotrophoblasts, which express c-sis mRNA (Goustin et al , 1985) Both cell 
lmes lack the 3 5-kb c-sis transcript and express low levels of a 2 6-kb transcript that 
hybridizes with c-sis cDNA probe pSM-1 A 2 6-kb transcript is also expressed in the 
PC3 cells K562 myeloid leukemia cells treated with the tumor promoter TPA were 
included m the panel as a model for bone marrow megakaryocytes Although expression 
of c-sis mRNA in undifferentiated K562 cells has not been described, we reproducibly 
found low but significant amounts of the 3 5-kb c-sis transcript in these cells Finally we 
included primary Hufi in the panel as a negative control cell type 
By means of a run-on assay, we first examined whether we could detect 
transcriptional activity of the c-sis gene in nuclei derived from cultured primary human 
foreskin fibroblasts Fig IB shows that the C-JJS gene is not detectably transenbed in 
nuclei from fibroblasts Transcriptional activity of the c-sis gene can readily be detected in 
nuclei from PC3 cells and the /3-actin gene is transcribed in nuclei derived from both cell 
types Thus, Northern-blot and run-on analyses suggest that the lack of c-sis mRNA in 
cultured dermal fibroblasts results from absence of transcription of the gene or from a low 
transcription rate immediately followed by rapid degradation of the transcript 
We next examined whether genomic rearrangements or amplification of the c-sis 
gene could be involved in the differential c-sis mRNA content of the cell panel Therefore 
Southern blot analysis was performed on chromosomal DNA derived from the cells 
Hybridization with genomic probes PR16 and PR9 (Fig 2) revealed that no gross 
rearrangement or amplification of the c-sis gene transcription unit and its downstream 
region had occurred (data not shown) 
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Fig. 2. Restriction map of the human c-sis gene (C-SIS) and schematic overview of genomic probes 
that were used for Southern-blot hybridizations. Hatched boxes indicate c-sis exons 1-7, open boxes 
indicate genomic probes numbered PR*, the broken line indicates the 3' end of cosmid clone ALLW-1283 
CI 21 (Van den Ouweland et al , 1985), Η, ЯішШІ. E, EcoRl 
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Induction of c-sis mRNA expression in K562 cells upon megakaryocyte 
differentiation induced by TPA was already shown by others to take place at the 
transcriptional level (Colamonici et al., 1986). Here, we measured the stability of the 3.5-
kb c-sis mRNA in PC3, and TPA treated K562 cells. Therefore cells were treated with 5 
μg/ml actinomycin D for 0-7 h. K562 cells were treated with TPA (2 ng/ml) for 24 h 
prior to addition of actinomycin D. Cells were harvested at 1 h intervals and c-sis mRNA 
content was examined by means of Northern-blot analysis (Fig. 3). The half-life of c-sis 
mRNA varies over 2-3 h in these cells. This is not significantly different from half-lives 
of 2.5 h in T24 cells (Press et al., 1988), 2.3 h in TPA-treated A172 glioblastoma cells 
(Press et al., 1989), 1-1.5 h in U-MG343a glioblastoma cells (Harsh et al., 1989), and 3-4 
h in HeLa cells (data not shown). 28S rRNA remained stable throughout the actinomycin 
treatment and therefore served as a control for the amount of RNA loaded. We conclude 
that the large differences in 3.5-kb c-sis mRNA content between these cells do not result 
from differences in stability of the transcript. 
PC3 
actinomycin D 0 1 2 3 4 5 6 7 
3.5 kb 
28 S 
1 
* 
actinomycin D 0 1 2 3 4 5 6 7 h 
K562 + 
TPA 
3.5 kb 
:=s 
Fig. 3. Determination of 
c-sis mRNA half-life in 
PC3 and TPA-treated 
K562 cells. Cells were 
treated with actinomycin D 
(5 ¿ig/ml) for 0-7 h. Total 
RNA (PC3, 30 ng; TPA-
treated K562, 15 /ig) was 
hybridized with the 2-kb 
BamHl fragment of c-sis 
cDNA clone pSM-1 and 
with a 28S rRNA probe. 
Structural and functional analysis of the chromatin at the c-sis gene promoter and its 
flanking regions 
Since the previous results suggest that c-sis mRNA content in our cell panel is 
mainly determined at the transcriptional level, we next focused on the с-ш gene 
promoter. Initially we examined whether the transcriptional activity of the gene correlated 
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with the chromatin structure at the promoter. As an active promoter region is usually 
hypersensitive to DNase I (Gross and Garrard, 1988), we examined the 5.2-kb Hindlll 
fragment that contains c-sis exon 1 for the presence of DH sites (Figs 2 and 4A). The c-
sis promoter was found to be hypersensitive in HeLa, T24, PC3, and TPA-treated K562 
cells (DH site +0.0), which matches the expression of the 3.5-kb c-sis mRNA in these 
cells. By using endogenous markers for DNA fragment length, we determined that DH at 
the promoter extends from approximately position -90 bp to +60 bp relative to the 
transcription-initiation site. The c-sis promoter appeared not to be hypersensitive in JEG-
3, JAR, Hufi and undifferentiated K562 cells. This corresponds with the absence of the 
3.5-kb c-sis mRNA in JEG-3, JAR and Hufi, but not with the low expression level in 
K562 cells. One weak DH site at -0.9 kb is present only in TPA-treated K562 cells. No 
other DH sites were found between the promoter and the Hindlll site at -3.7 kb, which 
was confirmed by rehybridization with probe PR5 (Fig. 2 and data not shown). Several 
cell-type-specific DH sites were found downstream of the promoter within exon 1. In 
dermal fibroblasts, a DH site was found to extend from positions +30 bp to +410 bp 
(region +0.2). This site is absent in JEG-3, JAR and both undifferentiated and TPA-
treated K562 cells. The region partly overlaps with a DH site found only in HeLa, PC3 
and T24 cells. This region (+0.4) could be localized at positions +280 bp to +500 bp 
and contains a cold spot in its center, which could reflect the presence of specific DNA-
binding proteins. A DH site at +0.6 kb is present in all cells examined; however, in 
TPA-treated K562 cells, it is very weak, and in undifferentiated K562 cells it could only 
be detected in a screening with probe PR16 (Fig. 4B). Finally, a DH site at +1.0 kb was 
found in all cells except undifferentiated and TPA-treated K562 cells. 
In order to assess whether the differences in chromatin structure at the c-sis 
promoter correlate with activity of the promoter in a transient expression assay, we placed 
DH site +0.0 (155 bp BstUl-Fspl fragment at positions -112/+43 bp relative to the 
transcription-initiation site) in front of the CAT reporter gene and measured CAT activity 
upon electropermeation. Table 1 shows that the c-sis promoter is active in all cell types 
tested, including those that do not express the endogenous gene. This suggests that the 
absence of the 3.5-kb c-sis mRNA in Hufi and the placental cell lines JEG-3 and JAR 
does not result from the mere absence of necessary transcription factors in these cells. 
When we compared CAT activity of the first 112 bp with that of the first 1758 bp 
upstream of the transcription-start site, we found no significant differences, from which 
we conclude that all basic promoter elements are included within these first 112 bp, and 
that the DH site at -0.9 kb in TPA-treated K562 cells does not play a detectable role in 
transcription regulation. Comparison of the activities of the c-sis promoter and the SV40 
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Fig. 4. Mapping of DH sites in and around c-sis exon 1 (A) and within the c-sis gene transcription 
unit (B). Nuclei from the indicated cells were treated with increasing amounts of DNAse I. Chromosomal 
DNA (50 jig/lane) was digested with Hindlll (A) or EcoRl (B) and subjected to Southern-blot analysis. The 
DNA was hybridized with probe PR7 (A) or PR16 (B) (see also Fig. 2). The positions of the intact 5.2-kb 
Hindlll fragment (A) and 22-kb EcoRl fragment (B) are indicated. DNase I concentrations: (a) 256 U/ml; 
(b) 512 U/ml; (c) 1024 U/ml; (d) 2048 U/ml; (e) 4096 U/ml. Only DH sites that were found in two 
independent experiments are named after their positions relative to the transcription-start site. 
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Table 1. Relative CAT activities of c-sis promoter, SV40 promoter/enhancer and ADA promoter. See 
legend to Fig 6 for details, except that CAT activity of pSV2CAT was given a value of 100% All data are 
means of 2-4 independent electropermeations n.d., not determined 
Plasmid 
PS1S-112/+43CAT 
psis 1758/+43CAT 
pSV2CAT 
pADACAT 
CAT activity 
K562 
0 95 ± 0 3 
0 59 ± 0 07 
1 0 0 ± 6 6 
nd 
K562 + TPA 
24 4 ± 6 3 
1 9 0 ± 1 1 
100 ± 31 6 
nd 
Hufi 
1 4 ± 0 07 
2 6 ± 0 4 
100 ± 4 3 
nd 
JEG-3 
5 9 ± 0 14 
4 8 ± 1 7 
100 ± 4 1 3 
nd 
HeLa 
0 39 ± 0 01 
0 53 ± 0 25 
100 ± 3 2 
0 88 ± 0 005 
PC3 
0 31 ± 0 01 
0 34 ± 0 006 
100 ± 2 59 
0 41 ± 0 003 
promoter/enhancer, which has high activity in primate cells, shows that the c-sis promoter 
has the lowest relative activity in HeLa and PC3 cells, and the highest in JEG-3 and TPA-
treated K562 cells Remarkably, the relative activity of the c-sis promoter is higher in 
Hufi than in PC3 cells When K562 cells were electropermeated with psis-112/+43CAT, 
the amount of cell lysate necessary to achieve equal CAT activity was 25-fold higher for 
untreated than for TPA-treated cells. Activity of the c-sis promoter relative to the SV40 
promoter/enhancer increases concomitantly (Table 1), which indicates that the highly 
increased c-sis mRNA level in the TPA-treated cells can be largely explained by direct 
activation of the 112-bp с-ш promoter fragment. This is in agreement with results 
described earlier by Pech et al. (1989b). In contrast, in HeLa and PC3 cells, which also 
show a large difference in с-ш mRNA content (Fig. 1), activity of the c-sis promoter 
relative to the SV40 promoter/enhancer does not differ significantly. As the activity of the 
SV40 promoter/enhancer could also differ between these cells, we compared the c-sis 
promoter with the promoter of a housekeeping gene, namely the adenosine deaminase 
(ADA) gene (Valerio et al., 1985). Activity of psis-112/+43CAT relative to pADACAT 
differs less than twofold between HeLa and PC3 cells. Therefore, differences at the 112-
bp c-sis promoter are not likely to account for the large difference in c-sis gene 
transcription rate between these cells. 
To test whether the other DH sites within exon 1 harbour sequences that could 
directly influence activity of the c-sis promoter, genomic fragments (Fig. 5) corresponding 
to one or more of these sites were inserted upstream of the с-ш promoter in 
psis-112/+43CAT (fragment l(s) in Fig. 5). The CAT activities of the resulting 
constructs were determined as described in Materials and methods and are displayed as 
values relative to the activity of reference construct psis-112/+43CAT (in Fig. 6, the 
relative activity of the reference construct R is defined as 100%). Fig. 6 shows that DH 
site +0.4 (fragment 2) strongly silences c-sis promoter activity in undifferentiated and 
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TPA-treated K562 cells relatively independent of orientation. However, since this region 
is not hypersensitive in these cells, this down-regulation could be an artifact. The same 
fragment down-regulates CAT activity more than twofold in HeLa cells, but only when 
placed in the antisense orientation upstream of the promoter. We also tested whether 
DH+0.2, which is specifically present in Hufi, could directly influence activity of the c-
sis promoter. However, in Hufi, CAT activity of psisDH+0.2CAT, in which DH+0.2 
was placed upstream of the c-sis promoter, did not differ significantly from the activity of 
the c-sis promoter alone (data not shown). In all cell types, except Hufi, a 2-3-fold 
decrease in CAT activity was observed when fragment 3, which contains DH+0.6, was 
inserted in the antisense orientation upstream of the c-sis promoter. The corresponding 
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Fig. 5. Summary of DH sites 
located within the c-sis gene 
transcription unit (A) and its 
immediate nanking regions (A, 
B), and a schematic overview of 
the c-si's/CAT gene-fusion 
constructs. The locations of DH 
sites in the panel of human cell 
lines are indicated by arrows. 
Thick arrows indicate very 
pronounced DH sites. The black 
bars correspond to genomic 
fragments that were used in CAT 
r e p o r t e r - g e n e c o n s t r u c t s . 
Fragment l(s/a) contains the c-s/s 
promoter which was placed in the 
sense (s) or the antisense (a) 
orientation upstream of the CAT 
reporter gene yielding plasmid 
psis-112/+43CAT. 2(s/a)-9(s/a) 
indicate fragments placed in the 
sense or antisense orientation 
upstream of the c-sis promoter in 
psis-112/+43CAT. 
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Fig. 6. Relative CAT activities of lysates from cells electropermeated with the indicated c-îii/C47"gene 
fusion constructs. Electropermeations, /3-galactosidase assays and CAT assays were done as desribed in 
Materials and methods. Results were normalized to mean ß-galactosidase activity obtained from 
simultaneously electropermeated pCHllO. CAT activities were determined as percentage acetylated 
[l4C]chloramphenicol/time. For background correction, mean CAT activity of the promoterless construct 
pSuperCAT was subtracted from each value. Activities of all constructs are indicated as values relative to 
the activity of psis-112/+43CAT (R/sense), which was defined as 100%. All data are mean values from 2-
6 independent electropermeations. SD are indicated by error bars. R, reference construct 
psis-112/+43CAT; 2-9, CAT constructs containing fragments 2-9 (Fig. 5) cloned in the sense or the 
antisense orientation upstream of the c-sis promoter in psis-112/+43CAT; *, not determined. 
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sense construct displayed this activity only in undifferentiated K562 cells. Finally, 
fragment 4, which harbours DH + 1.0, leads to a more than twofold increase in CAT 
activity in HeLa cells. This fragment also acts in an orientation-dependent fashion, as in 
the antisense orientation it does not affect promoter activity. 
Localization and functional analysis of DH sites within c-sis intron 1 
When we examined the 22-kb EcoRI fragment that harbours the entire c-sis gene 
transcription unit with probe PR16 (Figs 2 and 4B), we could confirm the DH sites found 
within exon 1. Additional sites could be localized within intron 1. A DH site at +1.9 kb 
and a hypersensitive doublet at +4.0/+4.4 kb are very pronounced in placental cell lines 
JEG-3 and JAR. DH site +1.9 is also detectable in HeLa, PC3, T24 and undifferentiated 
K562 cells, and DH site +4.0 in all cells except TPA-treated K562 cells. However, in the 
non-placental cell lines, DH sites +1.9 and +4.0 are much less pronounced. The sites at 
+ 1.9 kb and +4.0/+4.4 kb probably correspond with sites at +1.6 kb and +3.8/+4.3 
kb that were recently described by Franklin et al. (1991). Additional sites show more cell-
type specificity: DH sites +1.2 and +1.5 are especially pronounced in HeLa, DH site 
+2.9 is found in T24 cells only and DH site +6.8 is detectable in HeLa and TPA-treated 
K562 cells. The site at +6.8 kb may correspond with a site at +6.3 kb found earlier in 
U2-OS cells (Franklin et al., 1991). No DH sites downstream of DH+6.8 were found, 
which was confirmed by rehybridization with probe PR8 (Fig. 2 and data not shown). 
Again, we tested genomic fragments that harbour one or more of these DH sites for their 
ability to influence activity of the c-sis promoter (Figs 5 and 6). Fragments 5 and 6, 
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which contain DH sites +1.9 and +4.0, respectively, behave like strong, orientation-
independent silencers in undifferentiated K562 cells. Actually, CAT activities of these 
constructs are well below the background activity of pSuperCAT, which lacks a 
transcriptional promoter. The silencing activity matches DH at these sites in the 
undifferentiated cells, which suggests that these regions could indeed be involved in 
downregulation of c-sis promoter activity in untreated K562 cells in vivo. In TPA-treated 
K562 cells, fragments 5 and 6 in the antisense orientation inhibit CAT activity more 
strongly than the same fragments in the sense orientation, but since these activities are not 
accompanied by DH, their relevance in vivo is doubtful. When placed in the antisense 
orientation upstream of the c-sis promoter, fragment 5 down-regulates CAT activity 
tenfold in HeLa, fivefold in JEG-3 and only twofold in PC3 cells. Interestingly, this 
fragment also harbours sites DH + 1.2 and DH + 1.5, which are hypersensitive in HeLa 
cells but not in PC3 cells. Fragment 6 leads to a threefold decrease in CAT activity in 
JEG-3 cells, again only when in the antisense orientation. Finally, fragment 7, which 
harbours DH+6.8, was found to downregulate CAT activity by more than fivefold in 
undifferentiated K562 cells, but only in the sense orientation. However, this activity is not 
accompanied by DH at that site. Fragment 7 in the antisense orientation slightly activates 
promoter activity in TPA-treated K562 cells, which based upon the chromatin structure 
could indeed be relevant for these cells. Recently, c-sis intron 1 was shown to contain 
strong placenta-specific transcriptional activators (Franklin et al., 1991). Since our data do 
not agree with these results, we repeated the experiment described by Franklin et al. by 
cloning the 8-kb ВатШ fragment that contains almost entire intron 1 in the sense 
orientation upstream of the c-sis promoter of construct рАОІбб (Van den Ouweland et al., 
1986). Upon transfection of JEG-3 cells with this construct (by means of the calcium 
phosphate coprecipitation technique) we determined CAT activity and found a slight 
decrease in CAT activity, corresponding with the results found with fragments 5(s), 6(s) 
and 7(s) (data not shown). 
Localization of a transcriptional activator downstream of the c-sis gene 
Transcription regulatory elements can also be located downstream of a gene. 
Therefore we used probe PR9 (Fig. 2) to search for DH sites within the 8.5-kb EcoRI 
fragment immediately downstream of the с-ш gene. Fig. 7 shows that this fragment 
contains several DH sites that are cell-type specific. DH sites +23.0 and +23.3 are 
correlated with transcriptional activity of the gene, since they are present in those cells 
that express either 3.5-kb or 2.6-kb c-sis transcripts and are absent in Hufi and 
undifferentiated K562 cells. A site at +25 kb is most pronounced in JEG-3, JAR, 
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undifferentiated and TP A-treated K562 cells, weakly present in PC3 and T24 cells and 
undetectable in Hufi and HeLa cells. A site at +23.7 kb is present in all cell types 
examined except K562 cells. Finally, a site at +29.0 kb was found to be specifically 
present in the placental cell lines JEG-3 and JAR. Reporter gene experiments reveal that a 
transcriptional activator is located within genomic fragment 9 (Figs 5 and 6) that harbours 
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Fig. 7. Mapping of DH sites immediately downstream of the c-sis gene. See legend to Fig. 4. EcoRl-
digested DNA was hybridized with probe PR9 (see also Fig. 2). 
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DH+25.0. The activation is 2-3-fold in Hufi, JEG-3 and TPA-treated K562 cells, and 4-
8-fold in PC3, HeLa and undifferentiated K562 cells. In K562 cells, the activator seems to 
act independently of the orientation relative to the c-sis promoter. However, in HeLa and 
PC3 cells, the fragment displays activity lower in the antisense than in the sense 
orientation. Surprisingly, fragment 8, which contains DH sites +23.0 and +23.3 that are 
induced upon TPA-mediated activation of c-sis mRNA expression in K562 cells, strongly 
down-regulates activity of the c-sis promoter in these cells. The relevance of this effect is 
not yet understood, since of our cell panel TPA-treated K562 cells contain the highest 
level of 3.5-kb c-sis mRNA. Whether the placenta-specific DH site at +29.0 affects c-sis 
promoter activity could not be examined, since this site is located downstream of the 3' 
boundary of our genomic c-sis clone ALLW-1283-C1 21 (Fig. 2). 
DISCUSSION 
The results presented here suggest that at least three different regulatory mechanisms 
cause the widely varying c-sis mRNA levels in a diverse panel of human cell types: 
regulation of accessibility of the c-sis gene promoter; regulation of expression of 
activating transcription factors that act directly at the promoter; cell-type-specific usage of 
transcription regulatory elements that are located outside of the promoter. 
Our reporter-gene studies show that JEG-3 and Hufi, which lack detectable 3.5-kb c-
sis mRNA, express transcription factors that activate a 112-bp c-sis promoter fragment. 
Activity of the c-sis promoter relative to the SV40 promoter/enhancer is even higher in 
these cells than in PC3, which express high levels of the 3.5-kb transcript. This confirms 
earlier reports of activity of the c-sis promoter in cells that do not express the endogenous 
gene (Pech et al., 1989b; Franklin et al., 1991). As the c-sis promoter is not 
hypersensitive to DNase I in JEG-3, JAR and Hufi, the absence of 3.5-kb c-sis mRNA in 
these cells probably results from inaccessibility of the promoter for activating transcription 
factors. Concomitantly, in a runon assay, transcriptional activity of the c-sis gene is not 
detectable in nuclei isolated from Hufi. A DH site that extends from approximate positions 
+30 bp to +410 bp is specifically present in Hufi and could, by nucleosomal phasing, 
force the c-sis promoter into a position where it is inaccessible for its activating 
transcription factors. Another possible cause of inaccessibility of the c-sis promoter for 
activating transcription factors is methylation of essential CpG dinucleotides. Four CpG 
dinucleotides are located within the first 100 bp upstream of the c-sis transcription 
initiation site (Van den Ouweland et al., 1986) and their methylation status is currently 
being examined. 
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DH at the c-sis promoter clearly correlates with expression of the 3.5-kb transcript. 
The only exception is that low expression of c-sis mRNA in undifferentiated K562 cells is 
not accompanied by DH at the promoter. K562 cells that are induced by TPA to 
differentiate toward megakaryocyte cells or by retinole acid or sodium butyrate to 
differentiate toward erythroblast cells express c-sis mRNA (Colamonici et al., 1986; 
Alitalo et al., 1987). Spontaneous differentiation of a low percentage of K562 cells along 
one of these pathways could explain the presence of c-sis mRNA in the untreated cells. 
DH at the c-sis promoter in only a minority of the cells may not be detectable by 
Southern-blot analysis. CAT activity of c-sis promoter construct psis-112/+43CAT 
increases 25-fold upon TPA treatment of K562 cells. The induction is accompanied by the 
appearance of a DH site at the c-sis promoter in TPA-treated cells. This site, which 
extends from approximate positions -90 bp to +60 bp, is also present in the three 
carcinoma-derived cell lines that constitutively express the 3.5-kb transcript. As DH sites 
are thought to represent nucleosome free regions in the chromatin (Gross and Garrard, 
1988), probably only one nucleosomal core is absent from the promoter at this site. 
Except at -0.9 kb in TPA-treated K562 cells, DH sites were not found between the 
promoter and position -3.7 kb in any of the cell lines. Moreover, CAT activity of psis-
1758/+43CAT does not differ from that of psis-112/+43CAT, which suggests that the 
entire c-sis promoter could indeed be confined within the first 90 bp. Pech et al. (1989b) 
reported that the first 4 kb upstream of the start site showed the same promoter activity in 
K562 cells as the first 400 bp upstream of the start site. Together with the results 
presented here, we conclude that a DH site at -0.9 kb in TPA-treated K562 cells is not 
detectably involved in regulation of transcription of the c-sis gene. Sequences located at 
positions -140 bp and around -350 bp relative to the transcription-start site were shown to 
affect TPA inducibility in reporter-gene studies on K562 cells (Pech et al., 1989b). Our 
chromatin studies do not support a role for these sequences in TPA-mediated induction of 
c-iis mRNA expression in vivo. Earlier, TPA-mediated activation of c-sis gene 
transcription in K562 cells was shown to be dependent on protein synthesis, and gel-
retardation experiments showed that nuclear factors that bind the c-sis promoter are 
induced upon TPA treatment (Pech et al., 1989b). In conclusion, megakaryocyte-specific 
expression of an activating transcription factor that acts directly at the c-sis promoter 
probably is the main cause of the increase in c-sis mRNA level upon differentiation. In 
addition, DH sites at +1.9 kb and +4.0 kb may contribute to silencing the activity of the 
c-sis promoter in untreated K562 cells, and weakly activating elements at +6.8 kb and 
+25.0 kb could further increase activity of the promoter in TPA-treated cells. 
Surprisingly, a fragment that harbours DH sites +23.0, +23.3 and +23.7 strongly down-
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regulates c-ïù-promoter-driven reporter-gene activity in TP Α-treated K562 cells. Since 
this does not correlate with the high expression of the c-sis gene in these cells, we do not 
know the relevance of this activity. Possibly, the negative activity is an artifact due to 
sequences located outside of DH sites +23.0 and 23.3. The sites did not display 
detectable activity in the other cell types tested. Based upon their location immediately 
downstream of the c-sis transcription unit and their specific presence in cells that express 
either the 3.5-kb or the 2.6-kb c-sis mRNA, one could hypothesize that these sites are 
located at preferential transcription-termination sequences. Downregulation of CAT 
activity in TPA-trealed K562 cells could then result from interruption of read-through 
transcription of the circular reporter-gene construct. 
The wide variety in c-sis mRNA content in HeLa, T24, PC3 and K562 cells does 
not result from gross rearrangements or differences in copy number of the c-sis gene 
transcription unit, nor does it result from large differences in c-sis mRNA decay rate. 
However, the activity of the c-sis promoter relative to the SV40 promoter/enhancer 
displays large differences in these cells (Table 1). The c-sis promoter has equally low 
activity in HeLa and PC3 cells, while it is 50-60-fold higher in TPA-treated K562 cells. 
This does not correspond with the large difference in c-sis mRNA content between HeLa 
and PC3, nor with the slight difference in c-sis mRNA content of PC3 and TPA-treated 
K562 cells. Although the activity of the SV40 promoter/enhancer could also vary among 
these cells, we presume that factors outside of the c-sis promoter also play a role in 
determining c-sis mRNA levels. This is further supported by the fact that the activity of 
the c-sis promoter relative to the promoter of adenosine deaminase housekeeping gene 
does not differ between HeLa and PC3 cells. We found a number of sites outside of the c-
sis promoter that could regulate the transcription rate of the gene in vivo. First, the high 
c-sis mRNA level in PC3 cells compared with HeLa cells may partly result from cell-
type-specific usage of a transcriptional activator at +25 kb. When placed in the sense 
orientation upstream of the c-sis promoter in a reporter-gene construct, a genomic 
fragment derived from position +25 kb increases activity of the c-sis promoter 2-6-fold in 
HeLa, PC3 and TPA-treated K562 cells. However, DH at this site is restricted to PC3 and 
K562 cells and is not detectable in HeLa cells. Thus, analogous to the situation at the c-sis 
promoter, frans-acting factors that bind the downstream element in vitro may not gain 
access in vivo. Second, genomic fragment 5 down-regulates c-sis promoter activity by 
tenfold in HeLa cells and only by twofold in PC3 cells. This fragment contains DH + 1.2 
and DH + 1.5 that are specifically present in HeLa cells and DH + 1.9 that is present both 
in HeLa and in PC3 cells. Which DH site causes the inhibition of promoter activity 
remains to be determined. The same fragment downregulates c-sis promoter activity in 
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JEG-3 and in K562 cells. In HeLa and JEG-3 cells, down-regulation occurs only when 
this fragment is placed in the antisense orientation upstream of the C-JI'S promoter, but 
since we do not know the conformation of the chromosomal DNA at that site in vivo, we 
cannot exclude a role for this site. DH sites at +1.9 kb and +4.0/+4.4 kb are especially 
pronounced in the placental cell lines. Recently, Franklin et al. (1991) showed that a 
genomic fragment harbouring DH + 1.9, when cloned in the sense orientation upstream of 
the c-sis promoter, activates transcription fourfold in JEG-3 cells, while it reduces 
promoter activity 2-3-fold in U2-OS cells. Moreover, a fragment that contains DH+4.0 
appeared to activate the с-ш promoter by 4-8-fold in JEG-3 and U2-OS cells. This 
activating influence could not be detected when comparable fragments were tested in our 
cell panel, which includes JEG-3 cells. Moreover, we could not reproduce the strong 
activating influence of the 8-kb ВатШ fragment on promoter activity in JEG-3 cells, 
which was also described by Franklin et al. (1991). At present we do not have an 
explanation for the discrepancies between these results. 
Recently, Fen and Daniel (1991) described that human renal microvascular 
endothelial cells express a 2.8-kb c-sis mRNA. This transcript possibly derives from an 
alternative transcription start site located within c-sis exon 1 at +1.0 kb relative to the 
start site of the 3.5-kb transcript. The expression of a 2.6-kb c-sis transcript in JEG-3, 
JAR and PC3 cells, and the localization in these cells of a DH site at +1.0 kb are in 
accordance with the data provided by Fen and Daniel. However, nuclease protection 
assays revealed that the 2.6-kb c-sis transcript in the three carcinoma cell lines is not 
initiated within c-sis exon 1 (our unpublished results). 
In general, the patterns of DH sites in the cell panel show some remarkable features 
(summarized in Fig. 5). A site at +0.4, which extends from approximate position +280 
bp to +500 bp, was found in the c-sis expressing carcinoma-derived cell lines, but is 
absent from the placenta cell lines and from K562 cells. Although this site could not be 
linked to a clear function with respect to transcription regulation, it contains a CpG island 
(Van den Ouweland et al., 1986) and may bind iranj-acting factors in vivo (Fig. 4). Its 
putative funtion could be dependent on proper chromatin structure, which has to be 
determined. In addition, DH+25 is very pronounced in the placental cell lines and both 
in untreated and TPA-treated K562 cells, while it is not present in fibroblasts. Possibly, it 
plays a role in predisposition of placental cytotrophoblasts and bone marrow 
megakaryocytes to transcription of the c-sis gene. 
Future research should be directed towards identification of the factors that interact 
with the sites described in this study under normal and pathological conditions. 
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Chapter 3 
DNase-I-hypersensitive sites located far upstream of the human c-si's/PDGF В gene 
comap with transcriptional enhancers and a silencer and are preceded by (part of) a 
new transcription unit 
Ron P.H. Dirks, Hans J. Jansen, Carla Onnekink, Rob J.Α. de Jonge 
and Henri P.J. Bloemers 
Eur. J. Biochem. 216, 487-495 (1993) 
SUMMARY 
The human c-sis gene encodes the В chain of platelet-derived growth factor (PDGF), 
a potent mitogen for cultured cells of mesenchymal origin. PDGF is stored in the a-
granules of blood platelets, which are derived from bone marrow megakaryocytes and lack 
transcriptional machinery. Human myeloid leukemia cell line K562 can be used as a 
model for megakaryocytes. Phorbol-ester-mediated megakaryocytic differentiation of K562 
cells is accompanied by more than 200-fold increase in the c-sis mRNA level. We have 
now localized transcriptional enhancers at -8.6 kb and -9.9 kb relative to the human c-sis 
gene transcription start site. The enhancer at -8.6 kb increases activity of the c-sis 
promoter by 40-60-fold specifically in K562 cells and comaps with a DNase-I-
hypersensitivity (DH) site. The enhancer at -9.9 kb increases c-sis promoter activity by 5-
10-fold in K562 cells and DH at that site accompanies phorbol-ester-induced 
megakaryocytic differentiation. In phorbol-ester-treated K562 cells the two enhancers may 
be negatively influenced by a silencer that comaps with DH at -10.7/-11.0 kb. Reporter 
gene analysis predicted that combined activity of the upstream enhancers and the c-sis 
promoter may result in 100-1000-fold higher promoter activity in phorbol-ester-treated 
K562 cells compared with untreated cells, which can fully explain the more than 200-fold 
increase in c-sis mRNA level. DH at -8.6 kb and -9.9 kb was also detected in human 
fibroblasts and in the carcinoma cell lines HeLa and PC3, which express, respectively, 
undetectable, low and high levels of c-sis mRNA. Although the individual DH sites 
displayed 4-10-fold enhancer activity in all these cells, they lost most of their biological 
activity when combined in a larger fragment. 
In addition we localized (part of) a new transcription unit at approximately 13 kb 
upstream of the c-sis transcription start site. The corresponding 0.45-kb sis upstream 
region (sur) transcript is constitutively expressed in all cell lines examined. The expression 
of the sur transcript is independent of the expression of c-sis mRNA and of the pattern of 
DH sites far upstream of the c-sis gene. Thus, at present, there is no indication that the 
upstream DH sites are involved in regulation of expression of the sur gene. 
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INTRODUCTION 
Platelet-derived growth factor (PDGF) is a major mitogen for fibroblasts, smooth 
muscle cells, and glial cells. Several lines of evidence point towards a role for PDGF in 
wound healing and early development (reviewed in Ross et al., 1986). PDGF from human 
platelets is mainly a cysteine-linked heterodimer of A and В chains (Hammacher et al., 
1988a; Hart et al., 1990). The A chain precursor is encoded by a gene on chromosome 7 
(Betsholtz et al., 1986) and the В chain precursor by the c-sis proto-oncogene located on 
chromosome 22 (Dalla Favera et al., 1982; Swan et al., 1982; Waterfield et al., 1983; 
Doolittle et al., 1983; Chiù et al., 1984). Both are single copy genes and their exon-intron 
structures are similar (Rorsman et al., 1988). The genes can be expressed independently 
and all three possible dimeric isoforms of PDGF have been found (Stroobant and 
Waterfield, 1984; Heldin et al., 1986; Hammacher et al., 1988b). Although the mature A 
and В chains are homologous, only the В chain has high transforming activity in NIH 3T3 
cells (Beekman et al., 1988). Overexpression of В chains is also correlated with certain 
mesenchymal tumors, possibly as part of an autocrine loop (Eva et al., 1982). While 
epithelial cells do not express PDGF receptors in culture, recent evidence indicated that 
PDGF В and the /3-type receptor are coexpressed in lung carcinoma cells in situ 
(Antoniades et al., 1992). This suggests that PDGF В could also play a role in the 
etiology and/or maintenance of epithelial tumors in vivo. 
c-sis mRNA is expressed in a variety of normal cells, such as placental 
cytotrophoblasts (Goustin et al., 1985), activated monocytes (Martinet et al., 1986), 
vascular endothelial cells (DiCorleto and Bowen-Pope, 1983) and smooth muscle cells 
(Seifert et al., 1984). Blood platelets, from which PDGF was originally purified, lack 
transcriptional machinery. Transcription of the c-sis gene takes place in their precursor 
cells, the bone marrow megakaryocytes (Gladwin et al., 1990). Human leukemia cell line 
K562 can be induced to differentiate toward megakaryocytes by treatment with phorbol-
esters, which is accompanied by highly increased transcription of the c-sis gene and 
expression of PDGF (Colamonici et al., 1986; Alitalo et al., 1987). Upon differentiation, 
the c-sis promoter becomes hypersensitive to DNase I and its activity in a reporter gene 
assay increases 15-30-fold (Pech et al., 1989b; Dirks et al., 1993a). 
In general, varying c-sis mRNA levels seem to result mainly from differences in the 
transcription rate of the gene, rather than from differences in mRNA stability (Colamonici 
et al., 1986; Daniel and Fen, 1988; Kavanaugh et al., 1988; Press et al., 1988; Harsh et 
al., 1989; Dirks et al., 1993a). In previous studies transcription regulatory elements have 
been found in the c-sis promoter, exon 1, intron 1 and downstream of the gene (Pech et 
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al., 1989b; Franklin et al., 1991; Dirks et al., 1993a). Transcription regulatory elements 
located upstream of the c-sis promoter have not been found earlier. We now report the 
presence of several cell-type-specific DNase-I-hypersensitivity sites (DH sites) far 
upstream of the human c-sis gene transcription initiation site. 
MATERIALS AND METHODS 
Cell culture 
Cell lines K562, JEG-3, JAR, HeLa, T24 and PC3 were all from the American 
Type Culture Collection (Rockville, USA). Primary human dermal fibroblasts (Hufi) were 
derived from fresh foreskin biopsies, which were a kind gift of the Department of Surgery 
(University Hospital, Nijmegen). Cells were grown in Dulbecco's modified Eagle's 
medium supplemented with 10% fetal calf serum and 125 IU/ml streptomycin and 125 
IU/ml penicillin. Megakaryocyte differentiation of K562 cells was induced by addition of 
12-O-tetradecanoylphorbol 13-acetate (TPA; Sigma) to the culture medium (final 
concentration, 2 ng/ml). 
Isolation and analysis of RNA 
Total cellular RNA was isolated according to the LiCl/urea method (Auffray and 
Rougeon, 1980). RNA was glyoxylated, electrophoresed in 1% agarose gels containing 10 
mM Na2HP04,pH 7.0, and transferred to Hybond-N filters (Amersham, UK) as described 
(Sambrook et al., 1989). RNA was hybridized overnight in 0.5 M Na2HP04,pH 7.2, 1% 
bovine serum albumin, 7% SDS, 1 mM EDTA at 65°C with 32P-labeled DNA probes. 
Filters were washed at 65°C in 0.1 M Na2HP04, 0.5% SDS, 1 mM EDTA and exposed 
to Kodak XAR5 X-Ray film with two Cronex intensifying screens (Du Pont). 
Mapping of DH sites 
Nuclear isolations, DNase I digestions and chromosomal DNA purifications were all 
performed as previously described (Dirks et al., 1993a). Purified DNA (50-^g samples) 
was digested to completion with EcoW or HinàUl (both obtained from Gibco 
Laboratories), extracted once with phenol and chloroform, precipitated with ethanol and 
dissolved in 40 μ\ H20. The Hindlll fragments of phage λ (400 ng/lane) and the Haelll 
fragments of phage ΨΧ174 (200 ng/lane) were added to each sample as internal molecular 
size markers. DNA samples were electrophoresed in vertical 1% agarose gels (6 mm 
thick) and transferred to Hybond-N filters according to the Amersham protocol. DNA was 
hybridized overnight in 0.75 M NaCl, 75 mM sodium citrate, 0.1% SDS, 0.1% Ficoll, 
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0.1% bovine serum albumin, 0.1% polyvinylpyrrolidone, 100 μ£/ηι1 herring sperm DNA 
at 68°C with 32P-labeled DNA probes. Filters were washed at 68°C in 15 mM NaCl, 1.5 
mM sodium citrate, 0.1% SDS, then exposed to X-ray film with two intensifying screens. 
DNA probes 
Genomic c-sis probes (depicted in Fig. 1) were prepared as follows. PR12 is the 
0.9-kb HindUl-Kpnl fragment of pA056; PR13 is the 0.46-kb Smal-Hindlll fragment of 
pA0149; PR3 is the 0.61-kb Smal-EcoBl fragment of pA056. pA056 and pA0149 
contain, respectively, 11-kb and 5-kb EcoRI fragments derived from genomic c-sis clone 
ALLW-1283-C1 21 (Van den Ouweland et al., 1985), subcloned into pSVBR91 and 
pBR322, respectively. The c-sis cDNA clone pSM-1 was a kind gift of Dr S.T. Josephs. 
Probes I-VII are depicted in Fig. 4. Probes Mil consist of the 1.3-kb Bamñl-Hindlll 
fragment, the 0.65-kb ВатШ-Xbal fragment and the 0.65-kb Xbai-Hindlll fragment of 
pA079, respectively. pA079 has been described earlier (Van den Ouweland et al., 1985). 
Probes IV-VII consist of the 1.5-kb Hindlll-Xhol fragment, the 1.3-kb Sstl fragment, the 
0.9-kb Sstl fragment, and the 2.3-kb Sstl fragment of pA056, respectively. 
Reporter gene constructs 
All recombinant DNA constructs were made according to standard protocols 
(Sambrook et al., 1989). psis-112/+43CAT has been described earlier (Dirks et al., 
1993a). pSuperCAT is a promoterless chloramphenicol acetyltransferase (CAT) gene 
vector, a kind gift of Dr. B. Dekker. All other ÍÍ'Í-CAT fusion constructs were made by 
cloning the following genomic fragments in the sense (s) and/or antisense (a) orientation 
into the unique Smal site located immediately upstream of the c-sis promoter in 
psis-112/+43CAT (= l(s)CAT in Fig. 1): 10(s/a) contains the 6-kb Hindlll-BamHl of 
pA056; ll(s/a) contains the 1.5-kb Hindlll-Xhol fragment of pA056; 12(s/a) contains the 
0.6-kb BstVl fragment of pA056; 13(s) contains the 0.7-kb Sstl-Narl fragment of pA056; 
14(s/a) contains the 1.5-kb Pvull-BamHl fragment of pA056. pCHHO was purchased 
from Pharmacia LKB Biotechnology (Sweden). 
Electropermeations and CAT assays 
Supercoiled plasmid DNA was purified by CsCl gradient centrifugation (Sambrook 
et al., 1989) and quantitated by means of both EtBr staining and spectrophotometric 
measurement. 3-5 χ IO7 cells were electropermeated with 10 μg pCHHO and 10 pmol 
CAT construct as previously described (Dirks et al., 1993a). All cells except K562 were 
harvested 24-48 h after electropermeation. Immediately after electropermeation K562 cells 
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were divided equally over two dishes. TPA was added to one dish and 24 h later both 
undifferentiated and TPA-treated cells were harvested. Cell lysates were prepared 
according to Sambrook et al. (1989). The protein content of each lysate was determined in 
a protein assay (Bio-Rad) and fixed amounts of protein were tested for /J-galactosidase 
activity according to Edlund et al. (1985). Amounts of protein corresponding to equal ß-
galactosidase activity were compared for CAT activity according to the method of Gorman 
et al. (1982). First, pilot assays were carried out to determine what time and amount of 
protein derived from reference sample psis-112/+43CAT would yield approximately 10% 
conversion of [14C]chloramphenicol after subtraction of the background CAT activity of 
pSuperCAT. These parameters were then used to determine the relative CAT activities of 
all other constructs. Radioactive spots were quantitated by measuring in a liquid 
scintillation counter, from which the percentage acetylated chloramphenicol could be 
determined. CAT values were corrected for background activity by subtracting the mean 
values of pSuperCAT. 
RESULTS 
Localization of cell-type-specifîc DH sites far upstream of the human c-sis gene 
DNA elements that are actively involved in regulation of transcription are usually 
located within nucleosome-free regions (Gross and Garrard, 1988). During our search for 
DNA sequences that could participate in regulation of transcription of the human c-sis 
gene, we examined the upstream region for the presence of DH sites. Therefore, we used 
a panel of human cell lines that express widely varying amounts of 3.5-kb c-sis mRNA 
(Fig. 1). Nuclei from these cell lines were isolated and treated with increasing amounts of 
DNase I. The chromosomal DNA was analysed by hybridization with probe PR12, which 
binds to an 8.1-kb Hindlll fragment between -3.7 kb and -11.8 kb relative to the 
transcription initiation site (Figs 1 and 2A). DH sites at -9.9 kb, -10.7 kb and -11.0 kb 
were induced upon TPA-mediated megakaryocyte differentiation of K562 cells. A DH site 
at -8.6 kb was found to be constitutively present in K562 cells independent of TPA 
treatment. All four sites were also found in PC3, HeLa, and T24 cells, which express 
various levels of 3.5-kb c-sis mRNA. In addition, these carcinoma-derived cell lines 
contain a DH site at -7.3 kb. Only two sites, at -8.6 kb and -9.9 kb, are detectable in 
dermal fibroblasts, while no DH sites are detectable in choriocarcinoma cell lines JEG-3 
and JAR (these cell lines express a 2.6-kb c-sis mRNA but not the 3.5-kb c-sis mRNA; 
Fig. 5). When we examined a 9.2-kb EcoRI fragment by means of probe PR3 (Figs 1 and 
2B), we could confirm the locations of the DH sites. Hybridization with probe PR13 (see 
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restriction map in Fig 1) did not reveal additional sites (data not shown). Fig. 1 
summarizes the chromatin structure far upstream of the c-sis gene in the cell panel. 
Functional analysis of DH sites located far upstream of the c-sis gene 
TPA-mediated megakaryocyte differentiation of K562 cells accompanies the strong 
and stable induction of transcription of the c-sis gene. Pech et al. (1989b) estimated the 
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increase in c-sis mRNA level to be at least 200-fold. However, in a reporter gene assay, 
activity of the c-sis promoter increases only by 15-30-fold upon TPA treatment (Pech et 
al., 1989b; Dirks et al., 1993a). Since DH sites at -9.9 kb, -10.7 kb and -11.0 kb are 
linked with the megakaryocyte phenotype of the K562 cells, we examined whether these 
sites could affect activity of the c-sis promoter. Therefore, we cloned a 6-kb ffi'ndlll-
BamUl fragment (fragment 10 in Fig. 1), which harbours all of the DH sites between -6 
kb and -12 kb, in two orientations upstream of the c-sis promoter in a CAT reporter gene 
vector. K562 cells were electropermeated with these constructs, upon which the cell 
suspension was divided into two equal portions. One portion was treated with TPA. 
Transcriptional activity of the constructs was determined by means of a CAT assay as 
described in Materials and methods. The CAT activity of the promoter construct 
psisl(s)CAT in either untreated or TPA-treated K562 cells was defined as 100%. The 
TPA-induced increase in promoter activity of psisl(s)CAT varied between 15-30-fold (see 
also Pech et al., 1989b; Dirks et al., 1993a). In addition (as is shown in Fig. 3), fragment 
10 increases activity of the c-sis promoter in untreated K562 cells by 20-30-fold, and in 
TPA-treated K562 cells by 6-10-fold (i.e. 90-300-fold relative to the psisl(s)CAT activity 
in untreated K562 cells). The activation of transcription occurs relatively independently of 
the orientation of fragment 10, which is typically for a classical transcriptional enhancer. 
We also tested the activity of fragment 10 in HeLa, PC3, and Hufi, all of which contain 
DH sites between -6 kb and -12 kb. Fragment 10 does not affect c-sis promoter activity in 
HeLa cells or Hufi. However, it causes a threefold increase in promoter activity in PC3 
9.2kb 
-9 .9 
-7.3 
9.2kb 
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cells, again in an orientation independent way (Fig. 3). In conclusion, fragment 10 
displays strong enhancer activity in both untreated and TPA-treated K562 cells, and acts 
as a weak enhancer in PC3 cells. 
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Fig. 3. Relative CAT activities (on a 
logarithmic scale) of lysates from cells 
electropermeated with the indicated c-
íií/CAT gene fusion constructs. 
Electropermeations, 0-galactosidase 
assays and CAT assays were performed 
as described in Materials and methods. 
Results were normalized to mean 0-
galactosidase activity obtained from 
simultaneously electropermeated 
pCHl lO. CAT activities were 
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[ , 4 C]chloramphenicol / t imc. For 
background correction, mean CAT 
activity of the promoterless construct 
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value Activities of all constructs are 
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activity of PS1S-112/+43CAT (R), 
which was defined as 100%. All data 
For all constructs (except 14(s/a) two 
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independent plasmid preparations were tested. SD are indicated by error bars 
112/+43CAT; 10-14, CAT constructs containing fragments 10-14 (Fig. 1) cloned in the sense or the 
antisense orientation upstream of the c-sis promoter in psis-112/+43CAT; n.d., not determined. 
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Transcriptional activators comap with DH sites at -8.6 kb and -9.9 kb 
In order to examine which DH site(s) corresponded with the transcriptional enhancer 
function, we divided fragment 10 into four subfragments (Fig. 1). Fragment 11 contains 
DH sites at -10.7 kb and -11.0 kb, and fragments 12 and 13 contain DH sites at -9.9 kb 
and -8.6 kb, respectively. Despite several efforts, we did not succeed in cloning fragment 
13 in the antisense orientation upstream of the c-sis promoter. Fragment 14 harbours a 
DH site at -7.3 kb which is specifically present in HeLa and PC3 cells. The relative CAT 
activities of the constructs are depicted in Fig. 3. The figure shows that fragments 12 and 
13 contain strong activators of the c-sis promoter. Fragment 12 increases promoter activity 
by 5-10-fold both in untreated and TPA-treated K562 cells and relatively independently of 
orientation. Fragment 13 increases c-sis promoter activity by more than 60-fold in 
untreated and by nearly 40-fold in TPA-treated K562 cells. These results indicate that a 
strong transcriptional activator comaps with a DH site at -8.6 kb, which is constitutively 
present in K562 cells. The transcriptional enhancer in fragment 12 comaps with DH at 
-9.9 kb in TPA-treated K562 cells, but not in untreated cells. This could mean that in the 
untreated cells putative activating transcription factors do not gain access to an enhancer 
element at -9.9 kb in vivo. 
Especially in TPA-treated K562 cells, "full length" fragment 10 has significantly 
lower enhancer activity than fragment 13. This may result from differences in distance 
between the activator and the c-sis promoter. However, we also found that fragment 11 
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down-regulates the promoter in TPA-treated cells by more than tenfold in the sense 
orientation and by fourfold in the antisense orientation (Fig. 3). This fragment harbours 
DH sites at -10.7 kb and -11 kb which are present in TPA-treated K562 cells. DH at these 
sites was not detectable in untreated K562 cells and, moreover, fragment 11 has no 
significant influence on c-sis promoter activity in the untreated K562 cells. These results 
indicate that inhibitory factors affect the activity of the c-sis promoter in a cell-type-
specific manner in TPA-treated K562 cells. The enhancer effect of fragment 10 may thus 
be the net effect of several activating and inhibitory elements located throughout this 
fragment. 
Although fragment 10 did not affect c-sis promoter activity in HeLa cells and 
fibroblasts and displayed only weak enhancer activity in PC3 cells, we were curious 
whether the individual subfragments would show biological activity in these cells. As is 
shown in Fig. 3, both fragment 12 and fragment 13 act as transcriptional enhancers in all 
three cell types. The enhancer effect of fragment 12 varies over 4-10-fold in these cells, 
which is comparable with the activity of this fragment in untreated and TPA-treated K562 
cells. However, the enhancer effect of fragment 13 is only 4-5-fold in these cells 
compared with approximately 40-60-fold in K562 cells. Fragment 11 does not detectably 
affect c-sis promoter activity in these cells, while fragment 14 displays weak (2-3-fold) 
enhancer activity in HeLa cells only. 
(An exon belonging to) a novel transcription unit is located close to the DH sites far 
upstream of the human c-sis gene and is expressed independently of the 3.5-kb c-sis 
transcript 
In a control experiment designed to check whether other transcription units were 
located in the neighbourhood of the DH sites far upstream of the human c-sis gene, we 
used four probes (fragment IV-VII in Fig. 4) from the region between -6 kb and -12 kb to 
perform Northern blot analysis on RNA from HeLa, PC3 and from undifferentiated and 
TPA-treated K562 cells. No transcript could be detected, even after long (two weeks) 
exposure. However, when we used fragment I (Fig. 4) as a probe we could readily detect 
a 0.45-kb transcript (Fig. 5). This transcript is expressed independently of the 3.5-kb c-sis 
mRNA (Fig. 5) and independently of the presence of DH sites between -6 kb and -12 kb 
(Fig. 2). When we used the 5' and 3' halves of fragment I as probes (fragments II and III 
in Fig. 4) only fragment II hybridized with the transcript (data not shown). Southern blot 
analysis of chromosomal DNA digested with ВатШ, Xbal, or EcoW, with fragment II as 
a probe, always revealed a single band of a size that corresponded with the genomic map 
of the human c-sis gene (data not shown). This indicates that the 0.45-kb transcript is 
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Fig. 4. Schematic overview of genomic probes I-VII which are derived from the c-sis gene upstream 
region and have been tested in Northern blot hybridizations. The black box indicates the location of 
genomic fragment II, that hybridizes with the 0.45-kb sur transcript. 
indeed derived from the sis upstream region. We propose to name this transcription unit 
sur, which stands for sis upstream region. The black box in Fig. 4 indicates the position 
of the sur exon relative to the c-sis transcription unit. 
DISCUSSION 
PDGF was originally isolated from blood platelets (Heldin et al., 1979; Antoniades 
et al., 1979), which are derived from bone marrow megakaryocytes. Blood platelets lack a 
cell nucleus and their phenotype is mainly determined by the transcriptional machinery of 
their precursor cells. The K562 cell line is derived from a patient with chronic myeloid 
leukemia and possesses both erythroid and megakaryoblastoid properties (reviewed by 
Alitalo, 1990). TPA specifically induces megakaryocyte differentiation of K562 cells, 
which is accompanied by a more than 200-fold increase in c-sis mRNA expression 
(Colamonici et al., 1986; Alitalo et al., 1987). The increase in c-sis mRNA is regulated at 
the transcription level and can be partly explained by a 15-30-fold increase in activity of 
the c-sis gene promoter (Colamonici et al., 1986; Pech et al., 1989b; Dirks et al., 1993a). 
The present results suggest that transcription regulatory elements located far upstream of 
the c-sis gene promoter may also play an important role in the megakaryocyte-specific 
expression of the human c-sis gene. We localized a strong transcriptional enhancer at 
approximately 8.6 kb upstream of the human c-sis gene transcription initiation site. This 
enhancer increases the activity of the c-sis gene promoter 40-60-fold in K562 cells. In 
both untreated and TPA-treated K562 cells the enhancer comaps with a DH site at -8.6 
kb. Additional DH sites at -9.9 kb, -10.7 kb and -11.0 kb are induced upon TPA-mediated 
megakaryocytic differentiation of K562 cells. A genomic fragment corresponding with DH 
at -9.9 kb has 5-10-fold enhancer activity and a fragment that contains DH sites at -10.7 
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Fig. 5. Comparison of expression of 
the 3.5-kb M B niRNA and the 0.45-
kb sur transcript. RNA derived from 
the indicated cells was subjected to 
Northern blot analysis: total RNA 
(TPA-treated K562 cells, 10 /xg; all 
other lanes, 30 itg) was hybridized with 
the 2-kb BamHl fragment of c-sis 
cDNA clone pSM-1, with genomic 
fragment II (see also Fig. 4) and with a 
28S rRNA probe, respectively. 
kb and -11.0 kb specifically down-regulates c-sis promoter activity by 4-10-fold in TPA-
treated K562 cells. In a CAT assay the enhancer corresponding with the DH at -9.9 kb is 
also active in untreated K562 cells, but this is not accompanied by DH in these cells. 
Possibly, CpG methylation renders the endogenous enhancer inaccessible for the activating 
protein(s). In T24, PC3 and HeLa cells, which show a DH at -10.7/-11.0 kb, the 
repressive effect of fragment 11 is not observed. This may indicate that the corresponding 
inhibitory transcription factor(s) is (are) inactive or absent in these cells. A 6-kb genomic 
fragment that maps between positions -12 kb and -6 kb combines all these DH sites. In 
untreated K562 cells this fragment shows only slightly weaker enhancer activity than the 
individual DH site at -8.6 kb. However, in TPA-treated K562 cells the fragment has 6-10-
fold enhancer activity, which may be the net result of competition between the enhancers 
at -8.6 kb and -9.9 kb and the silencer at -10.7/-11.0 kb. 
Fig. 6 summarizes the structural and functional analysis of the chromatin at the 
human c-sis gene transcription unit and its flanking regions in an extensive panel of human 
cell types (Dirks et al., 1993a; this article). In this figure biological activity of genomic 
fragments is only displayed if the activity comaps with DH. Although the present results 
do not directly prove that the cluster of DH sites between -11 kb and -7 kb is truely 
involved in megakaryocyte-specific activation of transcription of the c-sis gene in vivo, 
several features are in accordance with such a role. Firstly, the cell-type-specificity of the 
chromatin structure in this region is clearly illustrated by the complete absence of DH at 
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these sites in placenta cell lines JEG-3 and JAR (Figs 2A and 6). Regulation of 
transcription of the c-sis gene in placenta cytotrophoblasts may rather be mediated by 
elements located within c-sis intron 1 or immediately downstream of the gene (Franklin et 
al., 1991; Dirks et al., 1993a). Secondly, the combination of a strong transcriptional 
enhancer and a 15-30-fold increase in c-sis promoter activity can fully explain the more 
than 200-fold increase in c-sis mRNA level that accompanies TPA-induced 
megakaryocytic differentiation of K562 cells (Pech et al., 1989b). Depending on whether 
in vivo only the DH at -8.6 kb or the entire upstream cluster of DH sites is involved, the 
CAT assays predict a 100-1000-fold higher transcription rate from the c-sis gene 
promoter/enhancer in TPA-treated cells compared with the c-sis promoter in untreated 
cells. The high enhancer activity of the DH at -8.6 kb, together with the DH at that site in 
untreated K562 cells, are in contrast with the barely detectable expression level of the 3.5-
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Fig. 6. Structural and functional chromatin map of the human c-si's/PDGF В gene transcription unit 
and its flanking regions. DH sites are indicated by arrows. Thick arrows indicate very pronounced DH 
sites P, promoter; E, enhancer; S, silencer; small-size, medium-size and large size E and S indicate 2-3-
fold, 3-10-fold and >10-fold enhancer or silencer activity, respectively. E-, E + , S- and S+ indicate that 
the enhancer (E) or silencer (S) effect was only observed when the corresponding genomic fragment was 
cloned in the antisense (-) or in the sense (+) orientation upstream of the c-su promoter. A brace indicates 
that more than one DH site comaps with a genomic fragment that shows biological activity in a reponer 
gene assay The relative expression level of the 3.5-kb c-sis mRNA is indicated in correspondence with 
Fig. 1. Sites downstream of -2 kb were described previously (Dirks et al., 1993a). 
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kb c-sis mRNA in these cells. Possibly, the activity of the enhancer is relieved by two 
strong silencers located within c-sis intron 1 (Fig. 6). This is further supported by the fact 
that two DH sites that also map within intron 1 disappear upon megakaryocyte 
differentiation (Dirks et al., 1993a). Thirdly, the DH at -8.6 kb shows 40-60-fold 
enhancer activity specifically in K562 cells. It also enhances promoter activity in HeLa, 
PC3 and Hufi cells, but only by 4-5-fold. Moreover, the 6-kb genomic fragment (-12/-6 
kb) does not detectably affect c-sis promoter activity in HeLa and Hufi cells and retains 
only 3-fold enhancer activity in PC3 cells. 
In PC3 cells, low enhancer activity of the 6-kb genomic fragment may contribute to 
the high expression level of the 3.5-kb c-sis mRNA compared with, for example, HeLa 
cells. Earlier, we showed that cell-type-specific activity of a transcriptional activator 
downstream of the c-sis gene and of a transcriptional inhibitor within intron 1 may also 
explain the expression levels in these cells (Fig. 6; Dirks et al., 1993a). Although the 
CAT assays show that the 6-kb fragment has low or negligible activity in HeLa, PC3 and 
Hufi cells, the individual DH sites at -9.9 kb and -8.6 kb show 4-10-fold and 4-5-fold 
enhancer activity, respectively, in all three cell-types. Whether the individual DH sites 
play an active role in vivo in these cells cannot be concluded at this moment. In fact, DH 
may reflect the active state of putative transcription regulatory elements at these sites. 
In Hufi, the presence of two active enhancers may have important consequences. 
Reporter gene analysis showed that the c-sis promoter has relatively high activity in Hufi 
(Dirks et al., 1993a). The absence of c-sis mRNA in these cells probably results from 
epigenetic mechanisms, such as specific nucleosome phasing or CpG methylation (Dirks et 
al., 1993a). Disturbing the negative regulation of the c-sis gene in Hufi may immediately 
result in activation of the promoter, which, in combination with the upstream enhancers, 
may quickly cause a high expression level of c-sis mRNA. PDGF is a potent mitogen for 
fibroblasts and overexpression of normal PDGF В chains induces cellular transformation 
of NIH 3T3 cells (Clarke et al., 1984; Gazit et al., 1984). Pech et al. (1989a) showed that 
a recombinant retrovirus that expresses high levels of normal c-sis mRNA induces 
fibrosarcomas in mice. Likewise, the combination of transcriptional enhancers and a 
deregulated c-sis promoter may, via an autocrine loop, play a role in the etiology of 
fibrosarcomas. The localization of DH sites at -9.9 kb and -8.6 kb in human fibrosarcoma 
cell line HT-1080 (data not shown) supports this hypothesis. 
Control Nothern blot hybridizations designed to check whether the DH sites between 
positions -11.0 kb and -7.0 kb could belong to another gene led to the localization of (part 
of) a transcription unit at approximately -13 kb relative to the c-sis gene transcription start 
site. A genomic fragment derived from this site hybridizes with a 0.45-kb transcript that 
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we named sur (after sis upstream region). The sur transcript is constitutively expressed in 
all human cell-types examined thus far (see e.g. Fig. 5). The expression pattern of the sur 
transcript does not match with either the pattern of DH sites between -11.0 kb and -7.0 kb 
or the pattern of expression of the 3.5-kb c-sis mRNA. Therefore, there is no indication 
that these DH sites play a role in regulation of the sur gene. 
The human c-sis gene is specifically expressed in very diverse cell-types, such as 
placental cytotrophoblasts (Goustin et al., 1985), bone marrow megakaryocytes (Gladwin 
et al., 1990), vascular endothelial cells (DiCorleto and Bowen-Pope, 1983) and smooth 
muscle cells (Seifert et al., 1984). Previous studies indicated that the amount of 3.5-kb c-
sis mRNA is mainly regulated at the transcription level (Colamonici et al., 1986; Daniel 
and Fen, 1988; Kavanaugh et al., 1988; Press et al., 1988; Harsh et al., 1989; Dirks et 
al., 1993a). However, the mechanisms that regulate the cell-type-specific transcription of 
the human c-sis gene are only poorly understood. Earlier, we suggested that at least three 
different mechanisms are involved in regulation of transcription of the c-sis gene (Dirks et 
al., 1993a): accessibility of the transcriptional promoter; expression of transcription 
factors that activate the promoter; cell-type-specific usage of transcription regulatory 
elements located outside the promoter. In the present paper, the last aspect is highlighted. 
The chromatin map in Fig. 6 indicates that several transcription regulatory elements that 
are located outside the promoter may be actively involved in regulation of transcription of 
the c-sis gene. Fine mapping of the transcription regulatory DNA elements within the DH 
sites and characterization of the proteins with which they interact will be necessary in 
order to understand how these DH sites affect the activity of the c-sis gene promoter. 
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Chapter 4 
In vivo footprinting and functional analysis of the human c-sis/PDGF В gene 
promoter provides evidence for two binding sites for transcriptional activators 
Ron P.H. Dirks, Hans J. Jansen, Bart van Gerven, Carla Onnekink and 
Henri P.J. Bloemers 
Nucleic Acids Res. 23, 1119-1126 (1995) 
SUMMARY 
By in vivo DMS footprint and reporter gene analyses we identified two transcription 
factor binding sites in the human с-ш/PDGF В gene promoter. The low basal activity of 
the PDGF В promoter in HeLa and undifferentiated K562 cells, which express low PDGF 
В mRNA levels, and in PC3 cells, which express a high PDGF В mRNA level, results 
from binding of a weak transcriptional activator between positions -64 bp and -61 bp 
relative to the transcription start site. Cytotrophoblast-like JEG-3 cells, which do not 
express the 3.5 kb PDGF В mRNA, contain a transcriptional activator directed at the 
-64/-61 bp sequence, but DNA methylation may render the endogenous promoter 
inaccessible to this activator. A CCACCCAC element at position -61/-54 bp was identified 
as the in vivo binding site for a strong transcriptional activator in phorbol ester-treated 
megakaryocyte K562 cells, which express a high PDGF В mRNA level. Primary human 
fibroblasts, which do not transcribe the PDGF В gene, contain a transcriptional activator 
that recognizes an element between positions -60 bp and -45 bp but does not bind to the 
endogenous unmethylated promoter. Our results show that the complex expression pattern 
of the human PDGF В gene involves the cell type-specific expression of weak and strong 
transcriptional activators and regulation of promoter accessibility to these factors. 
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INTRODUCTION 
Platelet-derived growth factor (PDGF) is a collective term for the three dimeric 
proteins that can be constituted out of type A and/or type В polypeptide chains. The 
human PDGF A and В chain precursors are encoded by two homologous genes located on 
chromosomes 7 (Betsholtz et al., 1986) and 22 (Dalla Favera et al., 1982; Swan et al., 
1982), respectively. The В chain gene is identical to the c-sis proto-oncogene (Chiù et al., 
1984; Johnsson et al., 1984; Josephs et al., 1984a). PDGF is a potent growth factor and 
chemo-attractant for cultured cells of mesenchymal origin, such as fibroblasts (Kohier and 
Lipton, 1974; Seppä et al., 1982) and smooth muscle cells (Ross et al., 1974; Grotendorst 
et al., 1981). Expression of PDGF is tightly regulated in a cell type- and developmental-
stage-specific manner and is thought to play a role in wound healing and early 
development (reviewed in Ross et al., 1986). PDGF is synthesized in bone marrow 
megakaryocytes (Vinci et al., 1984; Gladwin et al., 1990) and stored within α-granules of 
platelets, from which it is released during the clotting process (Kaplan et al., 1979). Other 
examples of cell types that express PDGF are vascular endothelial (Dicorleto and Bowen-
Pope, 1983) and smooth muscle cells (Seifert et al., 1984), placental cytotrophoblasts 
(Goustin et al., 1985), macrophages (Shimokado et al., 1985) and activated monocytes 
(Martinet et al., 1986). Depending on the cell type, expression of PDGF can be affected 
by very diverse extracellular stimuli, such as transforming growth factor /3 (Leof et al., 
1986), hypoxia (Kourembanas et al., 1990) and shear stress (Hsieh et al., 1991). 
Via autocrine and/or paracrine pathways aberrant expression of PDGF may play a 
role in the etiology of atherosclerosis, fibrosis and certain types of cancer (reviewed in 
Ross et al., 1986). Whereas the PDGF A chain has only weak transforming activity, over-
expression of normal PDGF В chains induces transformation of NIH 3T3 cells with high 
efficiency (Clarke et al., 1984; Gazit et al., 1984; Josephs et al., 1984b; Beckmann et al., 
1988). The long and GC-rich leader of the PDGF В transcript can act as a potent 
translational inhibitor (Ratner et al., 1987; Rao et al., 1988). However, if transcription of 
the PDGF В gene is driven by a sufficiently strong promoter such as the SV40 early 
promoter/enhancer, the leader sequence does not prevent development of fibrosarcomas in 
mice (Pech et al., 1989a). Upon transfection of PDGF В cDNA into NIH 3T3 cells the 
acquisition of features of transformation was shown to correlate directly with the 
expression level of PDGF В mRNA (MacArthur et al., 1992). Modulation of the 
transcription rate is an obvious mechanism by which the expression level of the PDGF В 
chain under normal and pathological conditions could be regulated. 
Since localization of the transcription start site of the human PDGF В gene (Van den 
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Ouweland et al., 1986) only little progress has been made in understanding regulation of 
transcription of the gene. An attractive model system in which to study regulation of the 
PDGF В promoter is the human erythroleukemia cell line K562. Upon treatment with the 
phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) K562 cells differentiate to 
megakaryocytes (Colamonici et al., 1986), which is accompanied by a >200-fold increase 
in PDGF В mRNA content (Pech et al., 1989). The induction of PDGF В mRNA is at the 
transcriptional level (Colamonici et al., 1986) and is dependent on de novo protein 
synthesis (Pech et al., 1989b). In previous studies, DNA elements that may regulate 
activity of the PDGF В gene promoter during TPA-mediated differentiation of K562 cells 
were mapped by reporter gene analyses and gel retardation assays (Pech et al., 1989b; Jin 
et al., 1993). The first 72 bp upstream of the transcription start site were found to be 
sufficient for minimal promoter activity in untreated K562 cells (Pech et al., 1989b). 
Regions between positions -101 bp and -58 bp (Pech et al., 1989b), and -64 bp and -39 bp 
(Jin et al., 1993) were reported to be essential for TPA inducibility of the PDGF В 
promoter. In gel retardation assays, both regions were shown to interact specifically with 
nuclear proteins from K562 cells and some complexes correlated with TPA-mediated 
megakaryocyte differentiation (Pech et al., 1989b; Jin et al., 1993). A recent reporter 
gene analysis revealed that an AP-1-like sequence between -92 bp and -85 bp and an ETS-
like sequence between -80 bp and -70 bp relative to the major transcription start site are 
required for maximal activity of the PDGF В promoter in cultured vascular endothelial 
cells. An Spl-like sequence between -61 bp and -56 bp appeared to be required for basal 
PDGF В promoter activity in endothelial cells and was shown to interact with purified Spi 
in a DNase I footprint experiment (Khachigian et al., 1994). Reporter gene analysis of the 
PDGF В promoter in human osteosarcoma cell line U2-OS indicated that regions between 
-244 bp and -203 bp, -102 bp and -95 bp, and -63 bp and -44 bp relative to the 
transcription start site contain positive regulatory elements. By gel retardation analysis the 
-63/-44 bp sequence was shown to interact in vitro with an Spl-like factor present in 
nuclear extracts derived from U2-OS cells (Jin et al., 1994). In the studies that have been 
described thusfar, interactions between PDGF В promoter sequences and nuclear proteins 
have always been examined by reporter gene analysis and in vitro DNA binding 
experiments. However, in living cells the PDGF В promoter is part of a specific 
chromatin structure, which is not maintained in the in vitro experiments. Therefore, DNA-
protein interactions that were mapped in vitro may not always reflect the interactions that 
actually occur at the endogenous gene. We decided to try to map the actual protein 
binding sites at the PDGF В promoter in a diverse panel of human cell types by in vivo 
dimethyl sulfate (DMS) footprinting, which has become more readily applicable by the 
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development of the ligation-mediated polymerase chain reaction (LMPCR) (Mueller and 
Wold, 1989). To complement the in vivo footprint results with functional data, we also 
mapped transcription regulatory elements by reporter gene analysis of the PDGF В 
promoter. The combined results enable us to accurately map two transcription regulatory 
elements within the PDGF В gene promoter that are recognized by activating transcription 
factors in vivo in a cell-type-specific manner. 
Previous studies provided evidence for negative regulation of the PDGF В promoter: 
in cultured dermal fibroblasts and cytotrophoblast-like JEG-3 cells the PDGF В gene 
promoter is active in a reporter gene assay, whereas these cells do not detectably express 
the corresponding PDGF В transcript (Pech et al., 1989b; Franklin et al., 1991; Dirks et 
al., 1993a). Recently, we showed that the PDGF В promoter is not hypersensitive to 
DNase I in these cells and that nucleosome phasing may play a negative transcription 
regulatory role in fibroblasts. In addition, we mapped silencer elements within intron 1 
and downstream of the gene that may suppress activity of the promoter in JEG-3 cells 
(Dirks et al., 1993a). To examine a potential role for DNA methylation in regulating 
promoter activity we analysed the chromosomal methylation status at the PDGF В 
promoter by genomic sequencing (Church and Gilbert, 1984; Pfeifer et al., 1989) and 
restriction enzyme analysis. 
MATERIALS AND METHODS 
Cell culture 
Cell lines K562, JEG-3, HeLa and PC3 were all from the American Type Culture 
Collection (Rockville, MD). Primary human dermal fibroblasts (Hufi) were derived from 
fresh foreskin biopsies, which were a kind gift of the Department of Surgery (University 
Hospital, Nijmegen). Cells were grown in Dulbecco's modified Eagle's medium 
supplemented with 10% fetal calf serum and 125 U/ml streptomycin and 125 U/ml 
penicillin. Megakaryocytic differentiation of K562 cells was induced by addition of TPA 
(Sigma) to the culture medium (final concentration, 2 ng/ml). 
Reporter gene constructs 
All recombinant DNA constructs were made according to standard protocols 
(Sambrook et al., 1989). psis-112/+43CAT and psis-1758/+43CAT have been described 
earlier (Dirks et al., 1993a). psis-425/+43CAT was made by Aval digestion and 
subsequent recircularization of psis-1758/+43CAT. Unidirectional deletion mutants of 
Avail'Sstl linearized psis-425/+43CAT (Figure 1A) were made with exonuclease III 
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according to the technical manual of the Erase-a-Base System (Promega): mutants that 
were to be tested in a reporter gene assay were characterized by dideoxy sequence 
analysis (Sanger et al., 1977). psis-112/ + 18CAT was made by religation of the 130 bp 
Pstl fragment of psis-112/+43CAT into Ptfl-linearized psis-112/+43CAT (this results in 
the deletion of an internal 28 bp Pstl fragment). psis-112/ + 18mutaCAT was made as 
follows. The 130 bp Pstl fragment of psis-112/ + 18CAT was cloned into the Pstl site of 
pGEM3-Zf(-) (Promega) and ssDNA was isolated. A 24-bp oligonucleotide primer [5'-
d(GAG GTG GGT GAT АТС AGC CTT TCC)-3'] was used for site-directed-mutagenesis 
according to the Amersham protocol of the Oligonucleotide-Directed In Vitro Mutagenesis 
System Version 2 (Amersham). Dideoxy sequence analysis revealed that mutagenesis had 
resulted in a C-»A change at position -63 and the insertion of an A residue between 
positions -64 and -65 (data not shown). The mutated 130 bp Pstl fragment was recloned 
into the vector part of ΛίΙ-digested psis-112/+43CAT. pSuperCAT is a promoterless 
chloramphenicol acetyltransferase (CAT) gene vector. pCHHO (Pharmacia LKB) contains 
the /3-galactosidase gene driven by the SV40 promoter. 
Electropermeations and CAT assays 
Supercoiled plasmid DNA was purified by CsCl gradient centrifugation (Sambrook 
et al., 1989) and quantitated by means of both ethidium bromide staining and 
spectrophotometric measurement. Cells (3-5 χ IO7) were electropermeated with 10 μ% 
pCHHO and 10 pmol CAT construct as previously described (Dirks et al., 1993a). All 
cells except K562 were harvested 24-48 h after electropermeation. Immediately after 
electropermeation, K562 cells were divided equally over two dishes. TPA was added to 
one dish and 24 h later both undifferentiated and TPA-treated cells were harvested. Cell 
lysates were prepared (Sambrook et al., 1989) and the protein content of each Iysate was 
determined in a protein assay (BioRad). Fixed amounts of protein were tested for /3-
galactosidase activity (Edlund et al., 1985) and, subsequently, amounts of protein 
corresponding to equal /ï-galactosidase activity were assayed for CAT activity (Gorman et 
al., 1982). First, pilot assays were carried out to determine what time of incubation and 
amount of protein derived from reference sample psis-112/+43CAT would yield -20% 
conversion of [14C]chloramphenicol after subtraction of the background CAT activity of 
pSuperCAT. These parameters were then used to determine the relative CAT activities of 
all other constructs. Radioactive spots were quantitated by measuring in a liquid 
scintillation counter, from which the percentage acetylated chloramphenicol could be 
determined. CAT values were corrected for background activity by subtracting the mean 
values of pSuperCAT. 
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In vivo footprinting 
Monolayers of PC3, HeLa and Hufi cells were cultured to subconfluence on 15 cm 
dishes. The tissue culture medium was replaced by medium containing 0.1% dimethyl 
sulfate (DMS). After an incubation of 2 min at 37°C, the DMS-containing medium was 
quickly aspirated and cells were washed four times with phosphate-buffered saline (PBS) 
at 37°C. Cells were harvested in lysis solution (300 mM NaCl, 50 mM Tfis-HCl, pH 8.0, 
25 mM EDTA, 0.2% SDS, 200 μg/ml proteinase K) at 1.5 ml/15 cm dish and incubated 
overnight at 37 °C. To induce megakaryocyte differentiation, K562 cells were cultured in 
the presence of 2 ng/ml TPA for 5 before DMS treatment. Suspensions of untreated and 
TPA-treated K562 cells (3-5 χ 10s cells/ml) were centrifuged (5 min, 500 χ g, room 
temperature) and the cell pellet was resuspended in culture medium at 5 χ IO7 cells/ml. 
DMS was added to 0.1% and after a 1 min incubation at 37CC, the DMS-containing 
medium was diluted with 50 vol ice-cold PBS. Cells were quickly centrifuged (5 min, 500 
χ g, 4°C) and the cell pellet was washed three times with ice-cold PBS. Cells were 
resuspended in lysis solution at 2 χ 107 cells/ml and incubated overnight at 37 °C. 
Chromosomal DNA from all DMS-treated cells was further purified by repeated 
extractions with phenol, chloroform and diethyl ether. Subsequently, the DNA was 
precipitated with ethanol and dissolved in 10 mM Tris-HCl, pH8.0, 1 mM EDTA (TE). 
DMS methylation of control protein-free chromosomal DNA and piperidine cleavage of in 
vivo and in vitro methylated DNA at sites of modified guanine residues were performed 
according to Maxam and Gilbert (1980). Piperidine was removed by lyophilization and the 
DNA dissolved in 0.3 M sodium acetate pH 7.0. The DNA was ethanol precipitated 
repeatedly and finally dissolved in water. Trace amounts of piperidine were removed by 
lyophilization and the DNA was redissolved in TE at 0.4 /ig/ml. 
Genomic footprinting was done by means of LMPCR as described by Mueller and 
Wold (1989) and modified by Garrity and Wold (1992). The PDGF В promoter-specific 
primers l(s), 2(s) and 3(s), respectively [5'-d(CAT GGA CTG AAG GGT TGC TC)-3'], 
[5'-d(CTC TCA GAG ACC CCC TAA GCG CCC C)-3'] and [5'-d(AGA CCC CCT 
AAG CGC CCC GCC CTG G)-3'], were used for analysis of the lower strand. Primers 
1(a), 2(a) and 3(a), respectively [5'-d(CGC AAA GTA TCT СТА TCT AGG GAA)-3'], 
[5'-d(TAG GGA ATG AAA ATG GGC GCT GGC)-3'] and [5'-d(GGA ATG AAA AAT 
GGG CGC TGG CGG C)-3'] were used for the upper strand. For first strand synthesis, 2 
μg DMS/piperidine-treated DNA was annealed to primer l(s/a) at 60°C. During the PCR 
amplification (18 cycles), annealing of primer 2(s/a) was at 72°C. Annealing of the 
labeling primer 3(s/a) was at 74°C. First strand synthesis, PCR amplifications and 
labeling reactions were done using Thermococcus litoralis DNA polymerase (Vent; New 
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England Biolabs). Labeling reaction mixtures were electrophoresed on 6% sequencing 
gels. Gels were dried and exposed to X-ray film with two intensifying screens. The 
footprinting data were quantified by scanning the autoradiograms with a densitometer 
(Kipp & Zonen, Delft, The Netherlands). Nucleotide sequence markers were generated by 
dideoxy sequence analysis (Sanger et al., 1977) of human c-sis subclone pA0121 (Van 
den Ouweland et al., 1985). 
DNA methylation analysis 
Chromosomal DNA was isolated according to standard protocols (Sambrook et al., 
1989). Chromosomal DNA (-20 ^g) was digested with ЕсоШ and BamUl and 
subsequently with either Mspl or Hpall. Mspl and Hpaïl digestions were monitored by 
adding small aliquots of the digestion mixtures to undigested phage λ DNA. Upon 
complete digestion of the λ DNA, the chromosomal DNA samples were electrophoresed 
in a 1% agarose gel and transferred to a Hybond-N+ filter (Amersham, UK). DNA was 
hybridized overnight in 0.9 M NaCI, 50 mM sodium phosphate, 5 mM EDTA, pH 7.7, 
0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrollidone, 0.5% SDS, 20 
/tg/ml herring sperm DNA at 68°C with 32P-labeled probe PR16 (Dirks et al., 1993a; 
Feinberg and Vogelstein, 1983). Filters were washed at 68°C in 18 mM NaCI, 1 mM 
sodium phosphate, 0.1 mM EDTA, pH 7.7, 0.1% SDS and then exposed to X-ray film 
with two intensifying screens. 
For genomic sequencing, chromosomal DNA was treated with hydrazine in the 
presence of 1.5 M NaCI (Maxam and Gilbert, 1980). Piperidine cleavage, DNA 
purification and LMPCR were done as described above for in vivo DMS footprinting. 
Nucleotide sequence markers were generated by dideoxy sequence analysis (Sanger et al., 
1977) of human c-sis subclone pA0121 (Van den Ouweland et al., 1985). 
RESULTS 
Functional analysis of the human PDGF В promoter reveals cell type-specific 
transcription regulatory elements 
Earlier we showed that in a panel of human cell lines (listed in Fig. 5) the activity of 
the first 112 bp upstream of the PDGF В transcription start site does not differ 
significantly from the activity of the first 1758 bp upstream of that site (Dirks et al., 
1993a). To map the transcription regulatory elements within the 112 bp region in more 
detail, we prepared a set of unidirectional deletion mutants fused to the CAT reporter gene 
(depicted in Fig. 1A). The deletion mutants were tested for promoter activity in the same 
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panel of human cell lines that differ in level of PDGF В mRNA expression (see also Fig. 
5), namely untreated and TPA-treated (i.e. megakaryocytic) K562 cells, Hufi, 
cytotrophoblast-like JEG-3 cells and carcinoma-derived HeLa and PC3 cells. Culturing of 
K562 cells in the presence of TPA has already been shown to result in 15-30-fold 
increased activity of the 112-bp fragment after 24 h (Fig. 5; Dirks et al., 1993a). 
Therefore, data for untreated and TPA-treated K562 cells are presented in separate 
diagrams. Fig. IB shows that deletion up to position -64 does not significantly lower 
promoter activity, except for a slight decrease in JEG-3 cells. In TPA-treated K562 cells 
the 64 bp fragment displays > 4-fold increased activity compared with the 112-bp 
fragment. Further deletion up to position -60 results in > 5-fold decreased activity in PC3, 
HeLa, JEG-3 and untreated K562 cells compared with the activity of the 64-bp fragment, 
but does not significantly affect activity in TPA-treated K562 cells and in fibroblasts. 
Deletion up to position -44 leads to 10- and 3-fold decreased promoter activity in TPA-
treated K562 cells and fibroblasts, respectively, compared with the activity of the 60-bp 
fragment. A 36-bp promoter fragment, which extends to 6 bp upstream of the TATA box, 
displays near background activity in all cell lines tested. The results suggest that sequences 
located between positions -64 bp and -60 bp are required for activity of the PDGF В 
promoter in PC3, HeLa, JEG-3 and untreated K562 cells, but not in fibroblasts and TPA-
treated K562 cells. In these last two cell types sequences located between positions -60 bp 
and -44 bp appear to be indispensable for promoter activity. 
To provide unequivocal proof for the cell type-specific activity of the -64/-61 bp 
region site-directed mutagenesis was performed, which resulted in a C-»A change at 
position -63 and the insertion of an A residue between positions -64 bp and -65 bp. The 
necessary cloning steps inevitably resulted in deletion of a small downstream fragment 
located between positions +19 bp and +43 bp (see Materials and methods). Therefore, 
we also tested whether the +19/+43 bp region might affect reporter gene activity. As can 
be seen in Table I, the minor change in the -64/-61 bp region reduces activity of the 
PDGF В promoter to background levels in untreated K562 cells and PC3 cells and by 
> 5-fold in JEG-3 cells. However, it does not affect promoter activity in TPA-treated 
K562 cells, which is in agreement with the deletion mutant analysis. In addition, the 
results show that the +19/+43 bp region is dispensable for activity of the PDGF В 
promoter. The combined results from the reporter gene assays enable us to map two 
transcription activating elements. The first element harbours (part of) the -64/-61 bp 
region and is essential for promoter activity in PC3, HeLa, untreated K562 and JEG-3 
cells, whereas the second element is located between positions -60 bp and -44 bp and is 
required for promoter activity in TPA-treated K562 cells and fibroblasts. 
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Fig. 1. Reporter gene analysis of unidirectional deletion mutants of the human PDGF В gene 
promoter. (A) Schematic overview of PDGF В promoter deletion mutants Unidirectional deletion mutants 
were generated as described in Materials and methods Numbers indicate the positions of PDGF В 
sequences relative to the transcription start site The transcription start site is marked by an arrow (B) 
Relative CAT activities of lysates from cells electropermeated with the indicated PDGF В gene promoter 
deletion mutants Cells were electropermeated with a mixture of pCHHO and a deletion mutant Ahquots of 
lysate normalized to mean /3-galactosidase activity were tested for CAT activity CAT activities were 
determined as percentage acetylated [,4]chloramphenicol/time For background correction, mean CAT 
activity of the promoterless construct pSuperCAT was subtracted from each value For each cell type, the 
activity of psis-112/+43CAT was defined as 100% K562 cells cultured m the absence or presence of TPA 
are presented as two separate cell types Activities of deletion mutants are indicated as values relative to the 
activity of PS1S-U2/+43CAT All data are means from four to six independent electropermeations SD are 
indicated by error bars 
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In vivo DMS footprinting reveals protein binding sites in the human PDGF В promoter 
that co-map with the transcription activating elements 
Transient reporter gene assays are a powerful means to reveal the presence of 
transcription factors and to map transcription regulatory DNA elements. However, as the 
methylation status and chromatin structure at the promoter in the reporter gene construct 
may differ significantly from the situation at the endogenous promoter, the assays may 
provide an artifactual view of the promoter in situ. To study the PDGF В promoter 
directly in the living cell, we performed in vivo DMS footprint analyses in fibroblasts, 
untreated and TPA-treated K562 cells, HeLa cells and PC3 cells according to the method 
of Mueller and Wold (1989). In HeLa, PC3 and both untreated and TPA-treated K562 
cells methylation at G-61 in the lower strand was increased by 2-3-fold compared with the 
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Table I. Effect of site-directed-mutagenesis on PDGF В promoter activity. See legend to Figure IB for 
details, except that CAT activity of psis-112/ + 18CAT was defined as 100%. All data are presented as 
means ± SD of two to four independent electropermeations. Only the PDGF В promoter sequences present 
in the CAT constructs are indicated. 
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Fig. 2. In vivo DMS footprint analysis of the human PDGF В gene promoter. Open boxes indicate sites 
of hypomethylation and closed boxes sites of hypermethylation. Numbers indicate the positions of the G 
residues relative to the transcription start site. Nucleotide sequence markers were generated by dideoxy 
sequence analysis of human c-sis subclone pA0121 (Van den Ouweland et al., 1985). G residues in the 
genomic footprint lanes correspond with the complementary С residues in the nucleotide sequence ladders. 
(A) lower strand; (B) upper strand. 
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naked DNA lane (Fig. 2A). Enhanced methylation was sometimes observed at G-63 in 
PC3 and untreated K562 cells, but was never as pronounced as at G-61. In the same 
strand methylation at G-l was increased by 300% in PC3 and TPA-treated K562 cells and 
by nearly 200% in HeLa cells. In addition, methylation of all G residues from position 
-60 to -54 in the lower strand was decreased by almost 70% in TP A treated K562 cells. In 
the upper strand, we detected 2-3-fold increased methylation at G-2 in PC3 and TPA 
treated K562 cells (Fig. 2B). The hypermethylation at G-61 in untreated K562, HeLa and 
PC3 cells co-maps with the -64/-61 bp element that was identified in the reporter gene 
assays. Similarly, the footprint at -61/-54 bp in TPA-treated K562 cells corresponds with 
the -60/-45 bp element found in the reporter gene assays. No DMS footprint was found in 
fibroblasts, suggesting that the PDGF В promoter does not interact with transcription 
factors in vivo in these cells. The enhanced methylation close to the transcription start site 
in PC3, HeLa and TPA-treated K562 cells could not be directly linked to a functional 
element and may result from the binding of basal transcription factors. 
< 
-a 
Φ 
JX t o 
В 
upper strand 
A G С Τ 
ι Я, **«"*"· 
00Щ 
Шиш 
Я Д 
"*"" "'nfü * 
ШЩ*.-•'••••••* ****"" 
flp 
MWÊÈ 
*-"· 
р 
фртгі 
σ о 
С Q_ 
*** 
., 
• 
I f 
pi m 
II 
A G С Τ 
-а. 
іг-
Q 
" О 
CD 
^ г 
σ 
с= 
M — 
=J 
TL 
СчІ 
и з 
L D 
ъи 
σ 
ι 
ω 
-χ. 
Ю 
ο 
Q _ 
<r 
η 
ι — 
+ 
CM 
t o 
LT) 
Ъ£ 
G-61 
G-2 
95 
< 
CL 
CM CN | 
<X5 t O CD 
A G С Τ S £ ^ A G С Τ 
D-20 
D-48 
D-85 
D-94 
D-20 
D-48 
D-85 
D-94 
Fig. 3. Genomic sequence analysis of CpG dinucleotides within the human PDGF В gene promoter. 
Genomic DNA from the indicated cell types was subjected to (unmethylated) C-pecific DNA modification 
with hydrazin. The modified DNA was broken by piperidine and the resulting fragments were amplified by 
means of LMPCR using primers l(s), 2(s) and 3(s). The genomic sequence lanes show the С residues in 
the lower strand of the PDGF В promoter, which correspond with the complementary G residues in the 
dideoxy sequence ladders. CpG dinucleotides (indicated by open squares) are numbered after their positions 
relative to the transcription start site. Nucleotide sequence ladders were generated by dideoxy sequence 
analysis of c-sis subclone pA0121 (Van den Ouweland et al., 1985). 
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Fig. 4. Restriction enzyme analysis of the methylation status of the human PDGF В gene promoter. 
(A) Mspl restriction sites near the transcription start site of the human PDGF В gene promoter (Van den 
Ouweland et al., 1986). Numbers indicate the positions (bp) relative to the transcription start site. M, Mspl; 
E, EcoRl; P, Pvull; B, BamHl. The open box indicates the location of genomic probe PR16 (Dirks et al., 
1993a). The Mspl site at -85 bp relative to the transcription start site is marked by an asterisk. (B) Southern 
blot analysis of genomic DNA (20 μ% per lane) derived from HeLa (1), K562 (2), K562 + 1 day TPA (3), 
K562 + 5 days TPA (4), human fibroblasts (5), PC3 (6), and JEG-3 (7). The DNA was predigested with 
EcoRl and BamHl alone (-) or with EcoRl and BamHl and subsequently Pvull (P), Hpall (H) or Mspl (M). 
The DNA was hybridized with genomic probe PR16 (see also Fig. 4A). 
DNA methylation may inhibit accessibility of the human PDGF В promoter in JEG-3 
cells, but not in fibroblasts, HeLa and K562 cells 
Fibroblasts and JEG-3 cells express transcriptional activators of the PDGF В 
promoter, despite the absence of corresponding PDGF В mRNA in these cells (Pech et 
al., 1989b; Franklin et al., 1991; Dirks et al., 1993a; this paper). To examine whether 
DNA methylation could play a negative regulatory role in these cells or in HeLa and 
untreated K562 cells, which express very low levels of PDGF В mRNA, we analysed the 
chromosomal methylation status at the PDGF В promoter. Genomic sequencing analysis 
reveals that the CpG dinucleotides at positions -20, -48, -85 and -94 are heavily 
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methylated in JEG-3 cells, whereas they are unmethylated in fibroblasts and in untreated 
and TPA-treated K562 cells (Fig. 3). These results are in full accordance with an 
isoschizomer experiment focussing on the chromosomal methylation status of a 
representative Mspl site at position -85 of the PDGF В promoter (Fig. 4A). Chromosomal 
DNA was pre-digested with ZscoRI and ВатШ, and subsequently with either Mspl or its 
methylation-sensitive isoschizomer Hpall. As can be seen in Fig. 4B, the Mspl site at -85 
bp is unmethylated in fibroblasts, HeLa and untreated K562 cells, as well as in PC3 and 
TPA-treated K562 cells, which express high levels of PDGF В mRNA. Only in JEG-3 
cells are most of the Mspl sites within the PDGF В promoter and the 5'-part of exon 1 
heavily methylated. In conclusion, these results do not support a role for CpG methylation 
in regulating activity of the PDGF В promoter in fibroblasts, HeLa and untreated K562 
cells. However, DNA methylation may inhibit activity of the PDGF В promoter in JEG-3 
cells. 
DISCUSSION 
By in vivo DMS footprint analysis and transient reporter gene assays (summarized in 
Fig. 5) we have demonstrated that the first 64 bp upstream of the human C-ÍIÍ/PDGF В 
gene transcription start site contain two specific binding sites for transcriptional activators. 
A transcriptional activator expressed in HeLa, РСЗ and untreated K562 cells recognizes an 
element containing at least part of the TCTC sequence at position -64/-61 bp. This is 
supported by the observation that unidirectional deletion of the -64/-61 bp region reduces 
promoter activity in a reporter gene assay to near background levels in all three cell lines. 
In addition, a site-directed mutation in the -64/-61 bp element abolishes promoter activity 
in РСЗ and untreated K562 cells. Finally, genomic footprinting reveals enhanced 
methylation at G-61 in all three cell lines, which indicates that the element is bound by a 
trans-acting factor in vivo. As the activity of the PDGF В gene promoter is 100-300-fold 
lower than that of the SV40 promoter/enhancer in untreated K562, HeLa and PC3 cells 
(Fig. 5; Dirks et al., 1993a), we conclude that the factor that binds to the -64/-61 bp 
element is a weak transcriptional activator. Although our previous results showed that the 
high PDGF В mRNA level in PC3 cells compared with HeLa cells probably results from 
a higher transcription rate in PC3 cells (Dirks et al., 1993a), both cell types use the same 
weak -64/-61 bp element for basal promoter activity. Presumably, the promoter activity in 
PC3 cells is increased by an enhancer element located downstream of the gene, while a 
silencer located within intron 1 may down-regulate promoter activity in HeLa cells (Dirks 
et al., 1993a,b). Despite contrary observations by others (Colamonici et al., 1986; Pech et 
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al., 1989b), we reproducibly detected a low expression level of PDGF В mRNA in 
untreated K562 cells (Dirks et al., 1993a,b). A low percentage of untreated K562 cells 
may differentiate spontaneously toward megakaryocytes (reviewed in Alitalo, 1990), 
which could explain the expression of PDGF В mRNA. However, our reporter gene 
assays demonstrate that activity of the PDGF В promoter in untreated K562 cells is 
abolished by mutagenesis of the -64/-61 bp element, whereas activity in TPA-treated 
megakaryocyte cells is not affected. In addition, hypermethylation of G-61 would not be 
expected if only a low percentage of untreated K562 cells had that site occupied by a 
transcription factor. Thus, our current data indicate that the PDGF В promoter is 
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Fig. 5. Summary of structural and functional analysis of the human PDGF В gene promoter. The 
nucleotide sequence of the PDGF В promoter (Van den Ouweland et al., 1986) is numbered relative to the 
transcription start site. Sites of DNA-protein interactions that were mapped by in vivo DMS footprint 
analysis are boxed and indicated by Roman numerals I, II and III; —, no detectable footprint, N D , not 
determined. Activity of the -64/-61 (underlined) and the -60/-45 (double underlined) transcription activating 
element in a transient reporter gene assay is indicated for each cell type The TATA box is shown in bold. 
Expression levels of 3 5-kb PDGF В mRNA are summarized from Northern blot analysis (Dirks et al., 
1993a) —, undetectable; + , + + + , + + + + + , increasing levels of expression. Activity of the PDGF В 
promoter (Dirks et al., 1993a) is indicated as the activity of contract psis-112/+43CAT relative to the 
activity of the SV40 promoter/enhancer construct pSV2CAT (100%). The methylation status of the CpG 
dmucleotides (m) was determined by restriction enzyme analysis (all cell types) and by genomic sequencing 
(all cell types except HeLa and PC3). no, unmethylated; yes, heavily methylated. 
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constitutively active in untreated K562 cells due to binding of a weak transcriptional 
activator to the -64/-61 bp element. The observation that the PDGF В promoter is fully 
demethylated in untreated K562 cells is consistent with this hypothesis. Whether the 
-64/-61 bp element interacts with a known transcription factor is unclear, as a TCTC 
sequence or its complement was not found as a specific binding site in a recent 
compilation of transcription factors (Faisst and Meyer, 1992). PDGF В promoter 
fragments previously used in gel retardation assays with nuclear extracts from K562 cells 
also contained the -64/-61 bp element, suggesting that at least part of the in vitro DNA-
protein complexes result from interaction with the weak transcriptional activator (Pech et 
al., 1989b; Jin et al., 1993). JEG-3 cells, which do not contain the 3.5-kb PDGF В 
mRNA, also express a transcriptional activator directed at the -64/-61 bp element. Earlier 
we showed that the PDGF В promoter is not hypersensitive to DNase I in JEG-3 cells 
(Dirks et al., 1993a), suggesting that the transcriptional activator does not bind to the 
endogenous promoter. We now show that the PDGF В promoter and a large part of exon 
1 are heavily methylated in JEG-3 cells, which might cause inhibition of PDGF В 
promoter activity. 
A second transcription activating element was localized by deletion mutant analysis 
between positions -60 bp and -44 bp and co-mapped with an in vivo DMS footprint 
extending from -61 bp to -54 bp in TPA treated K562 cells. TPA-mediated 
megakaryocyte differentiation of K562 cells is accompanied by a > 200-fold increase in 
PDGF В mRNA level and a 10-30-fold increase in activity of the PDGF В promoter in a 
reporter gene assay (Fig. 5; Pech et al., 1989b; Dirks et al., 1993a). In addition, the 
TPA-mediated increase in PDGF В mRNA is dependent on de novo protein synthesis 
(Pech et al., 1989b). Therefore, we conclude that the increased activity of the PDGF В 
promoter in TPA-treated K562 cells is the result of binding of a potent transcriptional 
activator to the -60/-54 bp element. Enhancer elements located downstream and far 
upstream of the PDGF В gene may further increase the transcription rate in TPA-treated 
K562 cells (Dirks et al., 1993a,b). Genomic footprinting revealed hypermethylation at 
G-61 in both untreated and TPA-treated K562 cells, which may result from binding of the 
same factor. This is supported by previous observations that complexes between PDGF В 
promoter fragments and nuclear proteins from either untreated or TPA-treated K562 cells 
migrate at similar positions in gel retardation assays (Pech et al., 1989b; Jin et al., 1993). 
Our observation that mutagenesis or deletion of the -64/-61 bp element does not affect 
PDGF В promoter activity in TPA-treated cells could be explained by assuming that the 
weak activity of this element is obscured by the potent transcription activating element 
located between -60 bp and -45 bp. Alternatively, hypermethylation at G-61 may result 
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from binding of different factors in untreated and TPA-treated cells. The footprint at 
-61/-54 bp in TPA treated K562 cells closely resembles an in vivo footprint at an identical 
sequence element shown to be required for full promoter activity of the GATA-1 gene in 
mouse erythroleukemic MEL cells. The GATA-1 gene encodes an erythroid transcription 
factor that is specifically expressed in erythroid precursors, mast cells and megakaryocytes 
(Tsai et al., 1991). In addition, the GATA-1 product itself may interact with CACCC 
binding transcription factors (Walters and Martin, 1992). This raises the interesting 
possibility that GATA-1 and PDGF В promoter elements are regulated by related 
transcription factors. CACCC element binding transcription factors were cloned from a 
murine erythroleukemia cell line (Miller and Bieker, 1993) and isolated from rat liver 
(DeVack et al., 1993). Recent in vitro binding studies indicated that the -61/-54 bp region 
of the PDGF В promoter interacts with purified Spi (Khachigian et al., 1994) and with 
Spi-like proteins present in nuclear extracts from a human osteosarcoma cell line (Jin et 
al., 1994). Whether known CACCC binding transcription factors are involved in 
regulation of the PDGF В promoter in megakaryocyte K562 cells remains to be 
determined. 
Our present results indicate that primary dermal fibroblasts express a transcriptional 
activator that recognizes DNA sequences between positions -60 bp and -45 bp of the 
PDGF В promoter. Inhibition of PDGF В gene expression in fibroblasts seems important, 
as overexpression of normal PDGF В chains in fibroblasts may cause the development of 
fibrosarcomas via autocrine stimulation of cell proliferation (Clarke et al., 1984; Gazit et 
al., 1984; Josephs et al., 1984b; Ross et al., 1986; Beckmann et al. 1988; Pech et al., 
1989a). Since we could not detect transcription of the PDGF В gene in a nuclear run-on 
assay (Dirks et al., 1993a) and the transcriptional activator does not detectably bind to the 
endogenous promoter in vivo (this paper), the gene is probably repressed at the 
transcriptional level. This is further supported by our previous observation that the PDGF 
В promoter is not hypersensitive to DNase I in fibroblasts (Dirks et al., 1993a). Thus far 
we have not found a transcriptional silencer within a region stretching out from -12 kb to 
+25 kb relative to the transcription start site of the PDGF В gene in fibroblasts (Dirks et 
al., 1993a,b). Now that we show that the PDGF В promoter is unmethylated in 
fibroblasts, a negative regulatory role for DNA methylation is also unlikely. Possibly, a 
DNase-I-hypersensitive site located immediately downstream of the transcription start site 
in fibroblasts (Dirks et al., 1993a) contains an element involved in specific nucleosome 
phasing, which may render the PDGF В promoter inaccessible to rranj-acting factors. A 
similar regulatory mechanism was suggested to explain the observation that the cAMP-
responsive element (CRE) located upstream of the tyrosine aminotransferase (TAT) gene 
101 
is inaccessible to the CRE-binding protein (CREB) in certain cell lines that express 
nuclear CREB, even after 5-azacytidine mediated demethylation of CpG residues in the 
TAT-CRE (Weih et al., 1991). 
In conclusion we provide direct in vivo evidence for the cell-type-specific binding of 
a weak and a strong transcriptional activator to the PDGF В gene promoter in a panel of 
human cell lines. In addition, we discussed the putative role of chromatin structure in 
negative and positive regulation of the gene. These studies illustrate the complexity of 
regulatory mechanisms used by this gene to achieve its broad, but highly specific, 
expression partem. 
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Chapter 5 
A novel human c-sis mRNA species is transcribed from a promoter in c-sis intron 1 
and contains the code for an alternative PDGF B-like protein 
Ron P.H. Dirks, Carla Onnekink, Hans J. Jansen, Aard de Jong and Henri P.J. Bloemers 
Nucleic Acids Res., in press (1995) 
SUMMARY 
The human platelet-derived growth factor (PDGF) В chain precursor is usually 
translated from a 3.5-kb C-ÍIÍ/PDGF В gene transcript. The first exon of the C-JÍJ gene 
contains the code for the signal peptide of the PDGF В chain precursor, preceded by a 1-
kb long untranslated sequence with potent translation inhibitory activity. In this paper we 
show that a novel 2.6-kb c-sis mRNA present in the human choriocarcinoma cell line 
JEG-3 initiates at an alternative exon 1, which we refer to as exon la. The 90-bp long 
exon la is located in the center of the first intron of the gene. It coincides with a very 
pronounced DNase-I-hypersensitive site and is preceded by a functional promoter. Of the 
three ATG codons present in exon la, the third one perfectly matches the criteria of a 
consensus startcodon. It initiates an open reading frame that is continuous with the code 
for the PDGF В chain precursor but lacks the code for a signal peptide. We conclude that 
this novel 2.6-kb c-sis mRNA species lacks the strong translation inhibitory potential of 
the regular exon 1 and contains the code for a PDGF B-like protein that may be targeted 
to the cell nucleus. 
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INTRODUCTION 
The human c-sis gene encodes the precursor of the platelet-derived growth factor 
(PDGF) В chain (Doolittle et al., 1983; Waterfield et al., 1983; Chiù et al., 1984; 
Johnsson et al., 1984; Josephs et al., 1984a), a potent growth factor for cells of 
mesenchymal origin. The gene is located on human chromosome 22 (Dalla Favera et al., 
1982; Swan et al., 1982). It consists of seven exons, which span approximately 22 kb 
(Rao et al., 1986; Van den Ouweland et al., 1987). Together the exons form an mRNA of 
3.5 kb, of which 2.8 kb consist of non-translated sequences. Exon 1 contains a 1-kb long 
5'-untranslated sequence with a strong translation inhibitory potential (Ratner et al., 1987; 
Rao et al., 1988; Ratner, 1989) and, in addition, codes for the signal peptide. Exons 2-6 
code for the major part of the PDGF В chain precursor, whereas exon 7 consists entirely 
of a 1.6-kb long 3'-untranslated sequence (Rao et al., 1986; Van den Ouweland et al., 
1987). In the endoplasmic reticulum (ER), the 28-kDa PDGF В chain precursor undergoes 
N-linked glycosylation and dimerizes with other В and/or A chain precursors (Graves et 
al., 1986; Igarashi et al., 1987; By water et al., 1988; Östman et al., 1988, 1992). The В 
chain precursors are proteolytically processed in the Golgi system at their amino- and 
carboxy-termini, which results in the loss of the N-linked carbohydrate. Finally, PDGF В 
chains are secreted as part of 30-kDa AB or BB dimers, whereas 24-kDa BB dimers 
remain cell associated and are degraded in lysosomes (Östman et al., 1988, 1992). 
The human c-sis gene is transcribed in specific cell types, such as vascular 
endothelial cells (Barrett et al., 1984), macrophages (Shimokado et al., 1985), activated 
monocytes (Martinet et al., 1986), placental cytotrophoblasts (Goustin et al., 1985) and 
bone marrow megakaryocytes (Gladwin et al., 1990). Furthermore, the gene is transcribed 
in several types of transformed cells (see e.g. Eva et al., 1982; Westin et al., 1982). The 
full length 3.5-kb c-sis transcript is found in most human cell types expressing the gene, 
but smaller transcripts have been described that hybridize under stringent conditions with 
c-sis or v-sis probes (Eva et al., 1982; Barrett et al., 1984; Graves et al., 1984; Bronzert 
et al., 1987; Versnel et al., 1988; Fen and Daniel, 1991; Franklin et al., 1991). Among 
these, an approximately 2.6-kb long transcript has been described most often. Fen and 
Daniel (1991) provided evidence that a 2.8-kb c-sis transcript expressed in human 
umbilical vein endothelial cells (HUVECs) lacks a major part of c-sis exon 1 and initiates 
at 15 nucleotides upstream of the PDGF В translation initiation codon. Since the code for 
the PDGF В chain precursor is presumably not affected in the 2.8-kb transcript, the main 
difference compared with the 3.5-kb mRNA would be the absence of the translation 
inhibitory capacity of the 5'-untranslated region (Ratner et al., 1987; Rao et al., 1988; 
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Ratner, 1989). Therefore, it was predicted that the 2.8-kb transcript would be much more 
efficiently translated than the 3.5-kb mRNA (Fen and Daniel, 1991). 
A 2.6-kb c-sis mRNA species expressed in human choriocarcinoma cell line JEG-3 
was also shown to lack exon 1-derived sequences and was suggested to be antisense to the 
major 3.5-kb с-ш mRNA (Franklin et al., 1991). Indeed, in JEG-3 cells the regular c-sis 
promoter does not coincide with a DNase-I-hypersensitivity (DH) site (Dirks et al., 
1993a), which strongly suggests that the promoter is not active in these cells. However, 
the presence of a DH site at the З'-end of the first exon in JEG-3 cells (Dirks et al., 
1993a) suggests that the 2.6-kb c-sis transcript could be derived from an alternative 
promoter, corresponding with the start site of the 2.8-kb c-sis mRNA in vascular 
endothelial cells (Fen and Daniel, 1991). When we performed primer extension and 
nuclease SI experiments, similar to those described by Fen and Daniel (1991), on RNA 
isolated from JEG-3 cells, we found that the 2.6-kb c-sis mRNA has the same orientation 
as the 3.5-kb mRNA and that its 5'-end extends 90 nucleotides upstream of exon 2-
derived sequences. Surprisingly, the 5'-end of the 2.6-kb transcript turned out to be 
different from the З'-end of the regular с-ш exon 1. These results prompted us to map 
the 2.6-kb c-sis mRNA from JEG-3 cells in more detail, which led to the discovery that 
the transcript initiates at an alternative exon located within c-sis intron 1. Our results 
indicate that in JEG-3 cells the c-sis gene uses a hitherto unknown expression pathway that 
may not only affect the translation efficiency of the c-sis mRNA, but also the structure 
and cellular location of its protein product. 
MATERIALS AND METHODS 
Cell culture 
Cell lines K562, JEG-3, JAR, HeLa and T24 were all from the American Type 
Culture Collection (Rockville, MD). Cells were grown in Dulbecco's modified Eagle's 
medium supplemented with 10% fetal calf serum and 125 U/ml streptomycin and 125 
U/ml penicillin. Megakaryocyte differentiation of K562 cells was induced by addition of 
12-O-tetradecanoylphorbol 13-acetate (TPA; Sigma) to the culture medium (final 
concentration, 2 ng/ml). 
Isolation and northern blot analysis of RNA 
Total cellular RNA was isolated according to the LiCl/urea method (Auffray and 
Rougeon, 1980). RNA was glyoxylated, electrophoresed in 1% agarose gels containing 10 
mM Na2HP04, pH 7.0, and transferred to Hybond-N filters (Amersham, UK) as described 
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(Sambrook et al., 1989). RNA was hybridized overnight in 0.5 M Na2HPO„, pH 7.2, 1% 
bovine serum albumin, 7% SDS, 1 mM EDTA at 65°С with 32P-labeled DNA probes. 
Filters were washed at 65°C in 0.1 M Na2HP04, 0.5% SDS, 1 mM EDTA and exposed 
to Kodak XAR-5 X-Ray film with two Cronex intensifying screens (Du Pont). 
Plasmids and probes 
A 2-kb BamHl fragment that contains sequences from C-JÍ'Í exons 1-7 was isolated 
from human c-sis cDNA clone pSM-1, which was kindly provided by Dr S.T. Josephs. A 
2-kb EcoW-Hindlll fragment containing all c-sis exon 1-derived sequences was isolated 
from pA0121. A 1.45-kb ВатШ fragment that contains the 3' half of exon 7 was isolated 
from human c-sis cosmid clone ALLW-1283-C1 21. The 0.6-kb Pstl-Bgill fragment of 
pSM-1 was cloned into pGEM-3Zf(+) and was used as the probe for nuclease SI 
analysis. The 0.35-kb Pstl-Kpnl fragment of pA078 was used as a probe for DH site 
mapping. pA078 contains the 8-kb ВатШ fragment of ALLW-1283-C1 21 cloned into 
pBR322. pA0152 contains the 2-kb Ніпа\\\-ВатЯ\ fragment of ALLW-1283-C1 21 cloned 
into pAT153. Genomic c-sis clones pAO70, pA0121 and ALLW-1283-C1 21 (Van den 
Ouweland et al., 1985) and pA0154 (Van den Ouweland et al., 1986) have been 
described earlier. Human PDGF A cDNA clone 13.1 was kindly provided by Dr С. 
Betsholtz. All DNA probes used in Southern blot and northern blot analyses were labeled 
with 32P by the random primer labeling method (Feinberg and Vogelstein, 1983) to 
specific activities of 108-10' cpm//ig DNA. 
The reporter gene construct psis-112/+43CAT has been described earlier (Dirks et 
al., 1993a). pSuperCAT is a promoterless chloramphenicol acetyltransferase (CAT) gene 
vector. pAltsis(s)CAT and pAltsis(a)CAT were made by cloning the 0.22-kb Ddel 
fragment of pA078 in the sense (s) or antisense (a) orientation into the Smal site of 
pSuperCAT. pSV2CAT was described earlier (Gorman et al., 1982). pCHllO (Pharmacia 
LKB) contains the /3-galactosidase gene driven by the SV40 promoter. 
Primer extension analysis 
cDNA was synthesized from 30 μg JEG-3 and JAR RNA using the 32P-end-labeled 
exon 2-derived antisense oligonucleotide 5'-(GTG CAG CAG GCG TTG GAG АТС АТС 
AAA GGA GCG GA)-3' as a primer, essentially as was described by Fen and Daniel 
(1991). Primer extension products were electrophoresed in a 6% sequencing gel and 
exposed to Kodak XAR5 X-ray film for 2 weeks with two intensifying screens. The same 
exon 2-derived oligonucleotide was used as a primer to generate a nucleotide sequence 
ladder (Sanger et al., 1977) of c-sis cDNA clone pSM-1, which served as a marker for the 
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primer extension analysis. 
Nuclease SI analysis 
Nuclease SI analysis was done as described earlier (Van Leen et al., 1986). The 
nuclease SI probe (see Fig. ЗА) was labeled with 3 2P according to Sanger et al. (1977) 
and purified by electrophoresis in a 6% sequencing gel. RNA from TPA treated K562 
cells (50 ftg) and JEG-3 cells (250 /¿g) was hybridized overnight at 40 °C with 32P-labeled 
probe. Treatment with nuclease SI (final concentration 2 U/μΙ) was for 60 min at 37°C. 
Protected fragments were electrophoresed in a 6% sequencing gel and exposed to Kodak 
XAR-5 film. The dideoxy nucleotide sequence ladder of the SI probe (Sanger et al., 
1977) was used as a molecular weight marker. 
cDNA cloning 
Polyadenylated RNA from JEG-3 cells was purified by oligo(dT)-cellulose affinity 
chromatography. cDNA synthesis and amplification were according to the protocol of the 
5'-AmpliFINDER RACE Kit (Clontech), which is based on the single-strand-ligation-to-
single-stranded-cDNA (SLIC) method according to Dumas et al. (1991). cDNA was 
synthesized from 2 μg polyadenylated RNA using с-ш exon 6-specific antisense 
oligonucleotide 5'-(GTC ACC CGA GTT TGG GGC GT)-3' as a primer. Upon ligation 
of the AmpliFINDER Anchor to its 3' end, the cDNA was amplified using an 
oligonucleotide complementary to the AmpliFINDER Anchor Primer and a nested c-sis 
exon 5-specific antisense oligonucleotide 5'-(CTC GCT GCT CCT GGG AAC CC)-3'. 
The cDNA was amplified in 35 cycles: denaturation was for 45 s at 94°C, annealing for 
45 s at 60°C and synthesis for 2 min at 72°C. The resulting 600 bp cDNA fragment was 
cloned into the Smal site of pGEM-3Zf(+), yielding pCORDl. 
Nucleotide sequence analysis 
DNA fragments were subcloned into pGEM-3Zf(+) and nucleotide sequences were 
determined according to the dideoxy chain termination method of Sanger et al. (1977). 
Sequence data were recorded, edited and compared using IntelliGenetics Suite software. 
The cDNA sequence of pCORDl (accession number X83705) and the genomic DNA 
sequence of the alternative exon la (accession number X83706) were submitted to the 
EMBL data library. 
Mapping of DH sites and Southern blot analysis 
Nuclear isolations, DNase I digestions, and chromosomal DNA purifications were 
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all performed as previously described (Dirks et al., 1993a). Purified DNA (25 μg) was 
digested to completion with Kpnl (GIBCO Laboratories, Grand Island, USA), extracted 
once with phenol and chloroform, precipitated with ethanol and dissolved in 20 μΐ of H20. 
The Hindlll fragments of phage λ (400 ng/lane) and the Haelll fragments of phage ΨΧ174 
(200 ng/lane) were added to each sample as internal molecular size markers. DNA 
samples were electrophoresed in 1% agarose gels and transferred to Hybond-N filters 
according to the Amersham protocol. DNA was hybridized overnight in 0.75 M NaCl, 75 
raM sodium citrate, 0.1% SDS, 0.1% Ficoll, 0.1% bovine serum albumin, 0.1% 
polyvinylpyrrolidone, 100 μg/ml herring sperm DNA at 68°C with 32P-labeled DNA 
probes. Filters were washed at 68°C in 15 шМ NaCl, 1.5 mM sodium citrate, 0.1% SDS, 
then exposed to X-ray film with two intensifying screens. For genomic localization of the 
alternative exon la, subcloned c-sis fragments were isolated according to standard 
protocols (Sambrook et al., 1989) and electrophoresed in a 1% agarose gel. Southern blot 
analysis was performed as described above using the 32P-labeled 60-bp EcoRi-Aval 
fragment of c-sis cDNA clone pCORDl as a probe. 
Electropermeations and CAT assays 
Supercoiled plasmid DNA was purified by CsCl gradient centrifugation (Sambrook 
et al., 1989) and quantitated by means of both ethidiumbromide staining and 
spectrophotometric measurement. Cells (3-5 χ 107) were electropermeated with 10 μg 
pCHHO and 10 pmol CAT construct as previously described (Dirks et al., 1993a). Cells 
were harvested 48 h after electropermeation. Cell lysates were prepared (Sambrook et al., 
1989) and the protein content of each lysate was determined in a protein assay (BioRad). 
Fixed amounts of protein were tested for j3-galactosidase activity (Edlund et al., 1985) 
and, subsequently, amounts of protein corresponding to equal /3-galactosidase activity were 
assayed for CAT activity (Gorman et al., 1982). Radioactive spots were quantitated by 
measuring in a liquid scintillation counter, from which the percentage acetylated 
chloramphenicol could be determined. 
RESULTS 
The 5'-end of a 2.6-kb c-sis mRNA species is derived from an alternative exon 
A representative northern blot analysis, using a probe that contains sequences 
derived from all seven c-sis exons, demonstrates the cell-type-specific expression of three 
c-sis mRNA species (Fig. 1A). A single 2.6-kb c-sis mRNA species is expressed in 
choriocarcinoma-derived JEG-3 cells, whereas bladder carcinoma-derived T24 cells 
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Fig. 1. Northern blot analysis of c-sis mRNA species. Total RNA isolated from JEG-3 (J), HeLa (H) and 
T24 (T) cells was hybridized with cDNA clone pSM-1 containing sequences derived from all seven c-sis 
exons (A), with genomic clone pA0121 containing the entire c-sis exon-1 (B), with a 1.45-kb genomic 
fragment containing the 3' end of c-sis exon-7 (C) and with PDGF A cDNA clone 13.1 (D). JEG-3 and 
HeLa lanes contain 10 /ig of RNA; T24 lanes contain 5 /xg of RNA. 
express the 3.5-kb, a 3.0-kb and a 2.6-kb transcript. Cervix carcinoma-derived HeLa cells 
express the 3.5-kb and a 3.0-kb species. A parallel northern blot analysis using a genomic 
probe that contains only c-sis exon 1 (Fig. IB) shows that the 2.6-kb transcript does not 
hybridize with exon 1-derived sequences. The 3.0-kb transcript hybridizes with the exon 1 
probe, but not as well as with the cDNA clone pSM-1 (Fig. 1A,B), which suggests that it 
lacks a significant part of exon 1. The hybridization signals obtained with a probe that 
contains only sequences derived from the З'-end of the 1.6-kb long exon 7 (Fig. 1С) are 
comparable with those obtained with pSM-1 (Fig. 1A), suggesting that the different sizes 
of the three transcripts do not result from alternative polyadenylation. Northern blot 
analysis with additional exon-specific probes indicated that the 2.6-kb transcript also 
contains sequences derived from c-sis exons 5 and 6 and from the 5'-end of exon 7 (data 
not shown). We conclude that the 3.0-kb c-sis mRNA expressed in HeLa and T24 cells 
initiates within c-sis exon 1 and may in fact be identical to a 3.0-kb mRNA species 
expressed in vascular endothelial cells (Fen and Daniel, 1991). The 2.6-kb mRNA species 
seems to lack exon 1-derived sequences, which is in agreement with the results described 
by Franklin et al. (1991). However, as was demonstrated for the 2.8-kb c-sis mRNA 
species expressed in vascular endothelial cells (Fen and Daniel, 1991), the 2.6-kb 
transcript might contain insufficient exon 1-derived sequences to allow visualization by 
northern blot analysis with an exon 1-specific probe. Since JEG-3, HeLa and T24 cells 
express significant levels of PDGF A mRNA (Fig. ID), it was even possible that the 
hybridization signal at 2.6 kb was caused by a PDGF A transcript cross-hybridizing with 
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Fig. 2. Primer extension analysis 
of the 2.6-kb c-sis mRNA. Total 
RNA derived from choriocarcinoma 
cell lines JEG-3 and JAR was 
hybridized with a c-sis exon 2-
specific oligonucleotide and the 
primer was extended using reverse 
transcriptase. The size of the single 
extension product is indicated. The 
sequence ladder was generated by 
dideoxy nucleotide sequence analysis 
of c-sis clone pSM-1 using the same 
exon 2-specific primer. The 
boundary between exon 2- and exon 
1-derived sequences is indicated by 
the arrow on the left. 
the c-sis probe. 
To examine whether the 2.6-kb mRNA expressed in JEG-3 cells starts at the 3'-end 
of c-sis exon 1, as has been demonstrated for the 2.8-kb c-sis mRNA expressed in 
endothelial cells (Fen and Daniel, 1991), the 5'-end of the transcript was mapped by 
113 
primer extension analysis, using the exon 2-derived primer described by Fen and Daniel 
(1991). A single 174-nucleotides primer extension product was found for JEG-3 cells as 
well as for JAR cells (Fig. 2), which also express only a single c-sis mRNA species of 2.6 
kb (Dirks et al., 1993a,b). The size of the primer extension product indicates that the 2.6-
kb transcript extends 90 nucleotides upstream of c-sis exon 2-derived sequences. Together 
with c-sis exons 2-7 and a poly A tail of -200 nucleotides this fully accounts for the 
length of the 2.6-kb transcript. To check whether these 90 nucleotides are derived from 
the З'-end of the regular c-sis exon 1, we performed nuclease SI protection analysis on 
RNA derived from JEG-3 cells using a probe that extended from the З'-end of exon 1 to 
the 5'-end of exon 4 (as depicted in Fig. ЗА). RNA from phorbol ester-treated K562 cells, 
which express only the 3.5-kb transcript, was used as a control. As expected, all c-sis-
derived sequences present in the nuclease SI probe were protected by the 3.5-kb transcript 
expressed in K562 cells, which resulted in a 435-nucleotides long fragment (Fig. 3B). 
Surprisingly, the nuclease SI probe protected only a 255-nucleotides long sequence in 
RNA from JEG-3 cells (Fig. 3B), instead of a 345-nucleotides long region that was 
expected if the 2.6-kb mRNA would start at the З'-end of exon 1. In fact, in JEG-3 RNA, 
the protected region initiates exactly at the boundary between exons 1 and 2. Thus, the 
combined results of the northern blot, primer extension and nuclease SI experiments 
indicate that the choriocarcinoma cell line JEG-3 expresses a 2.6-kb c-sis mRNA species 
that extends 90 nucleotides upstream of c-sis exon 2-derived sequences and initiates at an 
alternative exon. 
c-sis exon 1 2 3 4 5 6 7 
IA AAA 
A 
S1 probe seo bp 
Fig. 3. Nuclease SI analysis of the 2.6-kb c-sis mRNA. (A) Schematic representation of the probe that 
was used for the nuclease SI analysis, c-sis exons 1-7 are boxed. The probe is indicated by the black bar. 
(B) Total RNA derived from TPA treated K562 cells and JEG-3 cells was hybridized with the 32P-labeled 
nuclease SI probe (see Fig. ЗА). The RNA-DNA hybrids were treated with nuclease SI and the protected 
fragments were analysed by electrophoresis in a sequencing gel. The sizes of the protected fragments were 
determined by comparison with a parallel sequence ladder generated by dideoxy nucleotide sequence 
analysis of the nuclease SI probe. Arrows indicate the positions of the protected fragments and the position 
of the predicted 345-nucleotides fragment. 
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A 
50 
AGAGAGAGAGAGAGACTGACTGAGCAGGAATGGTGAGATGTTTATCATGGGCCTC ] GGGGA 
* M F I M G L G D 
M V R C L S W A S G 
100 
CCCCATTCCCGAGGAGCTTTATGAGATGCTGAGTGACCACTCGATCCGCTCCTTTGATGA 
P I P E E L Y E M L S D H S I R S F D D 
T P F P R S F M R C * 
150 
TCTCCAACGCCTGCTGCACGGAGACCCCGGAGAGGAAGATGGGGCCGAGTTGGACCTGAA 
L Q R L L H G D P G E E D G A E L D L N 
200 . . . . 
CATGACCCGCTCCCACTCTGGAGGCGAGCTGGAGAGCTTGGCTCGTGGAAGAAGGAGCCT 
M T R S H S G G E L E S L A R G R R S L 
250 . . . . 300 
GGGTTCCCTGACCATTGCTGAGCCGGCCATGATCGCCGAGTGCAAGACGCGCACCGAGGT 
G S L T I A E P A M I A E C K T R T E V 
350 
GTTCGAGATCTCCCGGCGCCTCATAGACCGCACCAACGCCAACTTCCTGGTGTGGCCGCC 
F E I S R R L I D R T N A N F L V W P P 
400 
CTGTGTGGAGGTGCAGCGCTGCTCCGGCTGCTGCAACAACCGCAACGTGCAGTGCCGCCC 
C V E V Q R C S G C C N N R N V Q C R P 
450 
CACCCAGGTGCAGCTGCGACCTGTCCAGGTGAGAAAGATCGAGATTGTGCGGAAGAAGCC 
T Q V Q L R P V Q V R K I E I V R K K P 
500 . . . . 
AATCTTTAAGAAGGCCACGGTGACGCTGGAAGACCACCTGGCATGCAAGTGTGAGACAGT 
I F K K A T V T L E D H L A C K C E T V 
550 . . . . 
GGCAGCTGCACGGCCTGTGACCCGAAGCCCGGGGGGTTCCCAGGAGCAGCGAG 
A A A R P V T R S P G G S Q E Q R 
Fig. 4. Nucleotide sequence and deduced amino acid sequence of c-sis cDNA clone pCORDl. (A) The 
3' boundary of the novel 55-bp long sequence is indicated by a bracket. ATG codons in the novel sequence 
are underlined. The consensus translation initiation site is double underlined. Translation termination codons 
are indicated by asterisks. The sequence complementary to the exon 5-derived oligonucleotide used m the 
SLIC-PCR procedure is shown in bold. (B) Alignment of the ATG codons in the novel 55-bp sequence with 
the consensus translation initiation site according to Kozak (1991). 
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The 2.6-kb c-sis mRNA species contains the code for a novel PDGF-B-like protein 
In order to identify the alternative c-sis exon, we decided to isolate a cDNA 
corresponding to the 5'-end of the 2.6-kb transcript by a cDNA amplification method 
(single-strand-ligation-of-cDNA or SLIC-PCR; Dumas et al., 1991). First strand cDNA 
was synthesized from JEG-3 RNA using a c-sis exon 6-derived primer. A single stranded 
adapter was ligated to the З'-end and the cDNA was amplified in a polymerase chain 
reaction using a nested c-sis exon 5-derived primer and an oligonucleotide complementary 
to the adapter. The resulting cDNA was cloned into a pGEM vector yielding clone 
pCORDl and its nucleotide sequence was determined (Fig. 4A). The cDNA clone 
contains the previously described c-sis exons 2-5 (Chiù et al., 1984; Johnsson et al., 1984; 
Josephs et al., 1984a) and, in addition, a novel 55-bp sequence located immediately 
upstream of exon 2. The novel sequence contains three ATG codons, two of which are in 
frame with the code for the PDGF В chain precursor that continues in exon 2. The first 
ATG is followed by a stopcodon in exon 2 and initiates an open reading frame of only 20 
codons. The third ATG codon perfectly matches the criteria of a consensus translation 
initiation site according to Kozak (1991; see Fig. 4B). Translation from this codon would 
result in the synthesis of a PDGF B-like polypeptide that contains the tripeptide met-gly-
leu at its amino-terminus, followed by amino acids that are encoded by exon 2. As a 
result, the signal peptide is replaced by an amino-terminus harbouring three negatively 
charged residues within the first ten amino acids. 
В 
-3 +4 
first Met codon GGA ATG G 
! I 
second Met codon GAG ATG Τ 
ι ι I 
third Met codon АТС ATG G 
I.I M I ι 
I • I I I I I 
consensus startcodon ACC ATG G 
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The alternative c-sis exon la is preceded by a functional promoter and coincides with a 
pronounced DH region in c-sis intron 1 
Earlier, we and others localized very pronounced DH sites within c-sis intron 1 in 
JEG-3 cells (Franklin et al., 1991; Dirks et al., 1993a). When we used the novel 55-bp 
cDNA fragment as a probe for Southern blot analysis of subcloned genomic c-sis 
fragments (Fig. 5A), c-sis intron 1 (subclone pAO70) was found to hybridize under highly 
stringent conditions (Fig. 5B). Ultimately, the hybridizing region could be localized on a 
1.4-kb Pvull fragment (Fig. 5C), of which the nucleotide sequence was partly determined 
(Fig. 6). Indeed, the PvuU fragment contains the same 55-bp sequence as is present in the 
5'-end of c-sis cDNA clone pCORDl. The 55-bp sequence is followed by a consensus 5'-
splice site. The 5'-end of the alternative exon, which we refer to as exon la, was 
localized at 90 bp upstream of its З'-end, according to the results of the primer extension 
experiment (Fig. 2). The presumptive transcription start site of the 2.6-kb transcript is not 
preceded by a TATA box and maps at a remarkable sequence, where a polypurine stretch 
(dGdA)7 switches to an alternating purine/pyrimidine stretch (dGdPy),,. 
A 
c-sis J 
locus 
В 
Κ Χ Ρ 
ι ι 
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Ρ к 
_ l L 
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Fig. 5. Localization of the 
alternative c-sis exon la. (A) 
Restriction enzyme map of c-sis 
intron 1 and flanking regions. 
Genomic subclones of the human 
c-sis gene are indicated by 
stippled boxes. Exons are 
indicated by black boxes. The 
open box indicates the genomic 
probe that was used for DH site 
mapping. The horizontal bracket 
indicates the region of DNase-I-
hypersensitivity (see also Fig. 8). 
H, «inaili; В, BamHl; E, 
EcoRl; К, Kpnl; X, Xhol; Ρ, 
Р иІІ. (Β) Inserts from the 
genomic c-sis gene subclones 
depicted in Fig. 5A were 
examined by Southern blot 
analysis using the alternative 
exon la as a probe. (C) Genomic 
subclone pAO70 was examined 
in more detail by Southern blot 
analysis of restriction enzyme 
digestions using the alternative 
exon la as a probe. 
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50 
cagctgcgctggcttccaggagggcgagtcccactgtcacgtgacgcgtctggcc [tcagc 
100 
acacttcttccgggaaagagtgaagggccccactgccctttgccatccagcttcctctgg 
150 
ctttgctaatggccctaggggcgaggagaccaactgctggaatcccagagccctggaggt 
200 . . . . 
gtgcaagggcaggtcaaacagaatttggaggatctggtgcaagagccaggaagagagaga 
*250 . . . * . 300 
gagagaGTGTGTGTGTGTGTGCGCGCGCATCTGA]GAGAGAGAGAGAGAGAGAGAGACTGA 
350 
CTGAGCAGGAATGGTGAGATGTTTATCATGGGCCTCgtaagtacctctccacgtcttgtc 
400 
ttcccctccccacattgaggagcctcttctgtgacaactcttcctatgttctggtttatt 
450 
tcattgtttattacctgctttctctactggagtgtcaaccccattagagagctttcctcc 
500 
tggtccccacttttagaacagtgccagagcctgtggacaatcagtaact 
Fig. 6. Nucleotide sequence οΓ the alternative c-sis exon la and Its flanking regions. The sequence 
starts at the Pvull site immediately upstream of the alternative exon la (see also Fig SA) Exon la 
sequences are in upper case The presumed transcription initiation site of the 2 6-kb c-sis mRNA is 
indicated by an asterisk The 5' end of cDNA clone pCORDl is indicated by an arrow ATG codons in 
exon la are underlined The consensus translation initiation site according to Kozak (1991) is double 
underlined The 0 22-kb Ddel fragment that displays promoter activity m a transient reporter gene assay is 
indicated by brackets (see also Fig 7). 
To test whether exon la is preceded by a functional promoter, a genomic Ddel 
fragment containing the region between positions -191 bp to +28 bp relative to the 
presumptive transcription start site (see also Fig 6) was cloned in front of the 
chloramphenicol acetyltransferase (CAT) gene and assayed for promoter activity in JEG-3 
cells (Fig. 7). In the sense orientation (pAltsis(s)CAT), the 0.22-kb Ddel fragment has 
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activity that is approximately 15-fold lower than the activity of the regular c-sis promoter 
(psis-112/+43CAT), whereas in the antisense orientation (pAltsis(a)CAT) it displays only 
background activity. 
To examine whether the alternative exon la coincides with a DH site previously 
found in JEG-3 cells (Franklin et al., 1991; Dirks et al., 1993a), we decided to map the 
boundaries of this DH site more precisely. By Southern blot analysis of a 3.3-kb Kpn\ 
fragment we could localize the DH site between 1.9 kb and 1.3 kb upstream of the 3'-
Kpnl site (Fig. 8), which corresponds exactly with the positions of the alternative exon la 
and its immediate upstream region (see also Fig. 5A). We could also detect two small 
protected regions within the DH site, which may result from the binding of specific trans-
acting factors. Our results indicate that the alternative exon la is preceded by a functional 
promoter and coincides exactly with a DH site in intron 1, at approximately 4 kb 
downstream of the transcription start site of the regular 3.5-kb c-sis mRNA. 
CA acetyl-CA 
plasmid 
pSV2CAT 
pSuperCAT 
psis-112/+43CAT 
pAltsis(s)CAT 
pAltsis(a)CAT 
• 
• · 
m 
# 
* % 
* 
• · 
1 
• 
CAT activity (% CA acetylation) 
87.5 ± 2 
0.18 ±0.03 
16.5 ±0.5 
1.1 ± 0.1 
0.25 ± 0.05 
Fig. 7. Transient reporter gene analysis of the regular and alternative c-sis gene promoter in JEG-3 
cells. Cells were electropermeated with a mixture of pCHHO and the indicated CAT constructs as 
described in Materials and methods. Aliquots of lysate normalized to mean /3-galactosidase activity were 
tested for CAT activity. CA, chloramphenicol; acetyl-CA, 1- and 3-acetyl-chloramphenicol. All data are 
means from two to four independent electropermeations. 
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Fig. 8. Fine mapping of the DH 
α b С d e f g site located in the center of c-sis 
intron 1. Nuclei from JEG-3 cells 
were treated with increasing amounts 
of DNase I. Chromosomal DNA (25 
μg) was digested with Kpn\ and 
subjected to Southern blot analysis. 
The DNA was hybridized with the 
genomic probe depicted in Fig. 5. 
DNase I concentrations: (-) no 
DNase I added; (a) 42 U/ml; (b) 84 
υ/ml; (c) 168 U/ml; (d) 294 U/ml; 
(e) 462 U/ml; (f) 672 U/ml; (g) 924 
U/ml. 
DISCUSSION 
The human c-s/s/PDGF В gene uses several different ways to regulate its expression. 
Transcription of the gene is regulated in a cell type- and developmental-stage-specific 
manner and can be influenced by several extracellular agents (reviewed in Ross et al., 
1986; Kaetzel et al., 1993). Translation can be inhibited up to 40-fold by the 1-kb long 
GC-rich leader of the 3.5-kb c-sis mRNA (Ratner et al., 1987; Rao et al., 1988; Ratner, 
1989). Expression of a 2.8-kb c-sis mRNA that initiates at the 3' end of exon 1 may 
provide a means to escape from the translation inhibitory effect of the leader sequence 
(Fen and Daniel, 1991). The 3.5-kb c-sis mRNA has a variable stability depending on the 
cell type in which it is expressed (see e.g. Press et al., 1988; Sariban and Kufe, 1988). 
All these regulatory mechanisms have in common that they modulate the expression level 
of the PDGF В gene, but do not affect the code for the PDGF В chain precursor. We now 
demonstrate a completely new expression pathway for the human c-sis gene: initiation of 
transcription at an alternative promoter located in intron 1, at 4 kb downstream of the 
transcription start site of the 3.5-kb transcript, yields a 2.6-kb c-sis mRNA that lacks the 
GC-rich leader. Sequence analysis of a cDNA that corresponds with the 5' end of the 2.6-
kb mRNA indicated that the transcript contains the regular c-sis exons 2-5. By northern 
blot analysis with exon-specific probes we could show that it also contains sequences 
derived from c-sis exon 6 and from the 5' and 3' parts of exon 7. Primer extension 
analysis showed that the alternative exon la is 90 bp long, which in combination with the 
regular exons 2-7 fully accounts for the length of the 2.6-kb transcript. Thus, the only 
difference between the 3.5-kb and 2.6-kb c-sis transcripts is the origin of their first exon 
sequences. 
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1.9 kb 
1.3 kb 
The alternative c-sis expression pathway that is followed in JEG-3 cells may have 
important qualitative and quantitative consequences for the gene product. The 5'-
untranslated sequence of the 2.6-kb c-sis mRNA is maximally 81 nucleotides long, has a 
GC content of only 52% and is not expected to adopt extensive secondary structures. 
Therefore, as was previously predicted for the 2.8-kb C-JI'Í mRNA expressed in vascular 
endothelial cells (Fen and Daniel, 1991), the absence of the GC-rich leader sequence may 
result in the synthesis of significant levels of protein product, even from relatively low 
levels of mRNA. Much more importantly, translation from the 2.6-kb c-sis mRNA may 
generate a novel PDGF B-like protein product. Exon la contains three ATG codons, of 
which the first one would initiate a peptide of only 20 amino acids. The third ATG codon, 
which is in frame with the code for the PDGF В chain precursor that continues in exon 2, 
has the best match with the consensus translation start site according to Kozak (1991). 
Initiation of translation at the third ATG codon is quite possible given the fact that 
translation of the 3.5-kb c-sis mRNA initiates even at the fourth ATG codon, which also 
meets the criteria of the Kozak consensus sequence (Van den Ouweland et al., 1986). The 
regular exon 1 codes for the signal peptide of the PDGF В chain precursor, which is 
essential for its translocation to the ER. Translation from the third ATG codon of the 2.6-
kb mRNA would generate a polypeptide containing 5 acidic residues among its first 20 
amino acids. Since this acidic amino-termimis does not constitute a signal peptide, we 
predict that the alternative polypeptide is synthesized at 'free' cytoplasmic ribosomes. The 
regular PDGF В chain precursor dimerizes in the ER and is proteolytically processed in 
the Golgi system yielding a 24-30-kDa dimeric protein that is secreted or remains 
membrane associated (Graves et al., 1986; Igarashi et al., 1987; By water et al., 1988; 
Östman et al., 1988, 1992). In contrast, the product of the 2.6-kb c-sis mRNA species is 
expected to be a monomeric 25-kDa polypeptide that is initially located in the cytoplasm. 
The PDGF В chain precursor has been shown to contain a functional nuclear localization 
signal (NLS) in its exon 6-derived sequence (Lee et al., 1987). The NLS is usually 
masked, due to the rapid translocation of the PDGF В chain precursor into the ER, and is 
subsequently removed by proteolytic processing in the ER. In the absence of a signal 
peptide, the NLS may target the product of the 2.6-kb c-sis mRNA to the cell nucleus. 
The alternative exon la is preceded by a functional promoter that coincides exactly 
with a very pronounced DH site in JEG-3 cells. DH sites are thought to represent 
nucleosome-free regions that often correspond with sites of specific DNA-protein 
interactions (Gross and Garrard, 1988). The DH site at the alternative promoter extends 
over ~600 bp, which indicates that three nucleosomes are absent or disrupted. The 
nuclease SI and primer extension analyses showed that the 2.6-kb c-sis mRNA extends 90 
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nucleotides upstream of the exon 2-derived sequence, which places the transcription 
initiation site 90 bp upstream of the 3' end of exon la. The transcription start site 
coincides with the switch from a (GA)7-repeat to a (GPy),,-repeat (Fig. 6) and is not 
preceded by a consensus TATA box. A (GA)12-repeat is located within exon la and starts 
at 64 bp upstream of the 3' end of the exon. Recently, binding of a GAGA transcription 
factor was shown to disrupt nucleosomes at a heat-shock promoter (Tsukiyama et al., 
1994). A similar mechanism may be responsible for the generation of the DH site at exon 
la. Two DNase-I-footprints could easily be distinguished within the nucleosome-free 
region (Fig. 8), which may reflect specific DNA-protein interactions at the alternative 
promoter. 
We are currently focusing on the structural and functional characterization of the 
putative protein product of the 2.6-kb c-sis mRNA. The regular c-sis gene product has 
transforming activity (Clarke et al., 1984; Gazit et al., 1984; Josephs et al., 1984b) and is 
associated with several tumor species (reviewed in Ross et al., 1986). Whether the 
putative PDGF B-like protein product of the 2.6-kb c-sis mRNA has transforming activity 
is questionable, as it was shown that mutagenesis of the signal peptide of the v-sis gene 
resulted in a nuclear localization of the protein product and a loss of transforming activity 
(Hannink and Donoghue, 1986). There is accumulating evidence that some growth factors 
exert their role in mitogenesis partly in the nucleus (e.g. Kimura, 1993; Wiedlocha et al., 
1994). Whether a similar phenomenon holds true for the putative product of the 2.6-kb c-
sis mRNA remains to be determined. 
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SUMMARY 
Polypeptide growth factors act as regulators of cell division and differentiation and 
play an important role in early development and tissue repair in higher eukaryotes. 
Platelet-derived growth factor (PDGF) is a potent mitogen for cells of mesenchymal origin 
and has chemotactic and vasoconstrictive activity. It is indispensable for the early 
development of the kidney and vasculature and is thought to play a role in wound healing. 
PDGF is also associated with several pathological processes, such as atherosclerosis, 
neoplasia, fibrosis and desmoplasia. PDGF consists of A and/or В chains, which are 
encoded by separate genes. Whereas both have mitogenic and chemotactic activity, only 
the В chain has high transforming activity. The expression of PDGF is regulated in a cell 
type and developmental stage specific manner and can be affected by diverse extracellular 
stimuli. Chapter 1 provides an extensive overview of the cell types that express PDGF and 
of the factors that modulate PDGF expression in these cells. It also summarizes current 
knowledge of the molecular mechanisms involved in regulation of expression of the PDGF 
genes. 
Chapters 2 to 5 contain a study of the mechanisms involved in regulation of the 
human PDGF В mRNA level in a panel of human cell lines: K562 erythroleukemia cells, 
in which phorbol ester mediated megakaryocyte differentiation is accompanied by a 
strong increase in PDGF В mRNA level; cultured dermal fibroblasts (Hufi), which do not 
express the PDGF В gene; JEG-3 and JAR choriocarcinoma cell lines, which have 
several characteristics of placental cytotrophoblasts and express an aberrant PDGF В 
mRNA; carcinoma-derived HeLa, T24 and PC3 cells, which express, respectively, low, 
medium and high levels of PDGF В mRNA. 
In chapter 2 it is demonstrated that the different expression levels of the 3.5-kb 
PDGF В mRNA in these cells mainly result from different transcription rates, rather than 
from differences in mRNA stability. This is supported by the observation that expression 
of the 3.5-kb PDGF В mRNA correlates directly with DNase-I-hypersensitivity (DH) at 
the endogenous promoter. Transient reporter gene analysis demonstrates that all cell types 
tested, including those that do not express the 3.5-kb PDGF В mRNA, contain 
transcription factors that can activate the PDGF В promoter, which indicates that the 
PDGF В gene is also negatively regulated. All DNA elements required for basal promoter 
activity are located within the first 112 bp upstream of the transcription initiation site. The 
more than 200-fold increase in PDGF В mRNA level during megakaryocytic 
differentiation of K562 cells can be partly explained by a 15-30-fold increase in activity of 
the 112-bp PDGF В promoter fragment. In contrast, the observation that the 112-bp 
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promoter fragment has equally low activity in HeLa and PC3 cells does not fit the much 
higher expression level of the 3.5-kb PDGF В mRNA in PC3 cells compared with HeLa 
cells. Several cell-type-specific DH sites are located within PDGF В exon 1, intron 1 and 
immediately downstream of the transcription unit. Genomic fragments harbouring DH 
sites from the first intron show silencer activity in K562, JEG-3 and HeLa cells, whereas 
a fragment that harbours a downstream DH site displays enhancer activity in K562, JEG-3 
and PC3 cells. Thus the different PDGF В mRNA levels in PC3 and HeLa cells may 
result from the interplay between the promoter and transcription regulatory elements 
located outside of the promoter. 
Chapter 3 deals with the localization and functional analysis of a cluster of five DH 
sites located far upstream of the PDGF В gene transcription unit. In K562 cells only one 
site is detectable, whereas three additional sites are generated during megakaryocyte 
differentiation. Two sites, at -8.6 kb and -9.9 kb, coincide with very potent transcriptional 
enhancers. Together with the 15-30-fold increase in activity of the 112-bp promoter 
fragment they can easily explain the more than 200-fold increase in PDGF В mRNA level 
during megakaryocyte differentiation of K562 cells. All five DH sites are present in 
HeLa, PC3 and T24 cells, whereas only two sites are detectable in Hufi and none in JEG-
3 and JAR cells. Although fragments containing single DH sites at -8.6 kb or -9.9 kb 
display enhancer activity in PC3, HeLa and Hufi cells, a genomic fragment harbouring the 
entire cluster retains enhancer activity only in PC3 cells. Thus the upstream enhancers 
may also contribute to the high PDGF В mRNA level in PC3 cells compared with HeLa 
eels. (Part of) a new transcription unit, which is being referred to as sur, is located 
immediately upstream of the DH site cluster and is transcribed into a 0.45-kb RNA 
species. The sur transcript is constitutively expressed in all cell types tested and thus far 
its function is unknown. 
Chapter 4 contains a detailed structural and functional analysis of the PDGF В gene 
promoter. The low basal activity of the promoter in K562, HeLa and PC3 cells is caused 
by the binding of a weak transcriptional activator to the -64/-61 bp region. A similar 
factor is present in JEG-3 cells, but does not bind to the endogenous promoter, probably 
due to CpG methylation. The high promoter activity in megakaryocyte K562 cells results 
from the binding of a strong transcriptional activator to the -61/-54 bp region. Hufi cells 
contain a transcriptional activator directed at the -60/-44 bp region that does not bind to 
the endogenous promoter. Since the PDGF В promoter is not methylated in Hufi, the 
mechanism responsible for the negative regulation of the PDGF В promoter in Hufi 
remains unsolved. Possibly specific nucleosome phasing renders the endogenous promoter 
inaccessible for trans-acting factors. 
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In chapter 5 the characterization of the alternative 2.6-kb c-sis mRNA species 
expressed in JEG-3 and JAR cells is presented. The 2.6-kb transcript lacks the regular 
exon 1 and initiates at an alternative first exon, which is referred to as exon la. Exon la 
is located in the center of the first intron of the PDGF В gene and coincides exactly with a 
very pronounced DH site. Exon la is preceded by a functional promoter that has 15-fold 
lower activity than the regular PDGF В promoter. The regular exon 1 is highly GC-rich 
and has potent translation inhibitory capacity. Since the 2.6-kb transcript lacks this GC-
rich leader, it is predicted to be much more efficiently translated than the 3.5-kb mRNA. 
Exon la harbours three ATG codons, of which the third one meets exactly with the 
criteria of a consensus translation startcodon. The presumptive startcodon initiates an open 
reading frame that codes for a PDGF В chain precursor lacking a signal peptide. Since the 
PDGF В precursor contains a nuclear localization signal, it is predicted that the 2.6-kb c-
sis mRNA is translated into a 25-kDa PDGF B-like nuclear protein. 
In conclusion it is demonstrated that regulation of expression of human c-sis/PDGF 
В mRNA involves at least four different regulatory mechanisms. (1) Cell-type-specific 
expression of weak and strong transcriptional activators of the PDGF В promoter and (2) 
cell-type-specific activity of enhancers and silencers located outside of the promoter 
determine the expression level of the 3.5-kb mRNA. (3) Presumably, CpG methylation 
and specific nucleosome phasing inhibit expression of the 3.5-kb transcript by blocking 
access to the endogenous promoter for transcription factors. (4) Transcription from an 
alternative promoter located in intron 1 presumably results in the expression of an 
alternative PDGF B-like protein that is targeted to the nucleus. 
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SAMENVATTING 
Polypeptide groeifactoren reguleren de deling en differentiatie van cellen en zijn 
belangrijk voor de vroege ontwikkeling en het herstel van weefsels bij hogere eukaryoten. 
'Platelet-derived growth factor' (PDGF) is een krachtig mitogeen voor cellen van 
mesenchymale oorsprong en heeft chemotactische en bloedvat vernauwende activiteiten. 
Het is onmisbaar voor de vroege ontwikkeling van nieren en bloedvaten en speelt 
waarschijnlijk een rol bij wondheling. PDGF wordt ook geassocieerd met allerlei 
pathologische processen, zoals athérosclérose, tumorvorming, bindweefselwoekering en 
desmoplasie. PDGF bestaat uit A en/of В ketens, gecodeerd door twee verschillende 
genen. Beide ketens hebben mitogene en chemotactische eigenschappen, maar alleen de В 
keten heeft sterk cel-transformerende activiteit. Expressie van PDGF wordt op een 
celtype- en ontwikkelingsstadium-specifieke manier gereguleerd en kan door allerlei 
extracellulaire stimuli worden beïnvloed. Hoofdstuk 1 bevat een uitgebreid overzicht van 
de celtypen die PDGF tot expressie brengen en van de factoren die de expressie van 
PDGF in deze celtypen beïnvloeden. Het vat ook de huidige kennis samen van moleculaire 
mechanismen die betrokken zijn bij de regulatie van expressie van de PDGF-genen. 
De hoofdstukken 2 t/m 5 bevatten een studie over de mechanismen die betrokken 
zijn bij de regulatie van het menselijke PDGF-B-boodschapper-RNA- (mRNA-) niveau in 
een groep menselijke cellijnen: erytroleukemische K562-cellen, die na behandeling met 
forbol esters differentieren tot megakarocyten, hetgeen gepaard gaat met een sterke 
toename van het PDGF-B-mRNA-niveau; gekweekte huidfibroblasten (Hufi), die het 
PDGF-B-gen niet tot expressie brengen; JEG-3- en JAR-choriocarcinoma-cellen, die 
verscheidene karakteristieke eigenschappen van placentale cytotrofoblasten bezitten en een 
afwijkend type PDGF-B-mRNA tot expressie brengen; HeLa-, T24- en РСЗ-cellen, die 
afkomstig zijn van carcinomen en, repectievelijk, lage, middelhoge en hoge PDGF-B-
mRNA-niveaus tot expressie brengen. 
In hoofdstuk 2 wordt aangetoond dat de verschillende expressie niveaus van het 3,5 
kilobasen (kb) lange PDGF-B-mRNA in deze cellen voornamelijk worden veroorzaakt 
door verschillen in transcriptie-snelheid, en niet door verschillen in stabiliteit van het 
mRNA. Dit wordt bevestigd door de waarneming dat er een direct verband bestaat tussen 
expressie van het 3,5 kb lange PDGF-B-mRNA en hypersensitiviteit voor DNase I van de 
endogene promotor. Transiente transfectie-studies met benulp van 'reportergenen' tonen 
aan dat alle geteste celtypen, inclusief de cellen die geen 3,5-kb-PDGF-B-mRNA tot 
expressie brengen, transcriptiefactoren bevatten die de PDGF-B-promotor kunnen 
activeren, hetgeen aantoont dat het PDGF-B-gen ook negatief gereguleerd wordt. Alle 
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DNA-elementen die nodig zijn voor basale promotor-activiteit bevinden zich in de eerste 
112 basenparen (bp) stroomopwaarts van de transcriptie-startplaats. De meer dan 200-
voudige toename van het PDGF-B-mRNA niveau tijdens de differentiatie van K562-cellen 
tot megakaryocyten kan ten dele worden verklaard door een 15-30-voudige toename van 
de activiteit van het 112-bp-promotor-fragment. Daarentegen strookt de waarneming dat 
het 112-bp-promotor-fragment zowel in HeLa- als in РСЗ-cellen een lage activiteit heeft 
niet met het feit dat het expressie-niveau van het 3,5 kb lange PDGF-B-transcript in PC3 
cellen veel hoger is dan in HeLa-cellen. Verscheidene celtype-specifieke DNase-I-
hypersensitieve regio's (DH regio's) bevinden zich in PDGF-B-exon-1, intron-1 en direct 
stroomafwaarts van de transcriptie-eenheid. Genomische fragmenten die DH-regio's 
bevatten afkomstig van het eerste intron vertonen 'silencer'-activiteit in K562-, JEG-3- en 
HeLa-cellen, terwijl een fragment dat een stroomafwaarts gelegen DH-regio bevat 
'enhancer'-activiteit vertoont in K562-, JEG-3- en PC3- cellen. Kortom, de verschillende 
PDGF-B-mRNA-niveaus in PC3- en HeLa-cellen zijn mogelijk het gevolg van een 
wisselwerking tussen de promotor en regulatoire elementen die buiten de promotor 
gelegen zijn. 
Hoofdstuk 3 behandelt de localisatie en functionele analyse van een cluster van vijf 
DH-regio's die zich ver stroomopwaarts van de PDGF-B-transcriptie-eenheid bevinden. In 
K562-cellen is slechts één regio waarneembaar, terwijl drie andere regio's verschijnen 
tijdens de differentiatie tot megakaryocyten. Twee regio's, gelegen op -8,6 kb en -9,9 kb, 
bevatten zeer krachtige transcriptionele 'enhancers'. In combinatie met de 15-30-voudige 
toename in activiteit van het 112-bp-promotor-fragment kunnen ze gemakkelijk de meer 
dan 200-voudige toename van het PDGF-B-mRNA niveau tijdens de differentiatie van 
K562-cellen tot megakaryocyten verklaren. Alle vijf DH-regio's zijn aanwezig in HeLa-, 
PC3- en T24-cellen, terwijl er slechts twee detecteerbaar zijn in Hufi en geen enkele in 
JEG-3- en JAR-cellen. Ofschoon fragmenten die de afzonderlijke DH-regio's op -8.6 kb 
of -9.9 kb bevatten 'enhancer'-activiteit vertonen in PC3-, HeLa- en Hufi-cellen, behoudt 
een genomisch fragment dat het gehele cluster omvat alleen in РСЗ-cellen zijn 'enhancer'-
activiteit. Zodoende kunnen de stroomopwaarts gelegen 'enhancers' ook bijdragen aan het 
hoge PDGF-B-mRNA-niveau in РСЗ-cellen vergeleken met dat in HeLa-cellen. Een 
(gedeelte van een) nieuwe transcriptie-eenheid, sur genaamd, is direct stroomopwaarts 
gelegen van het cluster van DH-regio's en wordt getranscribeerd tot een RNA van 0,45 kb 
lengte. Het siir-transcript komt constitutief tot expressie in alle onderzochte celtypen en 
zijn functie is tot nog toe onbekend. 
Hoofdstuk 4 bevat een gedetailleerde structurele en functionele analyse van de 
PDGF-B-promotor. De lage basale activiteit van de promotor in K562-, HeLa- en PC3-
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cellen wordt veroorzaakt door de binding van een zwakke transcriptionele activator aan de 
-64/-61 bp regio. Een gelijksoortige factor is aanwezig in JEG-3-ceIlen, maar bindt niet 
aan de endogene promotor, waarschijnlijk tengevolge van CpG-methylering. De hoge 
promotor-activiteit in megakaryocyt-achtige K562 cellen is het gevolg van de binding van 
een sterke transcriptionele activator aan de -61/-54 bp regio. Hufi cellen bevatten een 
transcriptionele activator die kan binden aan de -60/-44 bp regio, maar niet bindt aan de 
endogene promotor. Aangezien de PDGF В promotor niet gemethyleerd is in Hufi, blijft 
het mechanisme dat verantwoordelijk is voor de negatieve regulatie van de PDGF-B-
promotor in Hufi vooralsnog onopgehelderd. Mogelijkerwijs maakt specifieke fasering van 
nucleosomen de endogene promotor ontoegankelijk voor 'trans' werkende factoren. 
In hoofdstuk 5 wordt de karakterisering getoond van het alternatieve 2,6 kb lange c-
sis-transcript, dat tot expressie komt in JEG-3- en JAR-cellen. Het 2,6-kb-transcript mist 
het gangbare exon-1 en start bij een alternatief eerste exon, exon-la genaamd. Exon-la 
ligt midden in het eerste intron van het PDGF-B-gen en valt precies samen met een 
geprononceerde DH-regio. Exon-la wordt voorafgegaan door een functionele promotor die 
15 keer zwakker is dan de reguliere PDGF-B-promotor. Het gangbare exon-1 is zeer rijk 
aan GC-basen en heeft een krachtige translatie-remmende capaciteit. Aangezien het 2,6 kb 
transcript deze GC-rijke ongetransleerde regio mist, kan men voorspellen dat het veel 
efficiënter vertaald kan worden dan het 3,5 kb-transcript. Er bevinden zich drie ATG-
codons in exon-la, waarvan de derde precies voldoet aan de criteria voor een consensus-
translatie-startcodon. Dit vermoedelijke startcodon vormt het begin van een open leesraam 
dat codeert voor een voorloper van de PDGF-B-keten, echter zonder signaalpeptide. 
Aangezien de voorloper van de PDGF-B-keten een kernlocalisatie-signaal bevat, 
voorspellen wij dat het 2,6-kb-transcript vertaald wordt tot een 25 kDa-PDGF-B-achtig 
kemeiwit. 
Samenvattend wordt aangetoond dat tenminste vier verschillende mechanismen 
betrokken zijn bij regulatie van expressie van het humane c-sis/PDGF В mRNA. (1) 
Celtype-specifieke expressie van zwakke en sterke transcriptionele activators van de 
PDGF-B-promotor en (2) celtype-specifieke activiteit van 'enhancers' en 'silencers', die 
buiten de promotor gelegen zijn, bepalen het expressie-niveau van het 3,5-kb-transcript. 
(3) Waarschijnlijk verhinderen CpG-methylering en specifieke nucleosoom-fasering de 
expressie van het 3,5-kb-transcript, door een blokkade van de toegang voor 
transcriptiefactoren tot de endogene promotor. (4) Transcriptie vanaf een alternatieve 
promotor gelegen in intron-1 zou kunnen resulteren in de expressie van een alternatief 
PDGF-B-achtig eiwit dat naar de kern wordt geleid. 
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